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Arogenate is a key intermediate in the shikimate biosynthetic pathway to aromatic amino acids 
tyrosine and phenylalanine. Though two previous syntheses have been reported in the literature, 
no functionalised derivatives have yet been reported. This work focuses on a ‘reverse-biomimetic’ 
synthesis of arogenate starting from the inexpensive, enantiopure amino acid L-tyrosine. 
Interestingly, the synthetic route proceeds via a novel and mechanistically unusual dearomatising 
spirocyclisation reaction. This intramolecular acylation, which utilises a carbamoyl chloride 
tether to produce a spirocyclic lactam, can be performed using low-cost reagents and without the 
need for heavy metals or toxic species. A synthesis of arogenate has been realised with a 19.6% 
overall yield in seven steps. 
 
 
The biosynthetic pathways to aromatic amino acids are present in plants, bacteria and fungi but 
completely absent in animals. It has long been thought that arogenate analogues may be potent 
competitive inhibitors of arogenate dehydrogenase and dehydratase and enable the development 
of new, safe and selective herbicides and/or antibiotics. Using the many points for derivatisation 
of the spirocyclic intermediate on the route to arogenate provides an opportuntity for various 
functionalisations. The application of this new route to arogenate shows its efficacy to produce a 
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1. Introduction  
1.1 Arogenate  
Arogenate 1 (Figure 1), also known as pretyrosine, is a key intermediate in the shikimate pathway 
towards aromatic amino acids (AAAs).1  
 
Figure 1 - The chemical structure of arogenate, β-(1-carboxy-4-hydroxy-2,5-cyclohexadien-
lyl)alanine. 
AAAs are essential for the synthesis of the vast majority of proteins.1 In plants, AAAs function 
as precursors to numerous natural products which possess pharmacological or biological activities 
(Scheme 1), for example alkaloids, hormones, and salicylates; structural organic polymers, such 
as lignin, also often comprise large numbers of AAAs.1,2 Indeed, the AAAs Trp, Tyr and Phe, 
derived from the shikimate pathway, can account for up to 35% of a plant’s dry weight.1,3 
Scheme 1 - Assortment of natural products from AAAs L-Tyrosine and L-phenylalanine, derived 




Further down the metabolic pathway, the shikimate pathway branches into two distinct routes 
towards the synthesis of L-tyrosine 2 and L-phenylalanine 3. These are the phenylpyruvate/4-
hydroxyphenylpyruvate and arogenate pathways (Scheme 2).4  
 
Scheme 2 - Phenylpyruvate/4-hydroxyphenylpyruvate (red) and arogenate (green) pathways. 
(NADP+/NADPH, Nicotinamide Adenine Dinucleotide Phosphate; α-KG, α-ketoglutarate; Glu, 
glutamate; CM, chorismate mutase; PDH, prephenate dehydrogenase; PDT, prephenate dehydratase; 
PPA-AT, prephenate aminotransferase; PPY-AT, phenylpyruvate aminotransferase; HPP-AT, 4-
hydroxyphenylpyruvate aminotransferase; ADH, arogenate dehydrogenase; ADT, arogenate 
dehydratase.) 
The discovery of arogenate and its pathway came in 1974 by Stenmark et al., it was previously 
thought there was only one biosynthetic pathway to L-tyrosine 2, known as the 4-
hydroxyphenylpyruvate pathway (Scheme 3).5 The exact structure of arogenate was investigated 
in 1980 by Zamir et al., and was established through a variety of spectroscopic techniques 







Scheme 3 - 4-hydroxyphenylpyruvate pathway to L-tyrosine. 
(NADP+/NADPH, Nicotinamide Adenine Dinucleotide Phosphate; α-KG, α-ketoglutarate; Glu, 
glutamate; PDH, prephenate dehydrogenase; HPP-AT, 4-hydroxyphenylpyruvate aminotransferase.) 
Stenmark’s work revealed that several species of blue-green algae exploited this alternative 
arogenate pathway (Scheme 2) for the biosynthesis of AAAs.5 In this pathway arogenate is the 
last non-aromatic intermediate on the route to phenylalanine or tyrosine.7 The pathways to AAAs 
are present in plants, bacteria, fungi, and some protists. However, they are completely absent in 
animals, which must obtain these essential AAAs from their diet. Consequently, the pathway is 
an attractive target for herbicides, antimicrobial agents, and live vaccines.8–10  
In 2006, Ferrer et al. isolated and characterised a crystal structure for arogenate dehydrogenase 
derived from a species of fresh water bacteria, Synechocystis.11 The participation of a histidine 
residue in the prephenate dehydrogenase mechanism has been proven through site directed 
mutation.12 The similarities between prephenate dehydrogenase and arogenate dehydrogenase, 
particularly with respect to their pH profiles, suggest a histidine residue was also present in the 
arogenate dehydrogenase mechanism. Cleland et al. suggested the mechanism of hydride transfer 
and decarboxylation in prephenate dehydrogenases, and so indirectly arogenate dehydrogenases, 
could either be stepwise or concerted (Scheme 4).11,13  
 





Cleland et al. studied the 13C kinetic isotope effect of decarboxylation for both deuterated and 
non-deuterated substrates looking for a multiple isotope effect. Upon changing from non-
deuterated to deuterated substrate, they observed an impact on the 13C kinetic isotope effect for 
decarboxylation. Due to the deuterated substrate slowing down the 13C kinetic isotope effect, it 
can be concluded the mechanism is concerted – heavier isotopes cause an increased stability and 
therefore a lower velocity.13 
The crystal structure of arogenate dehydrogenase shows a water molecule is present in the active 
site, within 2.51 Å of His112. By replacing this water molecule with arogenate and performing a  
structure optimisation, a proposed model of active site showing key interactions between residues 
and arogenate was generated (Figure 2).11 
 
Figure 2 - Proposed model of the active site of Arogenate Dehydrogenase with Arogenate.11 
These projected interactions included the carboxyl group of arogenate pointing towards a 
hydrophobic pocket of Leu225, Met228 and Met229 which promotes the concerted 
decarboxylation reaction. The amino acid residue His112 is in close proximity to the 4-hydroxyl 
group of arogenate, whilst this facilitates hydride transfer it cannot abstract the hydroxyl proton 
preventing dienone formation as seen in the stepwise mechanism (Scheme 4). Whereas, the 
interaction between the C4 of NADP and the hydride at the C4 position of arogenate is optimised 
for hydride transfer. These modelled interactions also supported previous biochemical studies.11–
13 They therefore proposed the mechanism within the active site is a concerted mechanism 





Scheme 5 - Reaction mechanism of arogenate dehydrogenase. 
1.2 Herbicides and metabolic diversity  
1.2.1 Current herbicides  
There are various classes of herbicides depending on their mode of action. Of particular interest 
to this project are herbicides which inhibit the shikimate pathway toward AAAs. Both 
phosphonomethylglycinamide 9 (huangcaoling) and phosphonomethylglycine 10 (glyphosate) 
are enolpyruvylshikimate-3-phosphate (EPSP) synthase inhibitors, an enzyme involved early in 
the shikimate pathway (Figure 3).14 
 
Figure 3 - EPSP synthase inhibitors. 
These work by mimicking phosphoenolpyruvate 12 and binding competitively to EPSP synthase, 
the enzyme which catalyses the reaction of 11 to 13 (Scheme 6), and shuts down the pathway to 
AAAs.14–16  
 
Scheme 6 - EPSP synthase catalysed reaction. 
In 1970, Monsanto chemist John E. Franz first synthesised and tested glyphosate 10 for 




history.17,18 In 2014, the total worldwide glyphosate use was over 825,000,000 kg. Since it came 
to market in 1974, the global production of glyphosate has topped 8,563,000,000 kg.19 Following 
the introduction of glyphosate resistant genetically modified crops in 1996, the sales of glyphosate 
have increased almost 15-fold.19,20 Despite this, there are conflicting reports as to the safety of its 
use. In 2015, a World Health Organisation assessment identified glyphosate as ‘probably 
carcinogenic to humans’.21,22 However, there have since been articles published to dispel this 
statement which state that the replacement of glyphosate with other herbicides ‘is likely to have 
a negative impact on chronic health risks faced by pesticide applicators’.23 A meta-analysis 
published in 2019 by Zhang et al. reported that the risk of non-Hodgkins lymphoma was increased 
with the use of glyphosate-based herbicides particularly in high exposure groups.24 
1.2.2 Arogenate dehydrogenase and dehydratase inhibitors 
It has long been thought the use of arogenate analogues would make for potent competitive 
inhibitors of arogenate dehydrogenase and dehydratase.8,9 Similarly to glyphosate, arogenate 
analogues could feasibly inhibit enzymes in the shikimate pathway; however, unlike glyphosate 
this would occur at a much later stage in the pathway. A quick and efficient synthesis of arogenate, 
which would be easily modified to produce analogues, would prove an attractive target. There are 
several possible sites for derivatisation of arogenate (Figure 4). However, to date there have been 
no reports of arogenate variants despite the two total syntheses published in the literature (Section 
1.3). 
 
Figure 4 - Points of derivatisation of arogenate. 
1.2.3 Metabolic diversity 
Since arogenate’s discovery in 1974, it has been found that several plants and bacteria, including 
blue-green algae which was first discovered to utilise this pathway, produce AAAs via the 
arogenate pathway only.5 Others, such as the bacteria Pseudomonas aeruginosa utilise both the 
arogenate and phenylpyruvate pathways.25 It has also been previously reported that prephenate 
dehydrogenase has not been detected in several species including mung bean,26 corn,27 




In 1986, Zamir et al. investigated the pathways in operation towards phenylalanine 3 in higher 
plants (Scheme 7), namely Nicotiana sylvestris (tobacco) and spinach.33 They reported the 
presence of arogenate dehydratase in these vascular plants, whilst no prephenate dehydratase was 
found. The presence of only arogenate dehydratase suggests this pathway is used almost 
exclusively to produce AAAs.  
 
Scheme 7 - Pathways to L-phenylalanine; Arogenate pathway (green) and phenylpyruvate pathway 
(red). 
In 2007, Lewis et al. further explored the dehydratases involved in production of L-phenylalanine 
(Scheme 7) in Arabidopsis thaliana.34 The group cloned and expressed six genes from 
Arabidopsis; At1g11790, At3g07630, At2g27820, At3g44720, At5g22630, and At1g08250, and 
explored their activities. Previously these genes were considered PDT-like until 2005 when they 
were relabelled, by Douglas et al., as ADTs (ADT1 to ADT6) despite a lack of functional 
characterisations.35 From the work reported by Lewis et al. these have now all been provisionally 
characterised as arogenate dehydratases as a result of the functional characterisation carried out 
in this work. In particular, the genes ADT3, ADT4 and ADT5 utilised arogenate only, whereas, 
genes ADT1, ADT2 and ADT6 showed activity for mainly arogenate and low levels for 
prephenate.  
These reports suggest there is considerable metabolic diversity in the biosynthesis of AAAs in 
plants, particularly in higher plants. It is hoped that this metabolic diversity may provide a source 






1.3 Previous syntheses  
The first reported synthesis of arogenate was by Danishefsky et al. in 1981.36 They achieved the 
synthesis of arogenate, and its epimer, in eight steps with a key Diels-Alder reaction used to 
construct the dienone core (Scheme 8).  
 




Starting from L-pyroglutamate 14, L-glutamic acid in its cyclic lactam form, the enol reacts with 
the imine to produce an enamine which is followed by hydrolysis. The hydrolysed species 16 is 
then reacted with diphenyl disulfide and tri-n-butylphosphine to produce the vinyl sulphide 17. 
Oxidation using m-CPBA produced the sulfoxide 18 which then underwent the key Diels-Alder 
reaction to give 19. This was followed by reduction of the ketone, hydrolysis of the carbamate 
and ester linkages and finally hydrolysis of the lactam ring to generate the desired arogenate 
product 1. The authors stated that small amounts of phenylalanine and tyrosine were observed 
after the final step which could be separated using ion-exchange chromatography. It was also 
found that leaving the hydrolysis reaction for extended periods resulted in larger conversion to 
these undesired AAAs. However, a major drawback to this report is that no yield is quoted for the 








Scheme 9 - Crossley et al. synthesis of arogenate. 
In 1994, Crossley et al. published an alternative synthesis of arogenate in nine steps, utilising a 
Michael addition as the key step with an overall yield of 2.1% (Scheme 9).37 Using methyl 
benzoate 22 as the starting material, 1,4-dihydrobenzoate was produced using a Birch reduction 
followed by esterification using MeOH/BF3•Et2O to 23, as reported by Folsom et al.38 
Deprotonation and quenching with methyl 2-acetamidoacrylate was then carried out to produce 
the spirolactam 24. Hydrolysis of the ester, conversion to the acid chloride and finally 
esterification with (+)-menthol produced 25. They then performed a fractional crystallisation in 
order to separate the diastereomers, followed by acylation of the nitrogen to give the carbamate 
27. Oxidation of the C4 position with CrO3/3,5-DMP followed by reduction with DIBAL 




basic conditions to give arogenate 1 as the disodium salt. The authors noted issues with 
decomposition to phenylalanine and tyrosine being present in all samples of arogenate but 
provided no further information or a solution to overcome this. As part of this project, we reached 
out to Professor Maxwell Crossley in August 2019 who kindly supplied us with a copy of the 
thesis of Robert C. Reid in October 2019 to provide some more detail around this synthesis and 
provide insight into our own work. 
Nachtsheim et al. reported a partial synthesis of the arogenate core in 2012 using an oxidative 
iodine(III)-mediated spirocyclisation.39 Their work so far has produced a spirodienone lactam 32 
which they envisage could then undergo enantioselective reduction, N-deprotection, dienone 
reduction, ester hydrolysis and finally ring opening to give arogenate 1 (Scheme 10).  
 
Scheme 10 - Nachtsheim et al. proposed arogenate synthesis. 
First attempts at the spirocyclisation gave traces of the desired product 32 and a 40% yield of an 
undesired monohydroxylated product 37. Conveniently, this species could be converted to the 





Scheme 11 - First attempts and mechanism of spirocyclisation. 
Optimisations of the iodine(III)-mediated spirocyclisation were then carried out investigating 
temperatures, equivalents, solvents, generation of PIFA in situ and the effect of the ester 
substituent. The optimisation studies resulted in an increase in yield to 52% of the desired 
spirocyclic lactam 32, conditions below (Scheme 12). However, a readily separable side product 
was observed and found to be the 6-membered spirolactone 38. They state further studies into 
enantioselective reductions are underway, although to date no further papers have been published 
detailing this work. 
 




1.4 Dearomatising cyclisation 
There are several classes of dearomatising cyclisations. These types of reactions have been 
performed on various aromatic starting materials such as pyridines,40,41 furans,42,43 indoles44,45 and 
phenols.46,47  
1.4.1 Dearomatising spirocyclisations in the Clayden group 
Work in the Clayden group has focused upon dearomatising spirocyclisations of pyridine using 
various nucleophilic tethers. Initial work explored using lithiation chemistry of benzyl amides to 
produce spirocyclic β-lactams. Lithiation could be carried out alpha to the nitrogen; the resulting 
carbanion could then undergo nucleophilic attack onto the pyridine and quinoline carboamides. 
The use of LDA at 0 °C and addition of an electrophile produced cis-fused 5-endo cyclisation 
products 40. However, it was found that with deprotonation with LDA at -40 °C, directly followed 
by addition of an acylating agent altered reactivity to favour the 4-exo spirocyclic product 41. The 
reaction was successful with a range of acylating agents including methyl chloroformate, benzyl 








Scheme 13 - Pyridine and quinoline carboxamide spirocyclisations using LDA. 
Later, dearomatising spirocyclisations of N-anisylisonicotinamides, 47, with a tethered electron 
rich aryl group were found to occur upon exposure to trifluoromethanesulfonic anhydride 




pyridinium ring 48. This spirocyclic reaction was exploited to produce spirocyclic piperidines 
which are a moiety of interest in biologically active compounds such as MK-677 (Scheme 14).49 
 
Scheme 14 – Spirocyclisation of N-anisylisonicotinamides leading to spirocyclic piperidines. 
The spirocyclisation reaction was applied to a large range of derivatives to explore the substrate 
scope (Scheme 15). In most cases, the use of meta-substituted starting materials resulted in the 
regioisomeric products 53-55. As might be expected, electron deficient phenylamides impeded 
the spirocyclisation whereas electron donating groups activated the aryl ring towards nucleophilic 
attack.49 
 




The reaction was then applied to produce an isonicotinamide analogue. Switching from the amide 
to the ester 58 resulted in a lower reactivity with a yield of 43%; this is likely due to the ester 
moiety being less activating and its favoured s-cis conformation (Scheme 16).49 
 
Scheme 16 - Isonicotinic ester spirocyclisation. 
Further work in the group expanded these spirocyclisations of isonicotinamides to the use of 
nucleophilic heterocyclic tethers. Pyrroles, furans and thiofurans were used to explore the 
spirocyclisations reactions. A 1-substituted pyrrole and 3-substituted furan and thiophene all 
underwent spirocyclisation by nucleophilic attack from their 2-positions to give 61, 63 and 65 
respectively (Scheme 17).50 
 
Scheme 17 - 1-Substituted pyrrole and 3-substituted furan and thiophene spirocyclisations. 
With 2-substituted pyrroles, cyclisation occurred from the 3-position to give 67. Interestingly, the 
use of 2-substituted furans resulted in a doubly-dearomatised spirocyclisation producing two 
adjacent spirocyclic centres 69a/b (Scheme 18). This product resulted from initial reaction at the 
2-position of the furan; the resulting allylic oxonium ion was then trapped regioselectively by 




as nucleophiles giving reasonable yields. The addition of the trityloxy group occurs on the less 
hindered face of the furan, 69a, giving excellent diastereoselectivity.50 
 
Scheme 18 – Spirocyclisation of a 2-substituted pyrrole and furan. 
Finally, these spirocyclisations were applied to an alkenyl tether to give unsaturated 2,8-
diazaspiro[4.5]decanes which are of potential biological interest. The methodology was applied 
to a large range of both acyclic and cyclic alkene tethers linked by an amide to a pyridine or 
quinoline ring (Scheme 19). Reactions where a new stereocentre is formed, due to the 





Scheme 19 – Dearomatising spirocyclisations of pyridine and quinoline with alkenyl tethers. 
Several related products were also produced using chloroformates in place of the triflate 
electrophile in moderate to excellent yields. The reaction was expanded to the use of a 2-pyridine 
ring to allow for an ortho-spirocyclisation to take place giving 84. Pyrimidine rings were also 
found to undergo the dearomatising cyclisation to produce 86 (Scheme 20). All reactions proceed 
in between 5:1 and 9:1 dr but characterisation was not obtained due to their instability.51 
 




1.4.2 Dearomatising spirocyclisations of phenols 
The dearomatisation of phenol is an important transformation, allowing complexity to be built 
from a simple planar core. It has been a prominent reaction in the synthesis of complex natural 
products.52,53 Examples of natural products which have been successfully synthesised by 
exploitation of a dearomatising spirocyclisation include (+)-maritidine,54 dalesconol B,55 
platensimycin,56,57 and spirobacillene A58 (Figure 5), all of which will be discussed in greater 
detail later. 
 
Figure 5 - Examples of natural products synthesised using a key dearomatising spirocyclisation. 
Spirocyclic dienones are also an important motif in natural products such as argutosine D,59 
hopeanol,60 glaziovine,61 stepharine,62 annosqualine62 and spirocalcaridine B63 (Figure 6). 
 
Figure 6 - Natural products containing the spirocyclic dienone motif. 
The dearomatising spirocyclisation of phenols to yield spirocyclic dienones can be split into 
classifications depending on the mechanism involved. The most common method to produce 




oxidation of the phenol occurs followed by intramolecular ipso-cyclisation with a carbon 
nucleophile. Other methods include radical (Scheme 21b) spirocyclisations, as well as 

















Scheme 21 - Various methods to prepare spirocyclic dienones. 
Herein, we will discuss examples of these three methods to produce spirocyclic dienones, with a 
particular focus on the electrophilic approaches and tyrosine-based spirocyclisations which mirror 
our own work. 
1.4.3 Nucleophilic (oxidative) dearomatising spirocyclisations 
Oxidative nucleophilic approaches towards spirocyclic dienones are the most prevalent method 
seen in the literature. Numerous tethered nucleophiles have been utilised to achieve a variety of 




Guillou et al. employed a tethered aromatic ring in an oxidative spirocyclisation. The group 
discovered 1,2-dispirodienone 108 was produced in 15% yield from p-hydroxy acetanilide 106 
using a hypervalent iodine-mediated oxidative spirocyclisation method. They proposed this 
product was produced via oxidation of the phenol 106 to give 107, followed by loss of 
trifluoroethyl group.  107 was also isolated in 10% yield from the same reaction; to test this theory 
they subjected 107 to PIFA and obtained the spirocycle 108 exclusively in 75% yield. The group 
were able to produce a library of substituted 1,2-dispirodienones utilising this method and plan to 
further explore the method and the biological activities of these products (Scheme 22).64.  
 
Scheme 22 - Proposed spirocyclisation mechanism of p-hydroxy acetanilides by Guillou et al. 
Shigehisa et al. exploited an enamide tether 113, which could be prepared from the corresponding 
3,4-dihydroisoquinoline by acylation, in their work towards a spirodienone moiety.65 Using 
iodobenzene diacetate in trifluoroethanol at 0 °C, followed by reduction with NaBH4, the 




efficient route towards the proaporphine alkaloids Stepharinine (Scheme 23 - 94) and 
Pronuciferine (NH→NMe). 
 
Scheme 23 - Proposed mechanism of a tethered enamide spirocyclisation by Shigehisa et al. 
An oxidative spirocyclisation was exploited by Nicolaou et al. in their synthesis of platensimycin 
89. The reaction used PIDA as an oxidising agent in trifluoroethanol at -10 °C and afforded 120 
with a 68% yield (Scheme 24).66,67 
 
Scheme 24 - Spirocyclisation used in Nicolaou et al. synthesis of platensimycin. 
This method was later applied to alternative longer 121, branched 123 and linear chains 125; 







Scheme 25 - Spirocyclisation of allyl silanes reported by Nicolaou et al. 
1.4.4 Tyrosine-based spirocyclisations 
All tyrosine-based spirocyclisations in the literature reported thus far have been nucleophilic. The 
first of these reported in the literature was in 1988 by Pham et al., in which they report the 
synthesis of morphine alkaloids and analogues. A spirocyclisation of 127 was carried out using 
oxidation conditions to produce a salutaridine derivative (Scheme 26) in low yield, which could 
be later converted to codeine.68 
 




Spirolactams have been produced from tyrosine amides via oxidation using PIFA.69 Previous 
work had found the tendency for the oxygen atom of an amide to react with the electrophilic 
phenol ring, via an iminoether, which gives rise to spirolactones rather than the desired 
spirolactams (Scheme 27a).70 To overcome this, Peters et al. developed the 2-oxazolines 133 
which favour attack from the nitrogen and give rise to spirolactones 135 (Scheme 27b).69 
 
Scheme 27 – (a) Spirolactones from tyrosine amides and (b) Spirolactams from tyrosine oxazolines. 
These types of spirocyclisations have also been utilised in the synthesis of natural product 
discorhabdin A starting from the tyrosine methyl ester. Initial attempts at the total synthesis 
looked at carrying out a synthetic study to produce the core of discorhabdin A (Scheme 28). 71,72 
 




This model study was then applied to the total synthesis in which spirocyclisation of the more 
complex 142 was carried out giving 143 as a mixture of two diastereomers in a 1.5:1 ratio (Scheme 
29). 
 
Scheme 29- Tyrosine based spirocyclisation seen in the synthesis towards Discorhabdin A. 
A catalytic, hypervalent iodine-mediated spirocyclisation has also been achieved with H2O2 as the 
terminal oxidant, in which a variety of phenols undergo dearomatisation to form a new C-C bond 





Scheme 30 – Catalytic oxidative spirocyclisation of a tyrosine-based compound 144. 
In the reaction mechanism, bis(trifluoroacetyl) peroxide − generated in situ from TFAA and 
peroxide − oxidises the iodoarene giving the active catalyst species 146. This reactant can then 
carry out oxidation of the phenolic oxygen of 144, which in turn allows spirocyclisation to take 
place with concomitant regeneration of the iodoarene. The method has been applied to a variety 
of other phenolic substrates with yields between 51-80% (Scheme 30).73  
A spirocyclisation of N-protected tyrosine has been achieved using a polymer-supported 
hypervalent iodine oxidant (Scheme 31).74 These types of spirocyclisations have also previously 
been achieved with non-resin hypervalent iodine in the synthesis of antitumor antibiotic 





Scheme 31 – Spirocyclisation of N-protected tyrosines. 
1.4.5 Radical dearomatising spirocyclisations 
Radical dearomatisations are a subsection of nucleophilic spirocyclisations and are less prominent 
in the literature. However, a number of notable examples have been reported by several groups.  
 




Whiting et al. described a spirocyclisation of thiohydroxamate ester, 151, when heated under 
reflux and irradiated with a tungsten lamp. They demonstrated a radical ipso-addition of a carbon 
radical to an aromatic unit to produce a para-spirodienone (Scheme 32).77,78 The group utilised 
18O isotopic labelling of the biaryl ether to explore the mechanism. They proposed a mechanism 
in which an N-O homolysis occurs followed by decarboxylation to give 152 which can then 
undergo a cylisation to 153. A 6-endo-trig trapping of the carbon radical by oxygen of the ortho-
nitro group occurs, followed by N-O α-scission and finally fragmentation of the intermediate 













Scheme 33 - Proposed mechanism to spirocyclohexadienones Curran et al. 
Curran et al. described a radical spirocyclisation procedure for spirooxindoles and 
spirodihydroquinolones.79  They proposed the aryl radical 158 could cyclise in an ortho (a) or 
ipso (b) fashion to  give 159 or 160 which can interconvert by a 1,2 shift. Oxidation or β-
fragmentation of these products produced 161 or the spirodienone 162 (Scheme 33). They then 
utilised this technique in the formal synthesis of SR121463A, 166, a selective vasopressin 
inhibitor, and aza-Galanthamine 169 (Scheme 34). These examples demonstrate the effectiveness 






Scheme 34 - Curran et al. formal synthesis of (a) SR121463A via a spirooxindole and (b) aza-
galanthamine. 
A radical oxidative spirocyclisation reaction was reported by Kita et al. whilst studying aryl-aryl 
coupling using phenyliodine bis(trifluoroacetate) and a heteropoly acid, H3[PW12O40], as an 
alternative to heavy metal oxidising reagents. The use of phenol ether derivatives 170, particularly 
para-methoxy, allowed for preferential formation of spirodienones 174 over biaryls 173 in the 
presence of a water source (Scheme 35).80 They propose that the simplicity of the method, along 
with its lack of heavy metal reagent requirement and ease of handling of phenol ethers over 






Scheme 35 - Proposed mechanism to biaryls and spirodienones by Kita et al. 
A carbamoyl radical tether has been applied to a range of substituted phenol derivatives in a 
dearomatising spirocyclisation by Miranda et al. to produce spirodienonamides 176 (Scheme 36). 
By utilising carbamoylxanthates 175, carbamoyl radicals capable of undergoing radical 
spirocyclisation were generated.81 
 
Scheme 36 - Spirocyclisation with carbamoyl chlorides reported by Miranda et al. 
In their initial study, which employed dilauroyl peroxide in dichloroethane under microwave 
irradiation, they observed an undesirable thermal decomposition to give N-t-butyl-
dihydroisoquinolones 183 (Scheme 37 - path B). However, when the reaction was conducted at 
room temperature, with triethylborane as the radical initiator, the spirocycle 182 was afforded as 
the major product (Scheme 37 - path A). The group carried out computational modelling to 
explore these cyclisation pathways, finding the spirocyclisation transition state (Scheme 37 - path 
A)  is 4.64 kcal mol-1 lower compared to the direct ortho cyclisation (Scheme 37 - path B) This 
method was then successfully applied to several other examples, including a naphthalene 
derivative and even substrates with electron-withdrawing bromo substituents at both ortho and 






Scheme 37 - Proposed mechanism to give spirocycles and N-t-butyl-dihydroisoquinolones Miranda 
et al. 
1.4.6 Electrophilic dearomatising spirocyclisations 
There are numerous examples of electrophilic dearomatising spirocyclisations in the literature. 
These reactions employ a variety of leaving groups including sulfonates and halides as well as 
electrophilic tethers such as alkenes/alkynes, allenes, epoxides and nitriles. 
An early example of an electrophilic spirocyclisation by Masamune utilised a tethered sulfonate 
leaving group 184 to produce a spirodienone 185 in a 90% yield (Scheme 38).82  
 
Scheme 38 - Masamune spirocyclisation using a tosyl tether. 
To explore whether this spirocyclisation could occur with a less conformationally flexible starting 
material, Swanson et al. performed a similar reaction with the tetrahydrobenzocycloheptene 





Scheme 39 - Spirocyclisation using a tosyl leaving group reported by Swanson et al. 
Although in a much lower yield of 57%, the reaction did still proceed, demonstrating the 
versatility of this spirocyclisation.83 In addition to these examples, the use of a tethered sulfonate 
for a spirocyclisation has also been exploited in a concise total synthesis of platensimycin by 
Njardarson et al in 2009.56 
Gajewski reported a spirocyclisation reaction to 189 involving the electrophilic attack of a 
nitrilium ion (Scheme 40).84 Upon heating 189 in DMSO, these products could then undergo a 
rearrangement to rearomatise and give γ-(4-hydroxyphenyl)-α-phenylacetoacetonitrile, thus 
showing the mild instability of these spirocycles. 
 
Scheme 40 - Gajewski spirocyclisation using a nitrile tether. 
Halogens have also been exploited as a leaving group in dearomatising electrophilic 
spirocyclisations. An excellent example of this was demonstrated in a paper by Whiting et al. 
describing a variety of spirocyclisations using an iodine tether. This allowed for the production 
of tricyclospirodienones, which are valuable synthetic precursors to steroid mimics, following 





Scheme 41 - Spirocyclisations using an iodide leaving group reported by Whiting et al. 
As seen with other electrophilic spirocyclisations, the use of potassium t-butoxide in refluxing t-
butyl alcohol gave the desired spirocyclisation products in moderate to excellent yields. Whiting 











Scheme 42 - Spirocyclisations with a tethered epoxide reported by Whiting et al. 
Applying the same conditions used for the iodide tether, only the C2 chain epoxide 196 was 
successful in undergoing cyclisation. The 199 and 202 epoxides failed to react in either an 7- or 
5-endo fashion at the primary carbon, or a 4- or 6-exo cyclisation at the secondary carbon. The 
phenolic epoxide 196, with a two carbon tether, afforded the 6-endo stereoisomer 197 only (60% 
- Scheme 43 - green) with no evidence of a competing 5-exo cyclisation to 198 (Scheme 43 - red) 
– indicating that the cyclisations of epoxides are more constrained.85,86 
 
Scheme 43 - Whiting et al. possible regioisomers and their mechanisms. 
A palladium(0)-catalysed spirocyclisation reaction was developed by Buchwald et al. which 





Scheme 44 - Spirocyclisation utilising an activate aryl halide tether reported by Buchwald et al. 
They proposed a catalytic cycle beginning with oxidative addition into the carbon-bromine bond, 
followed by the electrophilic attack and finally reductive elimination (Scheme 45). 
 
Scheme 45 - Buchwald et al. proposed spirocyclisation mechanism. 
The scope of the reaction was explored with 14 aryl halides which cyclised in yields ranging 
between 44-91%. They investigated various ring substitutions, naphthalene derivatives and a 
longer tether chain length (n = 2). Electron donating groups were well tolerated on both rings. 
However, electron withdrawing substituents proved more challenging. When electron 
withdrawing groups were incorporated into the aryl halide, the reaction required either reduced 
concentrations or increased catalyst loading to proceed. Electron withdrawing substituents on the 
phenol ring reduced the electron density of the arene leading to complete shutdown of the 
spirocyclisation reaction. 
Activated alkynes have been reported in the literature to undergo spirocyclisation reactions when 
tethered to a phenol group.88–91 For example, Unsworth et al. reported an efficient synthesis of 





Scheme 46 - Spirocyclisation with a tethered activated alkyne reported by Unsworth et al. 
Using these conditions, they produced eight spirodienone products 210 in high yields. Examples 
included a simple butyl chain, phenyl, 4-methoxyphenyl, protected amines and alcohols, along 
with cyclopropane and cyclopentane in the R1 position and a methoxy substituent in the R2 
position. Most interestingly, the authors reported that ortho-spirocyclisations, to give 212, were 
viable using this method in yields between 90-99% (Scheme 47). 92 
 
Scheme 47 - Unsworth et al. ortho-spirocyclisation. 
They also demonstrated the versatility of the ortho spirocyclisation reaction conditions with 4 
examples, R1 = Cyclopropane, phenyl, 4-methoxy phenyl and 4-fluorophenyl (Scheme 47).  
Alkenes are another well utilised tether for electrophilic spirocyclisations of phenols.93,94 You et 
al. reported an iridium catalysed asymmetric spirocyclisation using an allylic carbonate tether 213 
(Scheme 48).95  They produced 11 examples with moderate to excellent yields and reasonable 
enantioselectivity. Examples included a variety of substitutions on both the phenol ring and chain, 
chain lengths (n = 1 and 2) and both carbon and nitrogen linkers (X).  
 




Mukherjee et al. utilised electrophilic spirocyclisations of phenols in total syntheses of the 
sesquiterpenes (±)-norzizanone and (±)-zizanene, demonstrating the usefulness of this reaction in 
the synthesis of complex natural products.96,97 In both syntheses, a halogen tethered 
spirocyclisation is exploited with a final functional group interconversion step allowing the 
synthesis of (±)-zizanene from (±)-norzizanone (Scheme 49). 
 
Scheme 49 - Use of a phenol ether spirocyclisation in natural product synthesis by Mukherjee et al. 
Other electrophilic spirocyclisation examples include nucleophile tethers, propargyl 
bromides/carbonates,98 activated allenes,99 along with other reports of  sulfonates,100 activated 
alkynes,101,102 activated alkenes103,104  and allylic carbonates105. To the best of our knowledge, no 
electrophilic spirocyclisations that yield dienones have utilised a carbamoyl chloride tether. 
1.5  Previous work  
Previous work in the group focused on producing imidazolidinone-derived carbamoyl chlorides 
to couple with nucleophiles to be utilised in synthesis of amino acids.106 Attempted coupling of 
the tyrosine derived carbamoyl chloride 220 with N-methylaniline to produce the corresponding 
urea 220 led to the discovery of an alternative spirocyclisation reaction to the dienone 222 





Scheme 50 - Alternative spirocyclisation reaction discovery 
It was proposed that the reaction proceeded via a more reactive, transient carbamoyl iodide 
generated in situ from potassium iodide (Scheme 51). 
 
Scheme 51 - Proposed mechanism of the alternative spirocyclisation reaction. 
The group postulated that this spirocyclic intermediate 222 could function as a precursor to the 




hydrolysis (Scheme 52). The diastereoselective reduction of 222 proceeded in moderate yield to 
225 and reasonable diastereoselectity in favour of the desired stereoisomer. 
 
Scheme 52 - Proposed route to arogenate. 
However, the hydrolysis of the reduced imidazolidinone did not proceed as expected, instead 
resulting in undesired products, one of which was identified as the dihydroisoquinolinone 226 
(Scheme 53). 
 





2. Results and discussion  
2.1 Aims of the project 
This project aimed to exploit a somewhat unconventional and previously unexplored starting 
material in the synthesis of arogenate, its own biosynthetic end product L-tyrosine, to give a 
process which is effectively the inverse of plant metabolism. We hoped that this ‘reverse-
biomimetic’ approach starting from an inexpensive, chiral amino acid would provide an efficient 
route to arogenate that would also provide an opportunity to generate analogues (Scheme 54). 
 
Scheme 54 - Overview of the synthetic concept. 
The project set out to investigate three interlinked routes, the original imidazolidinone route, an 
oxazolidinone route and a hydantoin route, and their feasibility to produce arogenate (Figure 7).  
 
Figure 7 - Expected products of the penultimate steps of the three routes. 
Since the imidazolidinone hydrolysis proved problematic, analogous oxazolidinone route was 
exploited as a means of overcoming this issue. It had been reported in the literature that the 
hydrolysis of oxazolidinones requires much milder conditions than their imidazolidinone 
counterparts.107 The use of an analogous hydantoin moiety was also investigated as the group has 
previously demonstrated their ease of synthesis and use in producing amino acids upon 
hydrolysis.108 
The second part of the project focused upon producing a variety of arogenate analogues as 
potential competitive inhibitors of ADH or ADT thereby interrupting aromatic amino acid 






Scheme 55 - Enzyme inhibition by arogenate derivatives. 
In particular, we intended to generate analogues which either remove or reduce the possibility of 
rearomatisation, as these would represent ideal candidates for agrochemical enzyme inhibition 
studies.4,10 
2.2 Unsuccessful routes 
2.2.1 Hydantoin route 
The hydantoins, 230 & 231, were synthesised from the methyl ester of tyrosine using a route 
which has been previously optimised within the group. From this species, phosgenation was 
performed to install the carbamoyl chloride unit, giving the potential precursor to the spirocycle 
228 (Scheme 56). 
 






2.2.1.1 Silyl route 
The first route explored the use of a silyl protecting group on the alcohol which was easily 
installed by reaction of L-tyrosine methyl ester 234 with TBSCl and imidazole to produce 235 in 
excellent yield. The heterocyclic core was then generated by firstly forming the urea 236 in a 
good yield using t-butyl isocyanate, followed by cyclisation using potassium t-butoxide to give 
the hydantoin 230 in a moderate yield (Scheme 57). 
 
Scheme 57 - Synthesis of hydantoin, 230, from amino acid ester, 234. 
Acylation was performed with either triphosgene or phenyl chloroformate in modest yields of 40 
and 41% respectively (Scheme 58). 
 




Unfortunately, desilylation of the phenol caused unforeseen issues. In both cases, the carbamate 
and carbamoyl chloride functionalities were removed as well as the silyl group, giving undesired 
hydantoins 238 (Scheme 59). 
 
Scheme 59 - Attempted removal of the silyl group. 
Silyl ethers have been reported to undergo spirocyclisation directly,99 so the possibility that 232 
may be capable of undergoing an in situ spirocyclisation/deprotection was proposed. In this case, 
the proposed spirocyclisation would first occur to give 240 followed by silyl deprotection by the 
chloride ion to give the desired spirocycle 228 (Scheme 60). 
 




A variety of conditions were trialled for this tandem reaction (Scheme 61); however, in all cases 




Scheme 61 - Attempted spirocyclisation of protected carbamoyl chloride, 232.* 
2.2.1.2 Benzyl route 
Since it appeared that the silyl group could not be removed without compromising the acyl group, 
a new method was developed based on the benzyl protecting group strategy which had proved 
successful in the imidazolidinone route (Section 2.3). The unprotected carbamoyl chloride 243 
could be produced in four steps. The first three steps of coupling with t-butyl isocyanate, 
cyclisation with potassium t-butoxide and acylation with triphosgene to give the protected 
carbamoyl chloride 233 followed the same procedures as the silyl route (Section 2.2.1.1). The 
carbamoyl chloride 233 was then debenzylated by hydrogenolysis to yield the precursor to 
spirocyclisation 243 (Scheme 62).  
 




Scheme 62 - Synthesis of the unprotected carbamoyl chloride, 243. 
With this in hand, several conditions for spirocyclisation were explored (Scheme 63). 
Unfortunately, no evidence of spirocyclisation products was observed. The first conditions 
trialled mirrored the conditions used in the imidazolidinone route (Section 2.3). However, a 
complex mix of undesired products was observed. Repeating these conditions without the use of 
potassium iodide was also explored as it was thought that any transient carbamoyl iodide formed 
may simply be too unstable to cyclise; however, this also gave a complex mixture of products. A 
final reaction with an alternative base, potassium carbonate, was attempted but again proved 
unsuccessful. From this reaction, a major ion peak was observed by mass spectrometry which 
suggested formation of the dimer 244; however, the mixture was inseparable by chromatography 
and was not explored further (Scheme 63). 
 




Accordingly, this route was suspended in favour of more productive avenues, with the conclusion 
that the conformation of the hydantoin is likely not oriented in such a way that it is in close enough 
proximity to facilitate the spirocyclisation. Computational modelling and crystal structures of 
these compounds may help determine if this is the case but this was not probed further due to 
success obtained in other routes (Section 2.3). 
2.2.2 Oxazolidinone route 
Similarly to the imidazolidinone route, an amino-acid-derived imine can be produced which can 
undergo cyclisation on treatment with an acylating agent.107 However, in this work, benzaldehyde 
was used instead of pivaldehyde to produce the imine. This was due to reports in the literature 
that the major product diastereoisomer formed in the cyclisation could be skewed by variation of 
the aminal substituent.109 The use of pivaldehyde resulted in cis selectivity, whereas  
benzaldehyde offered trans selectivity. It was then hoped that this oxazolidinone analogue would 
be susceptible to the same spirocyclisation reaction observed with imidazolidinones and generate 
a variant which would be more easily hydrolysable (Scheme 64).107 
 
Scheme 64 - Oxazolidinone - synthetic concept. 
The Schiff base 245 was synthesised according to a protocol reported by Davies et al.110 O-tert-
Butyl-L-tyrosine 247 was dissolved in sodium hydroxide and concentrated to produce the salt 






Scheme 65 - Method for producing imine. 
With the imine in hand, cyclisations were then attempted (Scheme 66). Initially the conditions of 
phosgene addition at -78 ⁰C were tested as low temperatures had been reported to favour the 
kinetic trans oxazolidinone.110 However, this approach gave a complex mixture in which the 
desired product could not be discerned. The less reactive phenyl chloroformate was then 
employed as the acylating agent but once again a complex mixture was produced. A final attempt 
was made using phenyl chloroformate in the presence of sodium hydride, to ensure the 
carboxylate of the starting material was fully deprotonated; however, this gave only a complex 
mixture. Possible traces of the desired product were observed following purification but in such 
small quantity as to be impractical for further exploitation. 
 
Scheme 66 - Attempts at tandem acylation/cyclisation. 
Previous work found the reaction of O-methyl protected tyrosine with phosgene resulted in 
formation of the N-carboxyanhydride 249. It was thought that this heterocycle could possibly be 
used in the synthesis of arogenate; however, attempts at phosgenation of this species resulted in 
polymerisation (Scheme 67).* 
 
 





Scheme 67 - An attempted phosgenation of N-carboxyanhydride 249. 
To ensure there were no issues with the starting material, a control reaction with benzoyl chloride, 
the acylating agent of choice as reported by Seebach et al. for producing oxazolidinones,109 was 
carried out (Scheme 68). The reaction proceeded in a modest yield of 37% and 4:1 dr. The same 
reaction was also previously performed using the equivalent O-methoxy tyrosine derivative which 
proceeded with a good yield of 70% and 2:1 dr.* This reaction showed that there was no issue 
with starting material and that instead problems were occurring due to the alternative acylating 
agent used. 
 

















2.3 Total synthesis of arogenate & its analogues 
2.3.1 Arogenate synthesis via an imidazolidinone route 
Since it appeared that the trans imidazolidinone was key to spirocyclisation, and the desired 
oxazolidinone could not be produced, attention returned to the imidazolidinone route. The original 
imidazolidinone route started from the O-benzyl-protected methyl ester of L-tyrosine which is 
commercially available (Scheme 69).  
 
Scheme 69 - Imidazolidinone route – overall synthetic concept. 
The Schiff base 251 was easily produced in two steps from the commercial ester 253. Firstly, 253 
was reacted with methylamine to generate the N-methylamide 254 in excellent yield. 
Condensation of 254 with pivaldehyde afforded the imine 251 in quantitative yield (Scheme 70). 
 
Scheme 70 - Synthesis of the Schiff base, 251. 
Tandem cyclisation/phosgenation of the imine 251 was then performed to yield the 
imidazolidinone, 252. Seebach et al. reported that, under kinetic control, intermediate 
acyliminiums (e.g 255) cyclise to give trans imidazolidinones preferentially so as to avoid 
clashing of the sterically demanding t-butyl and α-substituents (Scheme 71).111 The cyclisation 




trans imidazolidinone was desired as previous work found the cis isomer to be unreactive in the 
subsequent spirocyclisation. 
 
Scheme 71 - Phosgene cyclisation to 252 and possible mechanism. 
Unfortunately, a moderate yield of 55% was recovered in this step which may be attributed to 
poor solubility of the product in the purification step. Various solvent systems were trialled to 
help overcome this issue, but all proved unsuccessful; attempts at recrystallisation also proved 
futile resulting only in lower yields. Trituration with ether or 1:1 ether:pentane proved more 
effective than chromatographic purification giving an increase in yield to 72%. 
To enable the spirocyclisation reaction to occur, it was necessary for 252 to undergo 
hydrogenolysis to remove the benzyl protecting group, generating the phenol 220 in 95% yield. 
It should be noted that this debenzylation was carried out in THF in lieu of the more typical 
alcoholic solvents to avoid compromising the carbamoyl chloride moiety (Scheme 72). 
 
Scheme 72 - Hydrogenolysis of the benzyl protecting group. 
Previously, the spirocyclisation reaction of 220 had been performed using a mixture of 
triethylamine and stoichiometric potassium iodide at 60 ⁰C for 72 hours. It was proposed that the 
reaction went via a transient carbamoyl iodide, (Section 1.5 - Scheme 51). It was hoped the 




of conditions were screened in the microwave reactor, starting with conditions (Table 1– entry b) 
used previously in the group to perform a related Friedel-Crafts acylation.113  
Table 1 - Conditions for transferring the spirocyclisation reaction to the microwave. 
 
 Solvent Time 
Temp 
(⁰C) 




72 h 60 TEA 1.1 82 
Conventional 
heating 
b Acetonitrileb 5 min 150 Lutidine 1.1 




c Acetonitrileb 5 min 150 TEA 1.1 




d Acetonitrileb 5 min 150 TEA 0 




e Acetonitrileb 5 min 150 TEA 1.1 79 
Microwave 
(100mg) 
a 0.5M b 0.15M 
Using microwave irradiation, full conversion was observed after only 5 minutes. Substituting 2,6-
lutidine for the original base, triethylamine, gave no adverse effects (Table 1 - entry c). The 
reaction was also attempted without potassium iodide to determine whether pre-activation of the 
carbamoyl unit was necessary (Table 1 - entry e). The positive results showed that potassium 
iodide was not required for the spirocyclisation to proceed. Upon scaling up the reaction, a yield 
comparable to that obtained with conventional heating was obtained after purification (Table 1 - 
entry d). Interestingly, it was found that even at room temperature, starting material dissolved in 
DCM or CDCl3 showed signs of conversion to the spirocycle, 222, after 1 week – highlighting 
the favourable nature of this reaction. It was found that the reaction could be scaled up easily 
using concentrations up to 1 M, extending the reaction time to 10 minutes ensured full conversion 
in these larger reactions. Following work-up, the product appeared clean by NMR and required 






Scheme 73 - Luche reduction of the dienone 222. 
The spirocyclisation product 222 was reduced under Luche conditions to give a separable mixture 
of diastereomeric alcohols 225a and 225b (2.3:1 dr) in excellent yield (Scheme 73). It was found 
lowering the reaction temperature to -78 °C increased the diastereoselectivity to 3.1:1. With these 
products in hand, a variety of hydrolysis conditions to give arogenate, 1, could be explored. 
Provisional work suggested that barium hydroxide gave traces of the desired product in the basic 
hydrolysis of 225a (Scheme 74).* 
 
Scheme 74 - Preliminary hydrolysis result. 
Performing this reaction at lower temperature (30 °C) for extended time (16-18 h) resulted in 
fewer aromatic impurities; however, reduced conversion of the starting material was also 
observed. It was found that by simply washing the crude hydrolysis mixture with DCM, this 
unreacted starting material could be completely recovered. Hence, at this stage, it was deemed 
more of a priority to limit formation of unwanted aromatic impurities. 
 
Figure 8 - Structure of spiroarogenate 256.  
 





Figure 9 - Comparison of Zamir et al. isolated spiroarogenate (top) and synthetic spiroarogenate 
(bottom). 
Curiously, it was found that the major product produced was not in fact arogenate but another 
species bearing a remarkable similarity. Upon consulting the literature, it was discovered this 
species was most likely spiroarogenate, 256, itself a natural product previously reported by 
Zamir et al. upon isolation from red bread mould (Figure 8).114 256 is coincidentally also the 















2.3.2 Synthesis of analogues 
As previously mentioned, it has long been thought that analogues of arogenate may inhibit the 
arogenate enzymes and in turn produce herbicides or antibiotics.8,9 The natural products, 
arogenate and spiroarogenate, proved difficult to handle due to their small polar nature and 
inherent desire to rearomatise. Due to this, the project explored the application of this synthesis 
for the production of analogues, with particular interest in more stable analogues.  
2.3.2.1 ortho-Arogenate  
It was envisaged that the use of ortho-tyrosine 257 in the same synthetic pathway may lead to an 
alternative spirocyclisation reaction to give 259, which could potentially undergo hydrolysis to 
give a novel regioisomer of arogenate 260 (Scheme 75). 
 
Scheme 75 - Ortho spirocyclisation pathway to arogenate regioisomer 260. 
DL-o-tyrosine, 257, was commercially available and following a protecting group strategy using 
Boc anhydride and benzyl bromide, it was anticipated that the optimised method used to 
synthesise the para-tyrosine imidazolidinone could be employed. The protection strategy first 
involved installing a tert-butyloxycarbonyl group on the free amine to prevent N-benzylation in 
the next step. Using Boc anhydride and sodium hydrogen carbonate in a mixture of dioxane and 
water, the reaction proceeded to give 261 in good yield. Subsequent benzylation of both the acid 
and alcohol moieties was carried out using a mixture of benzyl bromide, potassium carbonate and 
tetraethylammonium iodide in DMF to give the protected species 262 in reasonable yield (Scheme 
76). 
 




Reaction of 262 with methylamine was performed using the standard conditions affording a good 
yield of 73% and 13% starting material recovery. Boc deprotection of 263 with acetyl chloride in 
methanol gave the desired product 264 in virtually quantitative yields (Scheme 77). 
 
Scheme 77 - Coupling with methyl amine and deprotection to 264. 
The debenzylated carbamoyl chloride 258 was obtained using previously applied procedures 
(Scheme 78 & Section 2.3). 
 
Scheme 78 - Synthesis of deprotected carbamoyl chloride 258. 
With this material in hand, the ortho spirocyclisation was attempted (Scheme 79). Using the same 
conditions optimised for the para derivative, complete consumption of the starting material was 
observed; however, the chemical shifts in the crude NMR spectrum appeared to be more 





Scheme 79 - Possible cyclisation products. 
Three plausible products were proposed; the expected spirocyclisation product 259, the Friedel-
Crafts acylation product 267 and the product of phenolic attack on the carbamoyl chloride to give 
a 7-membered ring 268. As each of these possible products had the same molecular weight, mass 
spectrometry could not aid us in distinguishing which product had been obtained. IR analysis 
showed no distinctive O-H stretch which would indicate product 267, hence this species could be 
ruled out. Based on the NMR spectra obtained, the number of chemical shifts in the aromatic 
region, six signals rather than four, suggest product 268 had formed. The lack of an additional 
peak in the carbonyl range (>160 ppm) in the 13C NMR spectra expected for product 259 further 
suggested product 268 had been produced instead. Even when the reaction was performed in 
DCM with TEA at room temperature the reaction went to full conversion of 268 – demonstrating 
















2.3.2.2 3-Methyl Arogenate 
To assess the robustness of the method substitution on the ring was carried out; an alternative 
starting material was utilised to install a methyl group at the aryl meta position. Starting from 3-
iodo-L-tyrosine, 269, a Boc protection followed by benzylation was carried out to produce 271. 
Amination with methylamine gave 272 in quantitative yield which was then followed by a Boc 
deprotection to give the free amine 273 (Scheme 80). 
 
Scheme 80 – Initial protection steps in the synthesis towards 3-Methyl arogenate. 
Two conditions for the Suzuki coupling using methylboronic acid were trialled to install the 
methyl group, 274. However, only starting material was recovered which may be due to the free 
amine coordinating to the palladium and preventing the reaction from occurring. In an attempt to 
circumvent this the Boc group was reinstalled to return to product 272. Gratifyingly, use of this 
species allowed the Suzuki coupling to be employed successfully in quantitative yield giving 275 





Scheme 81 – Attempted Suzuki couplings. 
With this installed, Boc deprotection was performed to produce 276. The original method could 
then be performed to produce the benzyl deprotected imidazolidinone carbamoyl chloride 278 
ready to undergo the spirocyclisation reaction (Scheme 82). 
 
Scheme 82 – Continued synthesis of 3-Methyl derivative starting from 3-iodo-L-tyrosine, 269. 
Upon attempting the spirocyclisation reaction it was found that two diastereomers had formed in 
a 1:1 ratio due to the methyl group producing a chiral spirocyclic centre. These were taken through 
to the Luche reduction, without prior separation, giving four different diastereomers which could 
be separated using standard column chromatography (Scheme 83). Upon repeating these 
reactions, the two diastereomeric dienones were separated beforehand in the hopes of offering 




diastereomers nonetheless gave tight chromatographic separation and provided similar overall 
yields. 
 
Scheme 83 – Spirocyclisation and Luche reduction of 3-Methyl derivative. 
2D NOESY and X-ray crystallography were used to determine the configuration of the four 
diastereomers. Due to the perpendicular geometry of the rings in the spirocycle, 280, a 2D NOE 
correlation was used to aid in determination of the configuration. Depending on the relationship 
between the carbonyl, oriented either up or down, and the methyl group; either the singlet peak 
(position 1) or the doublet peak (position 2) will observe the alpha proton. This was further 






























Figure 10 – Determination of configuration for 3-Methyl derivative. 
The trans relationship between the hydroxyl and amide groups (Figure 10) was found to be the 
minor diastereomer 280d, which corresponds with what is observed in the original synthesis. It 
was therefore assumed the other minor product, 280c, was also trans and the major diastereomers 








2.3.2.3 Grignard additions  
1,2-Additions were an attractive avenue for derivatisation as it is thought they could provide 
stability towards rearomatisation by removing the hydrogen adjacent to the hydroxyl group. 
Methylmagnesium bromide was the first Grignard reagent explored. Although the reaction did 
proceed, complete conversion could not be achieved causing difficulties in purification due to co-
elution of the product and starting material. A brief optimisation was carried out with the aim of 
obtaining complete consumption of starting material (Table 2).  





Eq. Temp Time (h) 
Conversion by NMR (%) 
281 282 
a 0.1 1.5 -78→RT 16-18 93 - 
b 0.2 1.5 -78→RT 16-18 81 - 
c 0.02 1.5 -78→RT 16-18 69 - 
d 0.2 1.5 -78 1 84 - 
e 0.1 3 -78→RT 16-18 - 83 
f 0.1 1.5 x 2 -78→RT 3 - 100 
 
However, at least >7% starting material always remained which could not be separated from the 
major diastereomer. Increasing  concentration (Table 2 – entry b) or decreasing concentration 
(Table 2 - entry c)both resulted in a decrease in yield. A similar yield was obtained when the 
reaction was left for only one hour at a 0.2 M concentration (Table 2 – entry d) suggesting no 
further reaction occurred with extended reaction times.  Increasing the number of equivalents used 
resulted in Grignard attack of the amide resulting in 282 (Table 2). Thus, the use of 




Alkylation with an alternative Grignard reagent was proposed in the hope of generating a product 
with better chromatographic separation. Gratifyingly, N-butylmagnesium chloride successfully 
yielded a product, with high diastereoselectivity (>9:1 dr), which could be easily isolated (Scheme 
84).   
 
Scheme 84 – Synthesis of n-butyl and phenethyl derivatives. 
Phenethylmagnesium bromide was also trialed in the hope of synthesising an analogue which 
could mimic NADP in the enzyme binding site pocket, based upon computational docking models 
of arogenate in arogenate dehydrogenase (2F1K)(Figure 11).115  
 
Figure 11 - Computational docking of arogenate (pink) in the crystal structure of arogenate 




2.3.2.4 Double bond reductions  
2.3.2.4.1 Fully saturated derivative 
To produce a derivative which was not susceptible to rearomatisation, reduction of the unsaturated 
ring was carried out. Hydrogenation in THF gave access to the fully saturated carbocycle 285 in 
good yield; ethanol was initially used as the solvent, but this resulted in the acetal by attack into 
the ketone. 285 was then reduced using NaBH4 to give the alcohol 286a and 286b in a 1:1.1 dr. 
The use of cerium chloride in this reaction gave no change in diastereoselectivity. 
 
Scheme 85 – Synthesis of saturated spiroarogenate. 
Attempts to identify the configuration of 286 using 1D and 2D NOE along with basic 
computational modelling proved difficult. We believe this is due to ring flipping giving two 
conformations in different populations resulting in NOEs of averaged intensities (Scheme 86). 
This likely could have been solved by computational calculations for the various populations and 
applying these to the interproton distances calculated by 1D NOE data.116  However, a crystal 
structure of 286a was obtained in the meantime showing a trans configuration (Figure 12). 
 










Figure 12 – Crystal structure of trans hydrogenated spirocycle. 
 
2.3.2.4.2 Partially reduced derivative 
It was initially hoped reduction with NaBH4 would allow access to partially saturated 
intermediates, however, the initial experiment produced a complex mixture of at least 8 species. 
This may be due to use of excess NaBH4 allowing multiple reductions with the possibility of 11 
different products (Scheme 87). 
 
Scheme 87 – Plausible products from the NaBH4 reduction. 
Reducing the equivalents of NaBH4 to one in the hopes of limiting the number of products formed 




previously been reported in the literature for use in the asymmetric desymmetrisation of a 
dienone.117 Although initial results with this reagent appeared promising, with only a single 
product formed, the conversion was only 23% by NMR and the product could not be successfully 
isolated and characterised; it is hoped through further optimisation this route can be made viable.* 
 
Scheme 88 – Diastereoselective reductive of the dienone 222 with [Rh(Phebox-sBu)]. 
An alternative approach which would result in removal of the alkene(s) would be to carry out 1,4-
additions. Gilman reagents, with and without TMSCl, and thioacetic acid were utilised as soft 
nucleophiles. However, this approach also proved difficult with the best example giving only 23% 
conversion by NMR.† Further optimisation will hopefully allow conversion to be maximised, 
along with investigation of the diasteroselectivity, which would allow for easier purification.  
 






* With thanks to Rachel Pankhurst for carrying out these reactions. 




2.3.2.5 Diels-Alder  
An attempt was made to carry out a Diels-Alder reaction between spirocycle 222 and the reactive 
and regioselective Danishefsky's diene 300. However, attempts at both room temperature and 100 
°C under microwave irradiation yielded only starting material by LCMS. It was thought the lack 
of reaction may be due to steric hindrance, reaction with cyclopentadiene may be worth 
exploration in the future. 
 
Scheme 90 – Diels-Alder reaction with 222. 
A further attempt of the Diels-Alder reaction (Scheme 91), replicated the conditions reported for 
a hindered cyclic enone and Danishefsky’s diene reported by Tang et al.118 The crude reaction 
mixture appeared promising by TLC-MS and NMR, however, purification proved problematic 
and the major isolated spot did not show any signs of product by NMR or mass spec.* 
 
Scheme 91 – Diel-Alder reaction following Tang et al. conditions. 
Although Danishefsky’s diene was selected for its excellent regioselectivity, due to the various 
stereogenic centres within the spirodienone there would still be eight possible diastereomeric 
products from this reaction. It was assumed four of these could be ruled out as the reaction was 
expected to follow the endo rule, in which there is favourable secondary orbital interaction 
 




between the diene and ketone.119 It was also hoped that selectivity, similar to that observed in the 
Luche reduction, may be observed due to the methylene group sterically disfavouring products 
301a and 301d (Scheme 92). 
 













2.3.2.6 Alkylation to produce arogenate-based quaternary amino acids 
Alpha-alkylations of the spirocycle 222 would allow access to a library of arogenate based 
quaternary amino acids. Previous work in the group found enolisation with KHMDS followed by 
alkylation with methyl iodide gave good results with similar imidazolidinones.113 Unfortunately, 
likely due to the unstable nature of the dienone and its tendency to rearomatise, applying these 
conditions to 222 proved unsuccessful resulting only in formation of an undesired product. By 
NMR, this side product showed two peaks which each integrated for 1H in the alkene region and 
phenolic aromatic protons. This, along with the loss of the α-proton suggests KHMDS caused 








Scheme 93 – Attempted alpha-alkylation of spirocycle 222. 
An alternative route was explored in which, to prevent the risk of rearomatisation, alkylation of 
a library of imidazolidinones 305 was carried out with the electrophile 1-(benzyloxy)-4-
(bromomethyl)benzene 306 to install the tyrosine motif in 307. These products could then 
undergo deprotection and spirocyclisation to give 308 (Scheme 94). 
 
Scheme 94 – Alternative route to alpha-alkylations. 
The electrophile 306 could be produced in quantitative yield by conversion of the alcohol 309 
using PBr3 (Scheme 95). Using this electrophile initial conditions were trialled using similar 





Scheme 95 – Synthesis of electrophile 306 using PBr3. 
Initial alkylations were carried out by addition of KHMDS to the imidazolidinone in dry THF at 
-78 ⁰C, followed by addition of the electrophile immediately afterwards. This gave a yield of 47% 
for the alanine imidazolidinone derivative 311, however, using these conditions with leucine, 
phenylalanine and tryptophan (later abandoned due to lack of starting material) derivatives gave 
complex mixtures with little to no product; which may be due to decomposition of the starting 
material by the base prior to alkylation. Adding KHMDS to a solution of imidazolidinone and 
electrophile in dry THF, degassed by nitrogen gas sparging, at -78 ⁰C resulted in a great 
improvement in yields; this optimisation was particularly marked for the alanine derivative 311 
which showed a 43% increase in yield (Scheme 96). 
 
Scheme 96 – Alkylations of various natural amino acid derived imidazolidinones with 1-
(Benzyloxy)-4-(bromomethyl)benzene. 
These alkylated products could then be debenzylated using reductive cleavage conditions, which 




was found that, with a substituent in the alpha position, extended times were required in the 
spirocyclisation to allow for full conversion to the products 317, 319 and 321 (Scheme 97). 
 
Scheme 97 – Debenzylation and spirocyclisation of alpha-alkylated imidazolidinones. 
The dienones produced were subjected to Luche reduction conditions to give the dienols 322-327 
(Scheme 98). It was assumed diastereoselectivity obeyed that seen in the original synthesis to 
give the  cis conformation (Scheme 73); introduction of a substituent in the alpha-position 





Scheme 98 – Luche reductions of alpha-alkylated derivatives. 
A final attempt at alkylation was attempted with the more stable analogue 285 using the original 
alkylation method in the hopes rearomatisation would be excluded in this route (Scheme 99). 
Alas, the crude reaction mixture contained many components and proved impossible to purify. 
With additional time, optimisation could be carried to explore the viability of this method. 
Alternatively, the route described in scheme 98 could be used, followed by hydrogenation of the 
alkenes to achieve product 328.  
 




2.3.3 Hydrolysis of arogenate and its analogues 
Having explored several methods for the synthesis of analogues, we returned to the challenge of 
the final step. Since initial attempts at hydrolysis and subsequent purification proved difficult, 
optimising the conditions was the first task undertaken. Initially this work focused upon 
production of spiroarogenate 256 due to it being the more stable and thus the easier to handle 
substrate. 
Table 3 - Exploring various bases for the hydrolysis of 9. 
 
All reactions performed at 30 ⁰C , overnight. 
A variety of inorganic bases were trialled to explore conversion to spiroarogenate 256 (Table 3). 
Barium oxide was investigated as a means of generating barium hydroxide in solution to see if 
this aided the reaction; however, this approach gave only similar ratios of starting material, 
spiroarogenate and aromatic impurities to using barium hydroxide itself (Table 3 - entries a&b). 









SM A B C 
a Ba(OH)2 3 D2O 0.2 52 39 - 9 Base added last 
b BaO 3 H2O 0.2 63 31 - 6 
Sonicated & 
Concentrated 
c NaOH 3 H2O 0.2 27 40 - 33 
Sonicated & 
Concentrated 
d LiOH 3 D2O 0.2 - - - - 
Sonicated. 
Complex mixture 
e KOH 3 D2O 0.2 50 23 - 27 Sonicated 
f Ca(OH)2 3 D2O 0.2 94 - - 6 Sonicated 




it also gave high levels of unwanted aromatic side products (Table 3 - entry c). Danishefsky et al. 
reported that the use of 1 equivalent of sodium carbonate in the hydrolysis of spiroarogenate 
increased the rate of hydrolysis. However, in our reaction, addition of this reagent resulted in a 
diminished yield of spiroarogenate and increased levels of aromatic impurities (Table 3 - entry 
g). Lithium hydroxide gave a complex product mixture which did not look particularly 
encouraging (Table 3 - entry d). Potassium hydroxide also appeared to increase rearomatisation 
whilst reducing levels of spiroarogenate (Table 3 - entry e). Calcium hydroxide gave a 
disappointing result with no conversion to spiroarogenate observed as well as small amounts of 
aromatic side products (Table 3 - entry g). 
Table 4 - Exploring various solvents, equivalents & concentrations for the barium hydroxide 










SM A B C 
a Ba(OH)2 3 D2O 0.2 52 39 - 9 Base added last. 
b Ba(OH)2 3 D2O:dioxane 0.2 99 t - t Base added last. 
c Ba(OH)2 3 D2O:MeOD 0.2 83 14 - 3 Base added last. 
d Ba(OH)2 3 D2O 0.4 62 32 - 6 Base added last. 
e Ba(OH)2 3 H2O 0.1 40 47 - 13 
Sonicated & 
Concentrated. 
f Ba(OH)2 12 H2O 0.1 22 57 t 21 
Sonicated & 
Concentrated. 
g Ba(OH)2 3 H2O 0.05 61 32 - 7 
Sonicated & 
Concentrated. 
h Ba(OH)2 12 D2O 0.05 44 40 t 16 
Sonicated & 
Concentrated. 




Confident in the knowledge that barium hydroxide was the most efficient base for the hydrolysis, 
the effect of solvents, reagent equivalents and concentrations were explored. Comparing to the 
best conditions so far (Table 4 - entry a), it was hoped the investigations would result in an 
increase of conversion to spiroarogenate whilst reducing conversion to aromatic impurities (Table 
4).  It was thought that the addition of organic solvent in the hydrolysis could aid solubility of the 
starting material and therefore allow the reaction to proceed more efficiently; however, the 
addition of dioxane (Table 4 - entry b) severely inhibited the reaction with only traces of 
conversion observed. The addition of methanol, which is more similar in polarity to water, also 
hindered the hydrolysis (Table 4 - entry c); nevertheless, some conversion was observed. It was 
concluded that the addition of organic solvents was detrimental to the hydrolysis and that future 
reactions would focus on aqueous systems only. 
Increasing the concentration of the reaction (Table 4 - entry d) resulted in only minor changes in 
the product ratio and if anything impeded the reaction slightly. On the other hand, decreasing the 
concentration (half compared to the original conditions) promoted conversion of the starting 
material (Table 4 - entry e & f). Increasing the number of equivalents of base from 3 to 12 (Table 
4 - entry f) gave higher levels of spiroarogenate but also undesired aromatics. However, further 
dilution (fourfold compared to the original conditions) did not further increase conversion as 
anticipated. Instead, the product to starting material ratio began to deteriorate again (Table 4 - 
entry g & h).  
Presently, the optimum hydrolysis conditions are barium hydroxide (3 or 12 eq.) in water (0.1 M) 
at 30 ⁰C. During the above investigations, it was found that the solubility of barium hydroxide in 
the reaction medium was poor and thus sonication of the base suspension was carried out to 
increase dispersion prior to addition of 225a which appeared to aid the reaction.  
As mentioned earlier, spiroarogenate was hydrolysed to arogenate by Danishefsky et al. in the 
final step of their arogenate synthesis. Therefore, repeating their conditions of sodium hydroxide 
in ethanol at 70 ⁰C was initially attempted on crude spiroarogenate material obtained from 
hydrolysis of the imidazolidinone (Table 5 - entry a).36 
 






The crude NMR spectrum from this reaction in D2O matched very closely to the NMR of synthetic 
arogenate produced by Danishefky et al. (Error! Reference source not found.):36 
1H NMR (400 MHz, Deuterium Oxide) δ 6.07 – 5.87 (m, 4H), 4.53 (m, 1H), 3.14 (m, 1H), 2.18 
(dd, J = 14.2, 5.3 Hz, 1H), 1.96 – 1.87 (m, 1H). – this work. 
 1H NMR (270 MHz, Deuterium Oxide) δ 6.05 (d, 1H), 5.96 (d, 1H), 5.94 (br s, 2H), 4.55 (m, 
1H), 3.07 (dd, 1H), 2.15 (dd, 1H), 1.88 (dd, 1H). – Danishefky et al.36 
carbony - Arogenate in D2O (blue) and CD3OD (black). 
Upon repeating the reaction on a small amount of >90% pure spiroarogenate (20 mg), isolated 
from purification by reverse phase chromatography (0-60% acetonitrile in water), no formation 
of arogenate was observed after 48h at 70 ⁰C. A further equivalent of base was added in the hope 
of aiding arogenate production; however, only aromatic side products were observed. 
Interestingly, after the addition of a small amount of water (10% by volume with respect to 
ethanol) and stirring for a further 16h, near complete conversion of starting material was observed, 




Hydrolysis of the minor spirocycle 225b was also attempted to determine whether use of a 
particular diastereomer would affect the rate of hydrolysis (Table 5). Hydrolysis of 225b would 
potentially allow access to epi-spiroarogenate/arogenate. 





















Ba(OH)2 3 D2O 0.2 99 t - - 
Base added 
last. 
All reactions performed at 30 ⁰C , overnight. 
Only minute traces of epi-spiroarogenate were observed after subjecting the minor diastereomer 
to the hydrolysis conditions previously optimised for the major, suggesting that the rate of 
hydrolysis for the 225b is significantly slower. 
2.3.3.1 Purification 
A large amount of time was spent developing methods for purification as the small, polar and 
unstable properties of spiroarogenate and arogenate, along with the large amount of salts present 
and the lack of solubility in organic solvents rendered this a difficult task. Since normal phase 
column chromatography was not possible, four other techniques for purification were explored.  
Reverse phase chromatography –  
Use of C18-reversed phase silica gel as a stationary phase was the first method explored. This 
allowed us to gain a better understanding of what exactly was present in the crude mixture but 
there were several issues that rendered the technique inadequate for purification. Carrying out the 
purification with a gradient of 0-100% H2O in methanol or acetonitrile gave little retention and 
caused extremely quick elution of a mixture of products. In reverse phase chromatography the 
solvent system is often spiked with an acid, such as TFA, acetic or formic acid, to aid with 
retention and peak shape for ionisable or strongly polar analytes. This retention is achieved by the 




retention. Several attempts were carried out using these various ion-pairing agents.* However, 
due to the acidity of these additives, major issues with rearomatisation were observed; both 
arogenate and spiroarogenate are known to convert to phenylalanine under mild acid 
conditions.6,121 
Purification carried out with a gradient of 0-100% H2O in MeOH (spiked with 0.1% NH4OAc 
[w/w]) gave the most promising results. Traces of arogenate were identified in one fraction, 
alongside several other co-eluted species. Among the compounds isolated were the 
imidazolidinone protected arogenate derivative 329, which may be of interest as a semi-stable 
source of arogenate, as well as the imidazolidinone protected tyrosine derivative 330 and the 
amine 331 (Figure 13). 
 
Figure 13 - Other products isolated from the hydrolysis purification. 
Hydrolysis of only the lactam ring and not the imidazolidinone accounted for the observation of 
329 and 330. From 329, a mechanism of imidazolidinone hydrolysis followed by 
disproportionation may explain product 331 (Scheme 101). 
 
 
* With thanks to Derick McCormack (Syngenta) and Daniel Leonard (UoB) for their guidance and 





Scheme 101 - Possible mechanism for formation of 331 from 329. 
Attempts using several reverse-phase HPLC columns also proved fruitless; with several columns 
being damaged by the basic nature of the crude sample as any acid for neutralisation or retention 
on the column caused rearomatisation issues. 
Ion exchange chromatography –  
The next method trialled was ion exchange chromatography; this technique had been used to 
purify arogenate in both the two previously reported syntheses and the natural product 
isolation.6,36,37,122 Efforts to purify using Dowex-chloride or Sephadex A-25, using methods set 
out in the literature, proved ineffective. All attempts resulted in little to no retention with elution 
of all products collectively. This may be due to the large salt concentration present in the crude 
mixture preventing effective binding of the negatively charged free acid. To obtain viable levels 
of retention, a very large dilution of the crude material was required which is impractical for our 
purposes. Another major disadvantage of ion exchange chromatography is the need for low eluent 
flow rates resulting in purification being a lengthy process and a large number of fractions to 
collect. 
Further exploration of ion exchange methods was carried out using a Dionex 3000 system to carry 




retention and optimisation focused upon the pH of the buffer system to optimise separation. 
Samples of phenylalanine, tyrosine, pure spiroarogenate and crude spiroarogenate were all ran 
independently for comparison. A crude arogenate sample was also tested but this was found to 
contain multiple components, so work focused on achieving purification of spiroarogenate before 
attempting the more complex arogenate mixtures. 
A 10 µl injection of each sample was run at a gradient of 10-90% buffer in water over 10 minutes. 
Using ammonium bicarbonate (0.1M) buffered at pH 9.0 gave the best separation however the 
separation proved inadequate. As can be seen below both phenylalanine and tyrosine have a 
longer retention time but streak off the column. The pure spiroarogenate produces a sharp peak at 
2.42 minutes but on attempting purification of the crude reaction mixture another component 
overlaps with spiroarogenate preventing a clean separation from being achieved (Figure 14).* Due 
to the lack of separation seen here and the inability to replicate the literature findings, ion 
exchange chromatography was deemed ineffective for purification.  
 
Figure 14 – Ion exchange trace using ammonium bicarbonate (0.1M) buffered at pH 9.0. 
HILIC (Hydrophilic interaction liquid chromatography) –  
HILIC is a variant of normal phase chromatography in which a hydrophilic stationary phase with 
reverse-phase type eluents. Despite using reversed-phase eluents the gradient begins with the 
organic solvent, typically acetonitrile. It is known to be particularly useful in separations of amino 
acids; hence it was thought that it may be suitable for this situation. It is also known to be an 
 




alternative method for purification of analytes which elute in the void volume in reserved-phase 
chromatography, as was experienced in this project.123,124 A Waters XBridge BEH Amide column 
was used with a gradient of 20-50% ammonium bicarbonate, buffered to pH 7.5 with glacial acetic 
acid, in acetonitrile as the optimised method. The various peaks were identified by running 
separate injections with pure spiroarogenate, phenylalanine and tyrosine. This technique gave 
some separation though very tight and unsatisfactory for purification; particularly on a larger scale 
(Figure 15).* 
 
Figure 15 – HPLC trace using HILIC conditions. 
Hypercarb –  
A Hypercarb column is a stationary phase of porous graphitic carbon (PGC) and is usually used 
under reverse phase conditions. Separation occurs based on hydrophobicity along with two other 
interlinked mechanisms of interactions. The first of which is the induction of a charge on 
polarisable surface of graphitic carbon. The second works on how close a fit the molecule has 
with the graphitic carbon. The more planar the molecule the more it can interact and induce a 
charge across the PGC surface providing an increase in retention.125 For example a planar 
molecule would allow for more interactions between the analyte and graphite surface in 


















Figure 16 – Hypercarb mechanism of interaction.126 
Due to the unique surface of the PGC, the Hypercarb column user guide states its benefits 
include127 – 
• Excellent for the separation of highly polar compounds  
• Stability across the entire pH range 0-14, due to unreactive surface (Figure 17) 
• Excellent batch-to-batch reproducibility 
• Homogeneous crystalline surface (Figure 17) 
• Enhanced selectivity for closely related compounds, including geometric isomers and 
diastereoisomers (Figure 18)  
 
Figure 17 – Comparison of Silica surface to PGC.125 
Close fit to surface by 





An excellent example of the  Hypercarb capabilities is demonstrated in the Hypercarb user guide 
in which the separation of a mixture of 20 underivatised amino acids is carried out (Figure 18). 
This highlights both the ability of PGC to retain polar molecules and also separate out several 
closely related compounds.125 
 
Figure 18 – Separation of 20 underivatised amino acids on a Hypercarb column.125 
Encouragingly, the initial runs carried out on the Hypercarb column, with a gradient of 0-100% 
MeCN in 100 mM ammonium bicarbonate buffer, provided excellent retention and separation. A 
mass ion for spiroarogenate was observed for the peak around 18 minutes (Figure 19).*  
Figure 19 – initial Hypercarb HPLC trace. 
 




Upon moving to a semi-preparative scale column and increasing loading, to lessen the number of 
runs, the retention time dramatically reduced and streaking occurred.  Optimisation of conditions 
found that increasing the rate of the eluent gradient provided sharper peaks and allowed for the 
isolation of 4 major peaks which were found to be arogenate 1, spiroarogenate 256, arogenate 









Figure 20 – Semi-preperative HPLC showing relevant peaks and corresponding compounds. 
A large problem in the isolation of these types of compounds is the sensitivity to pH. This was 
demonstrated during the isolation of spiroarogenate, where upon obtaining NMRs at several 
points in time decomposition could be seen. It was determined that the NMR sample was around 
pH 5, which was thought to be caused by contamination with acid during use of a communal 
freeze dryer. This slight pH change led to a 60:40 ratio of spiroarogenate to phenylalanine in only 




















Figure 21 – Decomposition of spiroarogenate, 256, to phenylalanine, 3, over two hours. 
To remove any issues of contamination an otherwise empty, clean freeze dryer was used for all 
future purifications. The reaction was then repeated using the optimised conditions and 
spiroarogenate was isolated in 27% yield with no sign of instability over the course of a month 
exposed to air (Scheme 102). Full NMR data, high resolution nanospray mass spectrometry, 
specific rotation and circular dichroism data have been obtained for spiroarogenate, 256. 
 
Scheme 102 – Hydrolysis to spiroarogenate, 256, using optimised conditions. 
During the HPLC runs it became obvious arogenate, 1, was also being produced directly from the 
spirocycle, 225a, rather than stepwise via spiroarogenate, 256. A quick optimisation found using 
an increased heat, 70 °C, with a reduced time of 5 hours gave the largest conversion to arogenate, 
1 (Scheme 103). A noteworthy observation is that following the repeated use of barium hydroxide 
reaction conversion began to reduce. It was proposed the top layer of barium hydroxide may have 
reacted with the air to produce traces of barium carbonate which catalysed the reaction. This may 
have been the reasoning behind the addition of sodium carbonate in the Danishefksy et al. 





Scheme 103 – Optimised hydrolysis of arogenate, 1, from spirocycle, 225a. 
During several attempts at purification of arogenate another issue of rearomatisation arose. The 
initial test purification produced stable arogenate, however, all further attempts resulted in 
moderate levels of rearomatisation, around 50% (Figure 22 – circled in red). It was discovered 
that collection of the product fraction without a minor peak observed slightly before the arogenate 
peak resulted in instability. By 13C NMR this peak corresponded to carbonate salts which appear 
to stabilise arogenate. 
  
Figure 22 – Rearomatisation of purified arogenate. 
Since arogenate is unstable as the free acid it was decided collection with these salts would be 
preferable. Both barium and sodium carbonate salt additives were trialled to compare product 
stability. Sodium carbonate, most likely the salt eluting with arogenate, was easier to handle due 
to better solubility and also resulted in minimal rearomatisation following standing in solution for 
2 days. 
With the knowledge that sodium carbonate provided product stabilisation, 1 mL of 1M sodium 
carbonate was added to each collected HPLC fraction to ensure saturation. However, upon 




present. It was proposed these were two different salt forms as arogenate is known to provide very 
different NMRs based upon the counterion and pH.6 As an ammonium bicarbonate buffer was 
used there was the possibility of three different salt forms; ammonium, barium or sodium. It was 
decided to switch to a 10 mM sodium bicarbonate/carbonate buffer (pH = 9) to remove the 
possibility of the ammonium salt formation, whilst also providing an easier method for addition 
and control of the salt present. Unfortunately, switching to this sodium salt buffer did not remove 
the splitting seen by NMR suggesting the two components were the barium and sodium forms of 
arogenate. This observation of multiple salt forms was also noted in the hydrolysis of arogenate 
analogues (Chapter 2.3.2). To confirm this theory approximately 10 equivalents of sodium 
carbonate was added to the available purified 3-methyl arogenate in solution in an attempt to 
observe a shift in the equilibrium to the sodium salt. This resulted in a change of NMR ratio from 
a 60:40 to a 80:20 mixture of the salts (Figure 23).  
 
Figure 23 – Addition of sodium carbonate to produce a shift in salt ratios. 
Due to the inclusion of sodium carbonate needed for stabilisation a weight-based yield could not 
be established. The instability of arogenate, particularly in the presence of acid, meant that most 
common D2O soluble quantitative NMR standards could not be used. A standard that could be 
easily removed from the arogenate which is only completely soluble in water was also desired. 
For these reasons, ethanol was chosen as a standard for these compounds as it posed no issue of 
incompatibility with arogenate, would be water soluble, easy to handle and could be easily 





and gave an error of >2%. The accuracy in the use of an ethanol standard was also confirmed by 
comparing the use of a 5% ethanol stock by Gilson pipette solution against the common standard 
of dimethyl sulfone with an accurate balance. This was carried out with reference to the fully 
saturated and therefore stable spiroarogenate analogue (Section 2.3.2.4.1). During purification the 
sample had become contaminated with an unknown salt resulting in being unable to calculate a 
yield based on weight. From the known total weight, a 20 mg amount was taken and to it was 
added the standard assuming 100% purity. Both the ethanol stock solution (0.5 eq.) and the 
dimethyl sulfone (1 eq.) showed the same 42% (±1%) concentration of product, showing 
consistency in the method. 
 
 
Figure 24 – Comparison of Ethanol standard (black – top) to dimethyl sulfone standard 
(red – bottom) on a stable spiroarogenate analogue.  
Analysis of the crude reaction mixture with an ethanol standard showed around 55% conversion 




qNMR of around 35%; however, several further hydrolysis attempts with sodium carbonate 
stabilisation gave yields in the range of 12-15%. Investigation into this drop in yield found that 
the starting material appeared to have undergone partial oxidation back to the dienone (Figure 
25).  
 
Figure 25 – Dienol conversion to dienone following months of exposure to air. 
An attempt was made to hydrolyse the dienone 222 to arogenate or spiroarogenate derivatives 
335 or 336. However, the rearomatised carbamate 337 was formed, most likely due to attack of 
the lactam ring by a hydroxide anion followed by rearomatisation (Scheme 104). This may be the 
cause behind the drop in yield of arogenate during later hydrolyses; as more rearomatised side 
products would be produced when the dienol material contaminated with dienone 222 was 
hydrolysed. 
 




Upon obtaining a fresh batch of starting material 225a and using the sodium carbonate buffer 
stabilisation method following hydrolysis, a 41% yield of 1 was calculated by qNMR using a 5% 
standard stock solution of ethanol. Full NMR data, high resolution nanospray mass spectrometry, 
specific rotation and circular dichroism data have been obtained for arogenate, 1 (Figure 26). The 
total synthesis of arogenate has been realised in seven steps with an overall yield of 19.6%. 
 
 
Figure 26 – Full NMR data for arogenate, 1. 
Using a compromise in temperature and time conditions in the hydrolysis, 40 ℃ for 18 hours, 
reasonable amounts of both arogenate 1 and spiroarogenate 256, along with some of the 
imidazolidinone protected arogenate 329, could be generated in the same reaction with only 
minimal amounts of the rearomatised side product 331 (Scheme 105). These conditions would be 
used for future analogues to provide both derivatised natural products from a single reaction. 
 
Scheme 105 – Yield of arogenate 1, spiroarogenate 256, imidazoldinone protected arogenate 329 
and aromatic side product 331 from the hydrolysis reaction at 40 ℃ for 18 hours calculated using 





2.3.3.2 Hydrolysis of 3-Methyl Derivative 
Hydrolysis produced 3-methyl arogenate, 338, in 16% isolated yield. The product appeared to 
have improved stability compared to arogenate with <10% rearomatisation in the isolated 
product NMR. 
 
Scheme 106 – Hydrolysis to 3-methyl arogenate. 
The reaction was then repeated with the addition of sodium carbonate to prevent decomposition. 
The 40 ℃ barium hydroxide hydrolysis conditions were used to produce both natural product 
analogues in the same reaction (Scheme 107). 
 
Scheme 107 - Yield of 3-methyl arogenate 338, spiroarogenate 339, imidazoldinone protected 
arogenate 340 and aromatic side product 341 from the hydrolysis reaction at 40 ℃ for 18 hours 
calculated using an ethanol standard for qNMR. 
Had time permitted, further optimisation of the hydrolysis conditions would likely allow for each 
natural product to be favoured over the other, as seen in the original synthesis. 
2.3.3.3 Hydrolysis of Grignard Derivatives  
The initial attempts at hydrolysis of 283 and 284 were carried out with sodium hydroxide and 
harsher heating conditions; initial test reactions showed lower temperatures provided little 
conversion. Despite requiring these harsher conditions to hydrolyse, suggesting increased 
substrate stability, following purification the arogenate derivatives still rearomatised by loss of 
the hydroxyl group to give 344 and 347 (Scheme 108). The hydrolyses were therefore repeated 





Scheme 108 – Initial hydrolysis attempt of the Grignard derivatives. 
Switching to the barium hydroxide conditions and use of sodium bicarbonate buffer in purification 
resulted in good yields of both arogenate 343/346 and spiroarogenate 342/345 derivatives. No 
rearomatised side product was isolated and only small amounts of the imidazolidnone protected 
arogenate 348/349 were observed. 
 
Scheme 109 –Yield of grignard analogues of arogenate 342/245, spiroarogenate 343/346 and 
imidazolidinone protected arogenate 348/349 from the hydrolysis reaction at 80 ℃ for 24 hours 




2.3.3.4 Hydrolysis of a Fully Saturated Derivative 
The hydrogenated spirocycle 286b proved more stable under hydrolysis conditions requiring a 
higher reaction temperature. The increased stability of the hydrogenated analogue is reflected in 
the yield of 80% (Scheme 85).  
 
Scheme 110 – Synthesis of saturated spiroarogenate.  
The trans derivative 286a was also hydrolysed in a 79% yield. Repeating the cis 286b reaction 
with barium hydroxide as the base gave an almost identical yield. Thus far, hydrolysis has only 
produced the spiroarogenate derivative 350 with no sign of the fully hydrolysed arogenate 
derivative. Various conditions, using barium hydroxide or HCl, were trialled in an attempt to 
convert 350 to the arogenate form 351 however the 5-membered lactam ring proved difficult to 
hydrolyse (Table 6).*   
Table 6 – Attempted hydrolysis conditions. 
 
 Reagent Eq. Solvent Temp. / ˚C Time / h 
NMR Ratio 
350 351 
a Ba(OH)2/ BaCO3 3/1 H2O 100 72 100 - 
b HCl 6 H2O 80 24 98 2 
c HCl 10 H2O 80 24 78 22 
d HCl 10 H2O 160 (MW) 19 Decomposed 
All reactions performed on a 10 mg scale. 
 
* With thanks to Rachel Pankhurst for hydrolysis of the trans derivative, hydrolysis with barium hydroxide 




2.3.3.5 Hydrolysis of Alkylation Derivatives 
Attempts were made to hydrolyse the major diastereomer from each Luche reduction, 322, 324 
and 326, using the milder hydrolysis conditions; 3 eq. Ba(OH)2, 1 eq. BaCO3 at 40 ⁰C for 18 hours 
(Scheme 111). However, the crude reaction mixtures proved very complex and despite weeks of 
trialling purification conditions using the HyperCarb column little separation of products could 
be achieved. Some separation was achieved for the alanine derivative 352, however the only 
components recovered were 12% starting material and >5% of a species with characteristics of 
the desired arogenate/spiroarogenate derivative. Attempts at purification of the leucine analogue 
353 proved futile and whilst moderate separation was achieved with the crude reaction mixture 
from hydrolysis of the phenylalanine derivative 354, only starting material or rearomatised 
product were detected. 
 







A novel synthesis of arogenate in seven steps with an overall yield of 19.6% has been attained; 
this is a marked improvement on the 2.1% overall yield of the previous reported synthesis.37 
Spiroarogenate, which is itself a natural product, has also been produced by this route and it has 
been discovered that altering the final hydrolysis conditions can favour conversion to either one 
of these natural products. Arogenate’s inherent instability has proved challenging but purification 
and stabilisation has been realised through the use of a HyperCarb column and the use of a sodium 
carbonate/bicarbonate buffer. With this knowledge in hand, it is hoped that this route will provide 
ample opportunity to derivatise arogenate, particularly with respect to improved stability, and 
open an avenue to explore the potential of such analogues in both agrochemicals and 
pharmaceuticals. 
The first derivatised analogues of both arogenate and spiroarogenate have been produced using 
this synthesis. Several successful functionalisations have been accomplished including producing 
a stable spiroarogenate analogue as well as introducing substituents in the 3- and 4- position of 
the carbocycle. These analogues are now available for testing purposes as potential herbicides as 
part of a collaboration with Syngenta. A collaboration with Professor Hiroshi Maeda at the 
University of Wisconsin has also been discussed to test their effect directly on arogenate 
dehydrogenase/dehydratase enzymes and other enzymes earlier in the shikimate pathway. 
Strides have also been made in the synthesis of partially reduced stable analogues of arogenate 
using asymmetric desymmetrisation using a rhodium catalyst, the use of soft nucleophiles for 1,4 
additions and Diels-Alder reactions. Hopefully, with further optimisation these will soon be 
realised. 
An alternative route has been established for the alpha-alkylation of amino acid derived N-
chloroformylimidazolidinones using a benzylic electrophile to install the tyrosine motif, opening 
up the possibility of accessing alpha-substituted arogenate analogues. This will hopefully allow a 








4. Future Directions 
Further investigations into the mechanism for the production of rearomatised side product 
331/359 would be of great interest as this would provide insight into potential avenues for 
blocking this rearomatisation pathway. It is hoped carrying out the Luche reduction using sodium 
borodeuteride would allow for deuterium incorporation in the position alpha to the hydroxyl group 
354 (Scheme 112). If the proposed mechanism is operating this could be seen in the proton NMR 
for the rearomatise side product 359 (Scheme 112). This would also further explain the lack of 
rearomatised products seen with the 1,2-addition derivatisation products (Section 2.3.2.3), where 
no proton is available for abstraction. 
 




Converting the phenol in 220 to an aniline to give 360 would provide a potential alternative 
substrate for spirocyclisation. The product imine 361, could then undergo reduction and 
hydrolysis to yield the amino arogenate derivative 362 (Scheme 113). The amine 362 could act 
as both a hydrogen bond donor and acceptor in the enzyme active site which may alter its binding 
and activity. This could also allow for production of further analogues with secondary and tertiary 
amines to explore their effect on the arogenate enzymes. Alternatively, bicyclic structures could 
potentially be produced using this spirocyclisation method. Naphthol128 and hydroxyquinoline129 
rings have been known to undergo spirocyclisation reactions and may be a sensible starting point 
for this investigation in the hopes of producing 365 and 368 (Scheme 113). 
 
Scheme 113 – Alternative ring systems for spirocyclisations. 
Thus far Diels-Alder reactions have proved unsuccessful; as an alternative [2+2] cycloadditions 
may be trialled for their potential in producing altermative polycyclic ring structures such as 370 
(Scheme 114). Epoxidation of the double bonds in tyrosine-based spirocycles has been previously 
reported in the literature and may provide an opportunity for further derivatisation whilst 





Scheme 114 – [2+2] cycloaddition or epoxidation to produce polycyclic ring structures. 
It would also be of interest to attempt the spirocyclisation from a homotyrosine derivative. The 
homotyrosine starting material 375 can be produced from phenol and N-TFA-Asp(Cl)-OMe via 
a Friedel-Crafts acylation followed by a reduction using Pd/C.130 375 could then be protected and 
converted to the carbamoyl chloride 376 allowing attempts at spirocyclisation to give the six-
membered arogenate analogue 377 (Section 2.3.2.1).  
 
Scheme 115 – Potential homoarogenate derivative from homotyrosine. 
With a stable analogue of spiroarogenate in hand, we hope that further derivatisations could be 
carried out on 350 itself. For example, it may be of interest to produce ester derivatives for use as 
pro-drugs or pro-cides (Scheme 116). Esterification should allow facile modification of physical 






Scheme 116 – Esterification of a stable analogues of spiroarogenate. 
Further work, particularly in the 1,4-addition and partial reduction derivatisations, will 
concentrate on optimisation of these reactions.  Focus will also be paid to whether any selectivity 
is observed in these reactions and exploration of whether temperature, solvents, chiral catalysts 
or ligands could be used to bias formation of particular diastereomers. 
Another transformation to be explored as a method of preventing rearomatisation would be the 
addition of a base-stable protecting group at the phenolic position (Scheme 117). This 
investigation would help to determine whether the hydrolytic rearomatisation side reaction 
proceeds via a stepwise or concerted mechanism as identified in previous arogenate 
dehydrogenase studies.13 For example, if the hydroxy group is alkylated, i.e. with a benzyl group, 
this should prevent a stepwise rearomatisation as the dienone could no longer form (Scheme 117). 
 
Scheme 117 - Derivatisation strategies to explore stepwise or concerted mechanism. 
An alternative avenue to be explored would involve carrying out peptide couplings with stable 
arogenate or spiroarogenate analogues (Scheme 118). A preliminary reaction could utilise 
tetrahydrospiroarogenate 350 due to its known stability. The spiroarogenate analogues are not 
expected to require any additional protection due to the N-terminus being involved in the lactam 
ring which reduces its reactivity. This could then be coupled with L-alanine methyl ester 386, 
using conditions employed in coupling of pyroglutamate amino acids,131 followed by deprotection 
of the ester using lithium hydroxide to give 385 (Scheme 118). Such compounds may be of 





Scheme 118 – Peptide coupling reactions with stable arogenate or spiroarogenate derivatives. 
A collaboration is in the process of being established which will allow derivatives to be tested 
against arogenate dehydrogenase and dehydratase assays to explore mode of action. Any positive 
testing of analogues could be explored further by co-crystallisation with arogenate 
dehydrogenase/dehydratase. This may give further information about substrate binding and offer 
further assistance in computational aided drug/herbicide discovery.  
As mentioned previously (Section 2.2.1.1), silyl ethers have been used in spirocyclisation 
reactions.99 Therefore, it was proposed that the use of a silyl ether in the ortho-tyrosine 
spirocyclisation may aid in promoting the desired spirocyclisation to 259 over the unwanted 
cyclisation to the carbamate 268 (Scheme 119). 
 




Future efforts could also include revisiting the oxazolidinone and hydantoin routes with the aim 
of achieving spirocyclisation which could generate more readily hydrolysable species for the 




























Unless stated otherwise, all reagents and chemicals were bought from commercial suppliers and 
used without further purification.  
When anhydrous conditions were necessary, reactions were carried out under nitrogen in flame‐
dried glassware using standard Schlenk syringe-septa techniques.  
Anhydrous dichloromethane, THF, MeCN and toluene were dried by passing through a modified 
Grubbs system of alumina columns, manufactured by Anhydrous Engineering. Petrol Ether 
indicates fractions of petroleum ether boiling at 40‐60 °C.  
Thin layer chromatography (TLC) was performed with aluminium backed silica TLC plates 
(Merck-Kieselgel 60 F254) with a suitable solvent system. Visualisation was via UV light (at 254 
nm) or by staining with potassium permanganate solution or ‘Seebach’ dip and heat.  
Flash column chromatography was performed on a Biotage Isolera™ four system using 10, 25, 
50 or 100 g silica Biotage® SNAP columns and a variable 200-400 nm wavelength detector 
scanning all wavelengths.  
Infrared spectra were recorded on a Perkin Elmer Spectrum (Spectrum One) FT-IR with an ATR 
accessory and frequencies are reported in wavenumbers (cm-1).  
1H and 13C NMR spectra were recorded in CDCl3 solutions (unless otherwise stated) on Jeol-ECS 
400, Varian 400/500, Bruker 400 and Bruker 500 (cryo-enhanced 13C probe) spectrometers at 
ambient temperature, and were referenced to the residual deuterated solvent peak for CDCl3 (7.26 
ppm for 1H and 77.16 ppm for 13C) or D2O (4.79 ppm for 1H). Chemical shifts (δ) are reported 
in parts per million (ppm) and coupling constants (J) in hertz (Hz). Multiplicities are denoted as 
singlet (s), doublet (d), triplet (t), quartet (q) or multiplet (m). COSY, HMBC and HSQC NMR 
spectra were routinely used to definitively assign the signals of 1H and 13C NMR spectra.  
Electrospray (ESI) mass spectra were recorded on a Bruker Daltronics MicrOTOF 2 mass 
spectrometer. Nanospray mass spectra were recorded on a UHPLC-MS (Dionex RS3000 LC 
system). Unless stated otherwise, mass spectrometry measurements are recorded for the isotope 
35Cl. 
Melting points were measured on a Stuart Scientific melting point SMP 10 apparatus and are 
uncorrected. 
Specific rotations ([α]𝑇𝐷) were measured on a Bellingham and Stanley Ltd. ADP220 polarimeter 
where c is given in g/100 mL. 




5.1 Hydantoin route 
5.1.1 Silyl route 
 
 
Methyl (S)-2-amino-3-(4-((tert-butyldimethylsilyl)oxy)phenyl)propanoate (235)132 
L-tyrosine methyl ester (3.00 g, 15.3 mmol) was dissolved in DCM (150 mL) under N2. To this 
imidazole (2.79 g, 18.3 mmol) and TBSCl (1.26 g, 18.3 mmol) were added. The mixture was 
stirred at room temperature overnight. A further equivalent of imidazole and TBSCl was added 
and the reaction mixture was stirred for a further 2 hours. The mixture was then quenched with 
saturated aqueous NH4Cl (100 mL) solution. Phases were separated and the aqueous layer was 
extracted with DCM (3 x 100 mL). The organic phase was dried over MgSO4, filtered and 
concentrated in vacuo. Purification was carried out by column chromatography on silica gel 
eluting with a gradient of 25-100% ethyl acetate in petroleum ether to yield 235 (4.15 g, 92%) as 
a colourless oil.  
1H NMR (400 MHz, Chloroform-d) δ 7.07 – 6.97 (m, 2H, H7), 6.80 – 6.73 (m, 2H, H6), 3.70 (m, 
4H, H1 & H3), 3.00 (dd, J = 13.6, 5.3 Hz, 1H, H4), 2.80 (dd, J = 13.6, 7.7 Hz, 1H, H4), 0.97 (s, 9H, 
H11), 0.18 (s, 6H, H9). 
HRMS-ESI (m/z) [M+H]+ calc. for C16H28NO3Si 310.1833, found 310.1833. 
Rf - 0.14 in 50% EtOAc in Petroleum ether  





To a solution of 235 (4.15 g, 13.5 mmol) in DCM (55.0 mL) under N2, tert-butyl isocyanate (1.85 
mL, 16.2 mmol) and triethylamine (3.76 mL, 27.0 mmol) were added. The resultant mixture was 




x 100 mL), sodium hydrogen carbonate (100 mL) and brine (100 mL). The organic phase was 
dried over MgSO4, filtered and concentrated in vacuo to yield 236 (4.87 g, 88%) as a pale-yellow 
oil. 
1H NMR (400 MHz, Chloroform-d) δ 6.96 (d, J = 8.4 Hz, 2H), 6.80 – 6.67 (m, 2H), 4.67 (dt, J = 
7.7, 5.8 Hz, 1H, H3), 4.54 (d, J = 7.7 Hz, 1H, NH), 4.24 (s, 1H, NH), 3.69 (s, 3H, H1), 3.00 (m, 
2H, H4), 1.29 (s, 9H), 0.97 (s, 9H), 0.17 (s, 6H, H9). 
13C NMR (100 MHz, Chloroform-d) δ 173.35 (C2), 156.23 (C12), 154.61 (C8), 130.28 (C6), 128.87 
(C5), 120.03 (C7), 53.80 (C3), 52.05 (C1), 50.51 (C13), 37.74 (C4), 29.59 (C10), 29.42 (C14), 25.64 
(C11), -4.44 (C9). 
HRMS-ESI (m/z) [M+H]+ calc. for C21H37N2O4Si 409.2517, found 409.2517. 




To a solution of 236 (4.86 g, 11.9 mmol) in THF (40.0 mL) under N2, potassium tert-butoxide 
(1.47 g, 13.1 mmol) was added. The resultant mixture was stirred at room temperature for two 
hours. The mixture was then washed with water (3 x 100 mL), sodium hydrogen carbonate (100 
mL) and brine (50 mL). The organic phase was dried over MgSO4, filtered and concentrated in 
vacuo. Purification was carried out by column chromatography on silica gel eluting with a 
gradient of 2-100% ethyl acetate in petroleum ether to yield 230 (2.97 g, 66%) as a white solid. 
1H NMR (400 MHz, Chloroform-d) δ 7.04 (d, J = 8.4 Hz, 2H), 6.83 – 6.63 (m, 2H), 5.51 (s, 1H, 
NH), 4.02 (ddd, J = 7.6, 3.7, 1.3 Hz, 1H, H3), 3.08 (dd, J = 14.0, 3.7 Hz, 1H, H4), 2.81 (dd, J = 
14.0, 7.6 Hz, 1H, H4), 1.49 (s, 9H), 0.97 (s, 9H), 0.16 (s, 6H, H9). 
13C NMR (100 MHz, Chloroform-d) δ 174.04 (C2), 158.02 (C1), 154.94 (C8), 130.43 (C7), 127.68 
(C5), 120.26 (C6), 57.61 (C12), 57.33 (C3), 37.32 (C4), 28.47 (C13), 25.65 (C11), 18.18 (C10), -4.45 
(C9). 
HRMS-ESI (m/z) [M+Na]+ calc. for C20H32N2O3SiNa 399.2074, found 399.2084. 









To a solution of 230 (200 mg, 0.53 mmol) in THF (5.00 mL) under N2 at 0 °C, potassium tert-
butoxide (65.0 mg, 0.58 mmol) was added and the reaction mixture was stirred for 5 minutes. 
Phenyl chloroformate (0.08 mL, 0.64 mmol) was then added and the mixture was warmed to room 
temperature and stirred for 2 hours. The mixture was then diluted with EtOAc (50 mL), washed 
with water (3 x 30 mL) and brine (30 mL). The organic phase was dried over MgSO4, filtered and 
concentrated in vacuo. Purification was carried out by column chromatography on silica gel 
eluting with 100% dichloromethane to yield 237 (106 mg, 40%) as a pale-yellow oil. 
1H NMR (400 MHz, Chloroform-d) δ 7.48 – 7.40 (m, 2H, H15), 7.33 – 7.27 (m, 1H, H16), 7.27 – 
7.22 (m, 2H, H14), 7.02 – 6.96 (m, 2H, H6), 6.80 – 6.75 (m, 2H, H7), 4.60 (dd, J = 4.8, 2.8 Hz, 1H, 
H3), 3.49 (dd, J = 14.2, 4.8 Hz, 1H, H4), 3.24 (dd, J = 14.2, 2.8 Hz, 1H, H4), 1.41 (s, 9H, H18), 
0.97 (s, 9H, H11), 0.17 (s, 6H, H9). 
13C NMR (100 MHz, Chloroform-d) δ 170.82 (C2), 155.32 (C1), 151.68 (C8), 150.02 (C12), 148.82 
(C13), 130.91 (C6), 129.61 (C15), 126.49 (C16), 125.74 (C5), 121.36 (C14), 120.31 (C7), 59.46 (C3), 
59.16 (C17), 34.43 (C4), 28.20 (C18), 25.66 (C11), 18.19 (C10), -4.45 (C9). 
HRMS-ESI (m/z) [M+Na]+ calc. for C27H36N2O5SiNa 519.2286, found 519.2272. 
Rf - 0.51 in 100% DCM 




carbonyl chloride (232) 
Pyridine (64 µL, 0.80 mmol) was added to a triphosgene (80.0 mg, 0.27 mmol) solution in dry 
dichloromethane (3.00 mL) in a flame-dried round bottom flask at -78 oC and the resulting 




in dichloromethane (2 mL). The resulting mixture was slowly warmed to room temperature and 
was stirred at that temperature for 5 h. The solvent was partially eliminated under reduced 
pressure and purification was carried out by column chromatography on silica gel eluting with a 
gradient of 0-100% ethyl acetate in petroleum ether to yield 232 (5 mg, 4.5%) as a colourless oil. 
1H NMR (500 MHz, Chloroform-d) δ 6.98 – 6.94 (m, 2H, H6), 6.81 – 6.76 (m, 2H, H7), 4.62 (dd, 
J = 4.8, 2.6 Hz, 1H, H3), 3.49 (dd, J = 14.4, 4.8 Hz, 1H, H4), 3.24 (dd, J = 14.4, 2.6 Hz, 1H, H4), 
1.39 (s, 9H, H14), 0.98 (s, 9H, C11), 0.18 (s, 6H, H9). 
13C NMR (100 MHz, Chloroform-d) δ 169.54 (C2), 155.56 (C1), 150.71 (C8), 143.63 (C12), 130.89 
(C6), 124.91 (C5), 120.47 (C7), 61.09 (C3), 59.87 (C13), 34.28 (C4), 28.07 (C14), 25.66 (C11), 18.21 
(C10), -4.45 (C9). 
HRMS-ESI (m/z) [M + Na+] calculated for C21H31ClN2NaO4Si, 461.1639, found 461.1634. 




To a solution of 237 (45 mg, 0.09 mmol) in dry THF (1.00 mL), tetrabutylammonium fluoride (1 
M in THF) (0.10 mL, 0.09 mmol) was added at 0 oC. The resulting solution was stirred at the 
same temperature for 30 min. The reaction was quenched with brine (10 mL) and extracted with 
DCM (3 x 10 mL). The organic phase was dried over MgSO4 and concentrated in vacuo. 
Purification was carried out by column chromatography on silica gel eluting with a gradient of 0-
100% ethyl acetate in petroleum ether to yield 238 (14 mg, 60 %) as a white solid. 
1H NMR (500 MHz, Methanol-d4) δ 7.00 (d, J = 8.4 Hz, 2H), 6.68 (d, J = 8.4 Hz, 2H), 4.07 (t, J 
= 4.3 Hz, 1H), 3.00 – 2.84 (m, 2H), 1.34 (s, 9H). 
13C NMR (126 MHz, Methanol-d4) δ 176.62, 173.04, 157.73, 132.28, 126.59, 116.07, 58.46, 
37.44, 28.82, 20.98. 








5.1.2 Benzyl route 
 
Methyl (S)-3-(4-(benzyloxy)phenyl)-2-(3-(tert-butyl)ureido)propanoate (242) 
To a solution of O-benzyl methyltyrosinate hydrochloride (2.84 g, 8.82 mmol) and triethylamine 
(2.60 mL, 18.6 mmol) in dichloromethane (40.0 mL) under N2, tert-Butyl isocyanate (1.20 mL, 
10.3 mmol) was added. The reaction mixture was stirred at room temperature overnight. The 
organic phase was washed with a saturated aqueous solution of NH4Cl (3 x 30 mL), a saturated 
aqueous solution of NaHCO3 (3 x 30 mL) and brine (30 mL), dried over MgSO4 and concentrated 
in vacuo to yield 242 (3.25 g, 96 %) as a white solid. 
1H NMR (400 MHz, Chloroform-d) δ 7.46 – 7.29 (m, 5H,H11,12&13), 7.03 (d, J = 8.5 Hz, 2H, H6), 
6.90 (d, J = 8.5 Hz, 2H, H7), 5.04 (s, 2H, H9), 4.72 – 4.65 (m, 1H, H3), 4.47 (d, J = 7.8 Hz, 1H, 
NH), 4.16 (s, 1H, NH), 3.72 (s, 3H, H1), 3.04 (m, H4), 1.30 (s, 9H, H16). 




To a solution of 242 (3.25 g, 8.46 mmol) in THF (30.0 mL) under N2, potassium tert-butoxide 
(1.04 g, 9.31 mmol) was added. The reaction mixture was stirred at room temperature for 2 h. The 
reaction was then quenched with saturated aqueous solution of NH4Cl (30 mL). The organic phase 
was separated and washed with a saturated aqueous solution of NaHCO3 (30 mL) and brine (30 
mL), dried over MgSO4 and concentrated in vacuo. Purification was carried out by column 
chromatography on silica gel eluting with a gradient of 0-70% ethyl acetate in petroleum ether to 




1H NMR (400 MHz, Chloroform-d) δ 7.45 – 7.28 (m, 5H, H11,12&13), 7.14 – 7.06 (m, 2H, H6), 
6.96 – 6.86 (m, 2H, H7), 5.34 – 5.16 (m, 1H, NH) 5.05 (s, 2H, H9), 4.01 (ddd, J = 8.0, 3.7, 1.3 Hz, 
1H, H3), 3.10 (dd, J = 14.0, 3.7 Hz, 1H, H4), 2.80 (dd, J = 14.0, 8.0 Hz, 1H, H4), 1.49 (s, 9H, H15) 
13C NMR (100 MHz, Chloroform-d) δ 174.14 (C2), 158.22 (C1), 158.03 (C8), 137.02 (C10), 130.60 
(C6), 128.75 (C12), 128.13 (C13), 127.58 (C5), 127.54 (C11), 115.29 (C7), 70.16 (C9), 57.81 (C3), 
57.49 (C14), 37.52 (C4), 28.62 (C15) 
HRMS-ESI (m/z) [M+Na]+ calc. for C21H24N2NaO3 375.1679, found 375.1689 
Rf - 0.24 in 50% EtOAc in petroleum ether 
IR νmax – 3266 (N-H), 2974, 2935 (C–H), 1700 (C=O) 
 
 
(S)-5-(4-(Benzyloxy)benzyl)-3-(tert-butyl)-2,4-dioxoimidazolidine-1-carbonyl chloride (233) 
To a solution of triphosgene (295 mg, 0.99 mmol) solution in dry dichloromethane (10.0 mL) 
under N2 at -78 oC, pyridine (0.24 mL, 2.98 mmol) was added. The resulting solution was stirred 
at the same temperature for 10 min before adding 231 (689 mg, 1.99 mmol) in dichloromethane 
(3.00 mL). The resulting mixture was slowly warmed to room temperature and stirred for 4 h. 
The mixture was concentrated in vacuo and purification was carried out by column 
chromatography on silica gel eluting with a gradient of 0-100% ethyl acetate in petroleum ether 
to yield 233 (378 mg, 47%) as a colourless oil.  
1H NMR (400 MHz, Chloroform-d) δ 7.43 – 7.29 (m, 5H, H11,12&13), 6.99 (d, J = 8.7 Hz, 2H, H6), 
6.90 (d, J = 8.7 Hz, 2H, H7), 5.04 (s, 2H, H9), 4.60 (dd, J = 4.8, 2.6 Hz, 1H, H3), 3.47 (dd, J = 
14.4, 4.8 Hz, 1H, H4), 3.23 (dd, J = 14.4, 2.6 Hz, 1H, H4), 1.34 (s, 9H, H15) 
13C NMR (100 MHz, Chloroform-d) δ 169.64 (C2), 158.63 (C1), 150.86 (C8), 143.73 (C10), 136.87 
(C16), 131.03 (C6), 128.73 (C11/12), 128.13 (C13), 127.50 (C11/12), 124.67 (C5), 115.38 (C7), 70.09 
(C9), 61.23 (C3), 60.00, 34.38 (C4), 28.14 (C15) 
HRMS-ESI (m/z) [M+Na]+ calc. for C22H23ClN2NaO4 437.1239, found 437.1243 
Rf - 0.63 in 50% EtOAc in petroleum ether 






(S)-3-(tert-Butyl)-5-(4-hydroxybenzyl)-2,4-dioxoimidazolidine-1-carbonyl chloride (243) 
To a solution of 233 (378 mg, 0.91 mmol) in THF (9.00 mL) under N2, palladium on active carbon 
(20 wt. %) (76.0 mg, 20 % wt.) was added. The mixture was then stirred at room temperature for 
1 hour under hydrogen atmosphere. The reaction mixture was filtered over a pad of celite and 
concentrated in vacuo. Purification was carried out by column chromatography on silica gel 
eluting with a gradient of 0-100% ethyl acetate in petroleum ether to yield 243 (200 mg, 68 %) as 
a white solid. 
1H NMR (400 MHz, Chloroform-d) δ 6.99 – 6.90 (m, 2H, H6), 6.78 – 6.71 (m, 2H, H7), 4.67 (s, 
1H, OH), 4.59 (dd, J = 4.8, 2.7 Hz, 1H, H3), 3.45 (dd, J = 14.4, 4.8 Hz, 1H, H4), 3.22 (dd, J = 
14.4, 2.7 Hz, 1H, H4), 1.36 (s, 9H, H10) 
13C NMR (100 MHz, Chloroform-d) δ 169.68 (C2), 155.53 (C1), 150.91 (C8), 131.24 (C6,11), 
124.55 (C5), 115.83 (C7), 61.26 (C3), 60.11 (C9), 34.39 (C4), 28.19 (C10) 
HRMS-ESI (m/z) [M+H]+ calc. for C15H17ClN2O4Na 347.0769, found 347.0774 
Rf - 0.55 in 50% EtOAc in petroleum ether 



















5.2 Oxazolidinone route 
 
 
Sodium (S,E)-2-(benzylideneamino)-3-(4-(tert-butoxy)phenyl)propanoate (245) 
O-tert-Butyl-L-tyrosine (600 mg, 2.53 mmol) was dissolved in NaOH (1M, 2.53 mL). The 
mixture was stirred at room temperature for 2 hours. The solution was then concentrated in vacuo 
and dried at 70 °C in vacuo overnight.  To the amino acid salt, molecular sieves, benzaldehyde 
(0.19 mL, 2.52 mmol) and absolute EtOH (4.50 mL) were added and the resultant mixture was 
stirred at room temperature for 5 hours. The mixture was then filtered and concentrated in vacuo. 
The residue was suspended in pentane, filtered, washed with pentane and dried at 70 °C in vacuo 
overnight to give 245 as a white solid (665.9 mg, 80%). 
1H NMR (400 MHz, Methanol-d4) δ 7.80 (s, 1H, H10), 7.66 (dd, J = 7.6, 2.0 Hz, 2H, H12/13), 7.41 
– 7.32 (m, 3H, H12/13&14), 7.08 (dd, J =  8.4 Hz, 2H, H5), 6.85 – 6.76 (m, 2H, H6), 3.99-3.92 (m, 
1H. H2), 3.38 – 3.33 (m, 1H,H3), 3.04 (dd, J = 13.5, 9.8 Hz, 1H, H3), 1.23 (s, 9H. H9)  
13C NMR (100 MHz, Methanol-d4) δ 179.57 (C1), 163.61 (c10), 154.48 (C7), 137.40 (C11), 135.97 
(C4), 131.63 (C14), 131.26 (C5), 129.45 (C13), 129.43 (C12), 125.00 (C6), 80.32 (C2), 79.36 (C8), 
41.03 (C3), 29.10 (C9) 













5.3 Synthesis of arogenate 
 
(S)-2-Amino-3-(4-(benzyloxy)phenyl)-N-methylpropanamide (254)133 
To a solution of O-Benzyl-L-tyrosine methyl ester hydrochloride (10.0 g, 31.1 mmol) in EtOH 
(60.0 mL), methylamine (33 % wt. in EtOH)(54.0 mL, 435.1 mmol) was added. The mixture was 
stirred at room temperature for 2 days. The solution was concentrated in vacuo, redissolved in 
dichloromethane (100 mL) and washed with a saturated aqueous solution of NaHCO3 (50 mL). 
The aqueous phase was extracted with dichloromethane (3 x 30 mL). The combined organics 
were washed with brine (30 mL), dried over MgSO4 and concentrated in vacuo to yield 254 (8.59 
g, 97 %) as a white powder. 
1H NMR (400 MHz, Chloroform-d) δ 7.46 – 7.27 (m, 5H, H11,12&13), 7.12 (d, J = 8.6 Hz, 2H, H6), 
6.92 (d, J = 8.6 Hz, 2H, H7), 5.04 (s, 2H, H9), 3.55 (dd, J = 9.3, 4.0 Hz, 1H, H3), 3.19 (dd, J = 
13.9, 4.0 Hz, 1H, H4), 2.80 (d, J = 5.0 Hz, 3H, H1), 2.63 (dd, J = 13.9, 9.3 Hz, 1H, H4) 
13C NMR (100 MHz, Chloroform-d) δ 174.86 (C2), 157.74 (C8), 137.01 (C10), 130.28 (C6), 130.21 
(C5), 128.59 (C12), 127.97 (C13), 127.45 (C11), 115.07 (C7), 70.06 (C9), 56.57 (C3), 40.19 (C4), 
25.81 (C1) 
HRMS-ESI (m/z) [M+H]+ calc. for C17H21N2O2 285.1597, found 285.1584 
Rf - 0.13 in 2% MeOH in EtOAc 





To a solution of 254 (4.06 g, 14.3 mmol) in dichloromethane (14.0 mL), MgSO4 (4 g, 100% wt.) 




overnight. The solution was filtered and washed with dichloromethane (10 mL). The filtrate was 
concentrated in vacuo to yield 251 (4.62 g, Quant.) as a white powder. 
1H NMR (400 MHz, Chloroform-d) δ 7.45 – 7.29 (m, 5H, H11,12&13), 6.98 (d, J = 8.5 Hz, 2H, H6), 
6.88 – 6.83 (m, 3H, H14, H7), 5.04 (s, 2H, H9), 3.65 (dd, J = 10.4, 3.1 Hz, 1H, H3), 3.28 (dd, J = 
13.5, 3.1 Hz, 1H, H4), 2.86 (d, J = 5.0 Hz, 3H, H1), 2.69 (dd, J = 13.5, 10.4 Hz, 1H, H4), 0.89 (s, 
9H, H16) 
13C NMR (100 MHz, Chloroform-d) δ 174.24 (C14), 173.44 (C2), 157.31 (C8), 137.07 (C10), 
131.01 (C6), 130.00 (C5), 128.52 (C12), 127.85 (C13), 127.32 (C11), 114.58 (C7), 74.49 (C3), 69.95 
(C9), 40.06 (C4), 36.21 (C15), 26.63 (C16), 25.86 (C1) 
HRMS-ESI (m/z) [M+H]+ calc. for C22H29N2O2 353.2224, found 353.2225 





 To a solution of 251 (3.10 g, 9.45 mmol) in THF (19.0 mL), phosgene (10.2 mL, 15% in toluene, 
14.2 mmol) was added. The mixture was stirred at room temperature for 2 hours. Pyridine (1.50 
mL, 18.9 mmol) was then added and the mixture stirred for a further 1 hour. The solution was 
concentrated in vacuo and redissolved in dichloromethane (30 mL). The organic phase was 
washed with HCl (1M, 50 mL) and extracted with dichloromethane (3 x 30 mL). The combined 
organics were washed with brine (20 mL), dried over MgSO4 and concentrated in vacuo. 
Purification was carried out by trituration using diethyl ether to yield 252 (2.85 g, 72 %) as a pale-
yellow powder. 
1H NMR (500 MHz, Chloroform-d) δ 7.45 – 7.36 (m, 5H, H11,12&13), 7.09 (d, J = 8.2 Hz, 2H, H6), 
6.86 (d, J = 8.2 Hz, 2H, H7), 5.03 (s, 2H, H9), 4.73 (s, 0.55H, H14), 4.62 (s, 0.45H, H14),  4.42 (s, 
0.55H, H3), 4.39 (s, 0.45H, H3),  3.80 (d, J = 14.6 Hz, 0.45H, H4), 3.69 (d, J = 14.6 Hz, 0.55H, 
H4), 3.29 (d, J = 14.5 Hz, 0.45H, H4), 3.21 (d, J = 14.5 Hz, 0.55H, H4) 2.87 (s, 1.65H, H1), 2.73 
(s, 1.35H, H1), 1.01 (s, 4.65H, H16), 0.94 (s, 4.35H, H16) – rotameric mixture 
 13C NMR (125 MHz, Chloroform-d) δ 169.82 (C2), 169.32 (C2), 158.07 (C8), 157.88 (C8), 147.30 




(C13), 127.56 (C11), 126.50 (C5), 126.10 (C5), 114.75 (C7), 114.58 (C7), 83.40 (C14), 82.79 (C14), 
69.92 (C9), 63.71 (C3), 62.79 (C3), 41.71 (C15), 41.57 (C15), 35.77 (C4), 32.05 (C1), 31.93 (C4), 
26.70 (C16), 26.44 (C16) – rotameric mixture 
HRMS-ESI (m/z) [M+H]+ calc. for C23H28ClN2O3 415.1783, found 415.1782 
Rf - 0.36 in 100% dichloromethane 





To a solution of 252 (1.25 g, 3.02 mmol) in THF (30.0 mL) under N2, palladium on active carbon 
(10 wt. %) (250 mg, 20 % wt.) was added. The mixture was then stirred at room temperature for 
4 hours under hydrogen atmosphere. The reaction mixture was filtered over a pad of celite and 
concentrated in vacuo to yield 220 (978 mg, 95 %) as a white powder. 
1H NMR (400 MHz, Chloroform-d) δ 7.04 (d, J = 8.0 Hz, 2H, H6), 6.72 (m, 2H, H7), 4.75 (s, 
0.53H, H9), 4.64 (s, 0.47H, H9), 4.40 (d, J = 11.9 Hz, 1H, H3), 3.81 (d, J = 14.6 Hz, 0.47H, H4), 
3.68 (d, J = 14.6 Hz, 0.53H, H4), 3.29 (d, J = 14.6 Hz, 0.47H, H4), 3.20 (d, J = 14.6 Hz, 0.53H, 
H4), 2.89 (s, 1.61H, H1), 2.76 (s, 1.38H, H1), 1.01 (s, 4.82H, H11), 0.94 (s, 4.18H, H11). – rotameric 
mixture 
13C NMR (126 MHz, Chloroform-d) δ 170.13 (C2), 169.61 (C2), 155.33 (C8), 154.99 (C8), 147.56 
(C12), 146.23 (C12), 131.50 (C6), 131.33 (C6), 126.23 (C5), 125.79 (C5), 115.47 (C7), 115.28 (C7), 
83.62 (C9), 83.02 (C9), 63.88 (C3), 62.99 (C3), 41.84 (C10), 41.70 (C10), 35.84 (C4), 32.23 (C1), 
32.00 (C4), 26.83 (C11), 26.56 (C11). – rotameric mixture 
HRMS-ESI (m/z) [M+H]+ calc. for C16H22ClN2O3 325.1313, found 325.1311 





Table 1 Crystal data and structure refinement for 220.  
Empirical formula  C16H21ClN2O3  
Formula weight  324.80  
Temperature/K  100(2)  
Crystal system  orthorhombic  
Space group  P212121  
a/Å  10.8233(2)  
b/Å  11.9161(3)  
c/Å  12.3076(3)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  1587.33(6)  
Z  4  
ρcalcg/cm3  1.359  
μ/mm-1  0.255  
F(000)  688.0  
Crystal size/mm3  0.426 × 0.396 × 0.166  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.758 to 55.812  
Index ranges  -8 ≤ h ≤ 14, -15 ≤ k ≤ 15, -16 ≤ l ≤ 16  
Reflections collected  14647  
Independent reflections  3800 [Rint = 0.0395, Rsigma = 0.0362]  
Data/restraints/parameters  3800/0/207  
Goodness-of-fit on F2  1.023  
Final R indexes [I>=2σ (I)]  R1 = 0.0298, wR2 = 0.0669  
Final R indexes [all data]  R1 = 0.0347, wR2 = 0.0691  
Largest diff. peak/hole / e Å-3  0.22/-0.21  






To a solution of 220 (5.20 g, 15.2 mmol) in MeCN (24.0 mL), triethylamine (2.70 mL, 19.1 mmol) 
was added. The mixture was then heated under microwave irradiation at 150 °C for 10 minutes. 
The reaction mixture was concentrated in vacuo, redissolved in dichloromethane (40 mL) and 




The combined organics were washed with brine (30 mL), dried over MgSO4, filtered and 
concentrated in vacuo to yield 222 (4.37 g, Quant.) as a yellow powder. 
1H NMR (400 MHz, Chloroform-d) δ 6.92 (dd, J = 10.1, 3.0 Hz, 1H, H6), 6.71 (dd, J = 10.1, 3.0 
Hz, 1H, H6), 6.47 (dd, J = 10.1, 1.8 Hz, 1H, H7), 6.40 (dd, J = 10.1, 1.8 Hz, 1H, H7), 4.85 (d, J = 
1.1 Hz, 1H, H1), 4.45 (t, J = 8.2 Hz, 1H, H3), 3.03 (s, 3H, H12), 2.61 (dd, J = 13.3, 7.4 Hz, 1H, 
H4), 2.46 (dd, J = 13.3, 9.0 Hz, 1H, H4), 1.04 (s, 9H, H11) 
13C NMR (100 MHz, Chloroform-d) δ 184.63 (C8), 173.86 (C2), 171.32 (C9), 146.11 (C6), 143.51 
(C6), 132.24 (C7), 130.86 (C7), 81.87 (C1), 56.85 (C3), 53.89 (C5), 38.35 (C10), 37.29 (C4), 31.44 
(C12), 25.77 (C11) 
HRMS-ESI (m/z) [M+Na]+ calc. for C16H21N2NaO3 311.1366, found 311.1365 
IR νmax – 2966 (C–H), 1698 (C=O) 
Rf - 0.31 in 100% EtOAc     
mp 193-195 °C 




spiro[cyclohexane-1,6'-pyrrolo[1,2-c]imidazole]-2,5-diene-1',5'-dione (225)  
To a solution of 220 (480 mg, 1.67 mmol) in dry methanol (17.0 mL) under N2, cerium(III) 
chloride heptahydrate (95.0 mg, 2.50 mmol) was added and stirred for 15 minutes at room 
temperature. The reaction mixture was then cooled to -78 °C and sodium borohydride (930 mg, 
2.50 mmol) was added. The resultant mixture was left to stir at -78 °C for a further 30 minutes 
and then quenched with water (10 mL). The mixture was then diluted with EtOAc (50 mL) and 
washed with water (30 mL). The aqueous phase was extracted with EtOAc (3 x 30 mL) and brine 
(30 mL). The organic phase was dried over MgSO4, filtered and concentrated in vacuo. 
Purification was carried out by column chromatography on silica gel eluting with 0-10% MeOH 
in dichloromethane to yield 225 (463 mg, 95 %, d.r. = 3.1:1) as white powders.  
Major - 225a                                                                                                                                                                                                                                                                                                                        
1H NMR (400 MHz, Chloroform-d) δ 6.23 (ddd, J = 9.9, 3.9, 1.7 Hz, 1H, H6), 6.14 (ddd, J = 9.9, 
3.9, 1.7 Hz, 1H, H7), 5.95 (ddd, J = 9.9, 2.3, 1.1 Hz, 1H, H7), 5.66 (ddd, J = 9.9, 2.3, 1.1 Hz, 1H, 




H3), 3.00 (s, 3H, H12), 2.49 (dd, J = 13.2, 7.7 Hz, 1H, H4), 2.16 (dd, J = 13.2, 8.7 Hz, 1H, H4), 
1.03 (s, 9H, H11) 
13C NMR (100 MHz, Chloroform-d) δ 177.84 (C2), 172.27 (C9), 131.56 (C6), 130.72 (C6), 129.74 
(C7), 128.50 (C7), 81.82 (C1), 61.45 (C8), 56.78 (C3), 50.62 (C5), 38.90 (C4), 38.38 (C10), 31.37 
(C12), 25.85 (C11) 
HRMS-ESI (m/z) [M+Na]+ calc. for C16H22N2NaO3 313.1522, found 313.1521 
IR νmax – 3392 (O-H), 3029, 2964, 2871 (C-H), 1695 (C=O) 
Rf - 0.23 in 5% MeOH in dichloromethane 
mp 58-59 °C 
[α]𝟐𝟔𝑫  = -4 (c = 1 in CHCl3) 
Minor – 225b 
1H NMR (400 MHz, Chloroform-d) δ 6.19 (ddd, J = 9.9, 3.1, 2.0 Hz, 1H, H6), 6.07 (ddd, J = 9.9, 
3.1, 2.0 Hz, 1H, H6), 5.92 (dt, J = 9.9, 2.0 Hz, 1H, H7), 5.63 (dt, J = 9.9, 2.0 Hz, 1H, H7), 4.82 (d, 
J = 1.2 Hz, 1H, H1), 4.71 (dtt, J = 8.9, 3.2, 1.7 Hz, 1H, H8), 4.38 (t, J = 8.2 Hz, 1H, H3), 3.03 (d, 
J = 0.6 Hz, 3H, H12), 2.51 (dd, J = 13.2, 7.5 Hz, 1H, H4), 2.23 (dd, J = 13.2, 8.9 Hz, 1H, H4), 1.04 
(s, 9H, H11) 
HRMS-ESI (m/z) [M+Na]+ calc. for C16H22N2NaO3 313.1522, found 313.1522 
IR νmax – 3335 (O-H), 2922, 2851 (C-H), 1692 (C=O) 
Rf - 0.15 in 5% MeOH in dichloromethane 
mp >220 °C decomposition 
[α]𝟐𝟔𝑫  = 8 (c = 1 in CHCl3) 
 
Table 1 Crystal data and structure refinement for 225b.  
Empirical formula  C16H22N2O3  
Formula weight  290.35  
Temperature/K  100(2)  
Crystal system  monoclinic  
Space group  P21  
a/Å  5.7583(3)  
b/Å  13.5711(6)  
c/Å  9.6541(5)  
α/°  90  
β/°  95.964(3)  
γ/°  90  
Volume/Å3  750.35(6)  
Z  2  
ρcalcg/cm3  1.285  
μ/mm-1  0.089  















To a solution of 225a (120 mg, 0.41 mmol) in water (2.00 mL), barium hydroxide (213 mg, 1.24 
mmol) was added. The mixture was stirred at 30 °C overnight, and then sodium carbonate 
anhydrous (263 mg, 2.48 mmol) and water (5 mL) were added. The resulting barium carbonate 
salt was separated by filtration and the aqueous layer was washed with dichloromethane (15 mL). 
The aqueous phase was then neutralised (approx. pH = 8) and lyophilised. The mixture was 
redissolved in ethanol and filtered to remove excess salt.  The product was purified by Hypercarb 
HPLC with a gradient of 0-100% acetonitrile in 100 mM ammonium bicarbonate buffer to yield 
256 (21 mg, 27 %) as a white powder. 
1H NMR  (600 MHz, Deuterium Oxide) δ 6.12 – 6.06 (m, 2H, H7), 5.90 (dt, J = 10.1, 2.0 Hz, 1H, 
H6), 5.84 (dt, J = 10.1, 2.0 Hz, 1H, H6), 4.59 (tt, J = 3.4, 1.5 Hz, 1H, H8), 4.27 (dd, J = 8.7, 6.3 
Hz, 1H, H3), 2.55 (dd, J = 13.3, 8.7 Hz, 1H, H4), 2.15 (dd, J = 13.3, 6.3 Hz, 1H, H4) 
13C NMR (150 MHz, Deuterium Oxide) δ 180.49 (C1), 180.16 (Br, C2), 129.97 (C6), 129.92 (C7), 
129.85 (C7), 129.37 (C6), 61.32 (C8), 55.83 (Br, C3) 48.54 (C5), 40.26 (C4) 
HRMS-Nanospray (m/z) [M-H]- calc. for C11H14NO5, 208.0610; found 208.0612 
CD spectra – Positive Cotton effect below 230 nm (consistent with literature) 
[α]𝟐𝟑𝑫  = -40 (c = 0.1 in H2O)  
 
Crystal size/mm3  0.534 × 0.23 × 0.136  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.242 to 55.984  
Index ranges  -7 ≤ h ≤ 7, -17 ≤ k ≤ 15, -12 ≤ l ≤ 12  
Reflections collected  10338  
Independent reflections  3447 [Rint = 0.0447, Rsigma = 0.0519]  
Data/restraints/parameters  3447/1/198  
Goodness-of-fit on F2  1.025  
Final R indexes [I>=2σ (I)]  R1 = 0.0411, wR2 = 0.0824  
Final R indexes [all data]  R1 = 0.0519, wR2 = 0.0867  
Largest diff. peak/hole / e Å-3  0.23/-0.21  







To a solution of 225a (32.2 mg, 0.11 mmol) in water (0.52 mL), barium hydroxide (52.0 mg, 0.32 
mmol) and barium carbonate (20.0 mg, 0.11 mmol) were added. The mixture was stirred at 80 °C 
for 5 hours, and then sodium carbonate anhydrous (70.0 mg, 0.63 mmol) and water (5 mL) were 
added. The resulting barium carbonate salt was filtered through a Whatman 0.45 μm Nylon 
syringe filter. The aqueous phase was lyophilised. The solid was redissolved in water (3 mL), 
filtered through a Millipore Millex-HN 0.45 μm Nylon syringe filter and purified by Hypercarb 
HPLC with a gradient of 0-80% acetonitrile in 10 mM sodium carbonate-bicarbonate buffer (pH 
9.2) to yield 1 as the disodium salt (41 % by quantitative NMR using a stock solution of EtOH) 
as a white powder. 
1H NMR (500 MHz, Deuterium Oxide) δ 5.93 – 5.86 (m, 3H, H6&7), 5.82 – 5.76 (m, 1H, H6&7), 
4.47 (d, J = 3.6 Hz, 1H, H8), 3.66 (dd, J = 10.5, 3.0 Hz, 1H, H3), 1.98 (dd, J = 14.3, 3.0 Hz, 1H, 
H4), 1.89 (dd, J = 14.3, 10.5 Hz, 1H, H4) (consistent with literature) 
13C NMR (126 MHz, Deuterium Oxide) δ 188.13 (C1), 186.94 (C2), 168.88 (Na2CO3), 138.06 
(C7), 137.81 (C6), 133.68 (C6), 132.19 (C7), 67.36 (C8), 60.57 (C3), 56.12 (C5), 46.94 (C4) 
(consistent with literature) 
CD spectra – Positive Cotton effect below 230 nm (consistent with literature) 
HRMS-Nanospray (m/z) [M-H]- calc. for C10H12NO5, 226.0715; found 226.0717 
 [α]𝟐𝟑𝑫  = -8 (c = 0.5 in H2O) 
 
 
Arogenate (1), Spiroarogenate (256), Imidazolidinone-protected arogenate (329) and 
rearomatised side product (331) 
To a solution of 225a (30.5 mg, 0.11 mmol) in water (0.52 mL), barium hydroxide (52.0 mg, 0.32 
mmol) and barium carbonate (20.0 mg, 0.11 mmol) were added. The mixture was stirred at 40 °C 
for 16 hours, and then sodium carbonate anhydrous (70.0 mg, 0.66 mmol) and water (5 mL) were 




syringe filter. The aqueous phase was lyophilised. The solid was redissolved in water (3 mL), 
filtered through a Millipore Millex-HN 0.45 μm Nylon syringe filter and purified by Hypercarb 
HPLC with a gradient of 0-80% acetonitrile in 10 mM sodium carbonate-bicarbonate buffer (pH 
9.2) to yield:  
1 as the disodium salt (36 % by quantitative NMR using a stock solution of EtOH) as a white 
powder. 
256 as the sodium salt (12 % by quantitative NMR using a stock solution of EtOH) as a white 
powder. 
329 as the disodium salt (14% by quantitative NMR using a stock solution of EtOH) as a white 
powder. 
331 as the sodium salt* (4 % by quantitative NMR using a stock solution of EtOH) as a white 
powder  
























2-((tert-Butoxycarbonyl)amino)-3-(2-hydroxyphenyl)propanoic acid (261) 
To a solution of DL-o-tyrosine (1.06 g, 5.85 mmol) in dioxane:water (30.0 mL, 1:1) sodium 
hydrogen carbonate (1.47 g, 17.53 mmol) was added portionwise. To this mixture boc anhydride 
(1.53 g, 7.02 mmol) was added and the reaction mixture was stirred at room temperature 
overnight. The resulting mixture was concentrated in vacuo to approx. 10 mL and the residue was 
acidified with 2M HCl to pH 2. The aqueous was then extracted with ethyl acetate (3 x 20 mL). 
The combined organic phases were washed with brine (20 mL), dried over MgSO4, and 
concentrated in vacuo to yield 261 (1.45 g, 88 %) as a white foam. 
1H NMR (500 MHz, Methanol-d4) δ 7.12 – 7.03 (m, 2H, H6&8), 6.82 – 6.73 (m, 2H, H7&9), 4.39 
(m, 1H, H3), 3.18 (m, 1H, H4), 2.95 – 2.80 (m, 1H, H4), 1.39 (s, 6.74H, H12), 1.34 (s, 2.26H, H12) 
13C NMR (125 MHz, Methanol-d4) δ 174.03 (C2), 157.82 (C1), 156.65 (C10), 132.24 (C6), 129.07 
(C8), 124.86 (C5), 120.54 (C7), 115.84 (C9), 80.40 (C11), 55.70 (C3), 33.37 (C4), 28.66 (C12) 
HRMS-ESI (m/z) [M+Na]+ calc. for C14H19NNaO5 304.1155, found 304.1153 
IR νmax – 3346 (O-H), 2978, 2933 (C-H), 1678 (C=O) 
Rf - 0.41 in 25% EtOAc in petroleum ether 
 
 
Benzyl 3-(2-(benzyloxy)phenyl)-2-((tert-butoxycarbonyl)amino)propanoate (262) 
To a solution of 261 (1.40 g, 4.98 mmol) in dry DMF (20.0 mL) under N2, potassium carbonate 
(1.72 g, 12.5 mmol), benzyl bromide (1.50 mL, 12.5 mmol), and tetraethylammonium iodide (160 




resultant mixture was diluted with ether (40 mL) and washed with water (30 mL). The aqueous 
phase was extracted with ether (3 x 30 mL) and the combined organics were washed with 1M 
HCl (20 mL) and brine (20 mL), dried over MgSO4, and concentrated in vacuo. Purification was 
carried out by column chromatography on silica gel eluting with a gradient of 2-50% ethyl acetate 
in petroleum ether to yield 262 (1.57 g, 68 %) as a white solid.   
1H NMR (500 MHz, Chloroform-d) δ 7.47 – 7.42 (m, 2H, H13), 7.37 – 7.29 (m, , 6H, H14,15,19&20), 
7.26 – 7.22 (m, 2H, H18), 7.20 (t, J = 7.5 Hz, 1H, H8), 7.11 – 7.04 (m, 1H, H6), 6.94 – 6.84 (m, 
2H, H9), 5.34 (d, J = 7.9 Hz, 1H, NH), 5.13 – 5.04 (m, 4H, H11&16), 4.60 (td, J = 8.0, 5.2 Hz, 1H, 
H3), 3.19 (dd, J = 13.7, 5.2 Hz, 1H, H4), 3.07 (dd, J = 13.7, 8.0 Hz, 1H, H4), 1.37 (s, 9H, H22) 
13C NMR (125 MHz, Chloroform-d) δ 172.37 (C2), 156.91 (C1), 155.40 (C10), 136.98 (C12), 
135.70 (C17), 131.46 (C6), 128.60 (Ar), 128.75 (C8), 128.54 (Ar), 128.30 (Ar), 128.03 (C13), 
127.34 (C14), 125.23 (C5), 121.15 (C7), 112.01 (C9), 79.68 (C21), 70.35 (C11), 66.89 (C16), 54.59 
(C3), 33.01 (C4), 28.43 (C22) 
HRMS-ESI (m/z) [M+Na]+ calc. for C28H31NNaO5 484.2094, found 484.2093 
IR νmax – 3415 (N-H), 3032, 2977, 2930 (C-H), 1742, 1713 (C=O) 




tert-Butyl (3-(2-(benzyloxy)phenyl)-1-(methylamino)-1-oxopropan-2-yl)carbamate (263) 
To a solution of 262 (1.67 g, 3.62 mmol) in EtOH (22 mL), methylamine (9.8 mL, 50.69 mmol) 
was added. The mixture was stirred at room temperature for 2 days. The solution was concentrated 
in vacuo, redissolved in dichloromethane (30 mL) and washed with a saturated aqueous solution 
of NaHCO3 (30 mL). The aqueous phase was extracted with dichloromethane (3 x 20 mL). The 
combined organics were washed with brine (20 mL), dried over MgSO4 and concentrated in 
vacuo. Purification was carried out by column chromatography on silica gel eluting with a 
gradient of 2-100% ethyl acetate in petroleum ether to yield 263 (1.02 g, 73 %) as a white solid. 
1H NMR (500 MHz, Chloroform-d) δ 7.51 – 7.45 (m, 2H, H13), 7.45 – 7.39 (m, 2H, H14), 7.39 – 
7.33 (m, 1H, H15), 7.25 – 7.16 (m, 2H, H6&8), 6.98 – 6.88 (m, 2H, H7&9), 5.82 (s, 1H, NH), 5.40 
(s, 1H, NH), 5.10 (d, J = 3.0 Hz, 2H, H11), 4.28 (s, 1H, H3), 3.16 (dd, J = 13.7, 4.8 Hz, 1H, H4), 




13C NMR (125 MHz, Chloroform-d) δ 172.42 (C2), 156.69 (C1&10), 136.88 (C12), 131.55 (C6), 
128.90 (C14), 128.38 (C8), 128.33 (C15), 127.78 (C13), 126.19 (C5), 121.39 (C7), 111.84 (C9), 79.93 
(C17), 70.52 (C11), 56.12 (C3), 33.40 (C4), 28.37 (C18), 26.17 (C16) 
HRMS-ESI (m/z) [M+Na]+ calc. for C22H29N2NaO4 407.1941, found 407.1954 
IR νmax – 3314 (N-H), 3064, 2976, 2932 (C-H), 1703, 1659 (C=O) 




To a solution of 263 (1.00 g, 2.60 mmol) in MeOH (10.0 mL) at 0 ⁰C, acetyl chloride (1.00 mL, 
14.0 mmol) was added dropwise. The solution was warmed to room temperature and left to stir 
overnight. The resultant mixture was diluted with dichloromethane (50 mL) and washed with a 
saturated aqueous solution of NaHCO3 (20 mL) and brine (20 mL), dried over MgSO4 and 
concentrated in vacuo to yield 264 (733 mg, 97%) as a clear oil. 
1H NMR (400 MHz, Chloroform-d) δ 7.48 – 7.30 (m, 5H, H12,13,14&15), 7.24 – 7.16 (m, 2H, H6&8), 
7.09 (s, 1H, NH), 6.99 – 6.90 (m, 2H, H7&9), 5.10 (s, 2H, H11), 3.64 (dd, J = 9.3, 3.9 Hz, 1H, H3), 
3.36 (dd, J = 13.6, 3.9 Hz, 1H, H4), 2.81 – 2.72 (m, 4H, H1&4) 
13C NMR (125 MHz, Chloroform-d) δ 175.39 (C2), 156.98 (C10), 137.10 (C12), 131.42 (C6), 
128.81 (C14), 128.13 (C15), 128.10 (C8), 127.41 (C5), 127.39 (C13), 121.24 (C7), 112.04 (C9), 70.24 
(C11), 56.09 (C3), 35.80 (C4), 25.90 (C1) 
HRMS-ESI (m/z) [M+Na]+ calc. for C17H20N2NaO2 307.1416, found 307.1412 
IR νmax – 3367, 3321 (N-H), 3066, 3032, 2932 (C-H), 1659 (C=O) 










To a solution of 264 (700 mg, 2.46 mmol) in dichloromethane (5.00 mL) under N2, MgSO4 (700 
mg, 100% wt.) and pivaldehyde (0.32 mL, 2.96 mmol) were added. The mixture was stirred at 
room temperature overnight. The solution was filtered and washed with dichloromethane (10 
mL). The filtrate was concentrated in vacuo to yield 265 (855 mg, Quant.) as a pale-yellow 
powder. 
1H NMR (500 MHz, Chloroform-d) δ 7.52 (d, J = 8.3 Hz, 2H, H13), 7.44 – 7.36 (m, 2H, H14), 
7.34 – 7.27 (m, 1H, H15), 7.18 – 7.10 (m, 1H, H8), 7.00 – 6.92 (m, 2H, H6 & NH), 6.88 (d, J = 8.3 
Hz, 1H, H9), 6.83 (t, J = 7.4 Hz, 1H, H7), 6.76 (s, 1H, H16), 5.12 (s, 2H, H11), 3.93 (dd, J = 10.8, 
3.4 Hz, 1H, H3), 3.58 (dd, J = 13.2, 3.4 Hz, 1H, H4), 2.88 (d, J = 4.9 Hz, 3H, H1), 2.80 – 2.72 (m, 
1H, H4), 0.81 (s, 9H, H18) 
13C NMR (125 MHz, Chloroform-d) δ 174.01 (C16), 173.97 (C2), 156.86 (C10), 137.43 (C5), 
132.47 (C6), 128.67 (C14), 127.87 (C8), 127.80 (C13), 127.05 (C15), 126.63 (C12), 120.53 (C7), 
111.90 (C9), 72.06 (C3), 69.79 (C11), 36.18 (C17), 35.99 (C4), 26.65 (C18), 26.01 (C1) 





To a solution of 265 (800 mg, 2.46 mmol) in THF (5.00 mL) under N2, phosgene (2.30 mL, 15% 
in toluene, 3.20 mmol) was added dropwise. The mixture was stirred at room temperature for 30 
minutes. Pyridine (0.40 mL, 4.92 mmol) was then added and the mixture stirred for a further 2 




organic phase was washed with HCl (1M, 3 x 20 mL) and brine (20 mL), then dried over MgSO4 
and concentrated in vacuo. Purification was carried out by column chromatography on silica gel 
eluting with 100% dichloromethane to yield 266 (432 mg, 42 %) as a white solid. 
1H NMR (500 MHz, Chloroform-d) δ 7.34 (d, J = 7.5 Hz, 2H, H13), 7.29 – 7.22 (m, 2H, H14), 
7.19 (t, J = 7.3 Hz, 1H, H15), 7.09 – 6.98 (m, 2H, H6&8), 6.81 – 6.70 (m, 2H, H7&9), 5.06 – 4.94 
(m, 2H, H11), 4.77 (s, 1H, H16), 4.40 (s, 1H, H3), 3.72 (s, 1H, H4), 3.29 (d, J = 14.5 Hz, 1H, H4), 
2.71 (s, 3H, H19), 0.89 (s, 9H, H18). – rotameric mixture – VT @ 50 ⁰C 
13C NMR (125 MHz, Chloroform-d) δ 169.98 (C2), 157.31 (C10), 137.46 (C1), 131.37 (C6), 128.71 
(C12), 128.57 (C14), 128.40 (C8), 127.89 (C15), 127.69 (C13), 127.12 (C5), 120.54 (C7), 112.28 (C9), 
83.20 (C16), 70.39 (C11), 62.29 (C3), 42.04 (C4), 32.18 (C19), 26.89 (C18). – rotameric mixture – 
VT @ 50 ⁰C 
 HRMS-ESI (m/z) [M+H]+ calc. for C23H28ClN2O3 415.1782, found 415.1785 
IR νmax – 3070, 3033, 2966, 2876 (C-H), 1744, 1713 (C=O) 
Rf - 0.57 in 50% EtOAc in petroleum ether 
 
 
2-(tert-Butyl)-5-(2-hydroxybenzyl)-3-methyl-4-oxoimidazolidine-1-carbonyl chloride (258) 
To a solution of 266 (400 mg, 0.97 mmol) in THF (9.00 mL) under N2, palladium on active carbon 
(10 wt. %) (80 mg, 20 % wt.) was added. The mixture was then stirred at room temperature for 2 
hours under hydrogen atmosphere. The reaction mixture was filtered over a pad of celite and 
concentrated in vacuo. Purification was carried out by column chromatography on silica gel 
eluting with a gradient of 0-100% ethyl acetate in petroleum ether to yield 258 (220 mg, 66 %) as 
a white solid. 
1H NMR (500 MHz, Chloroform-d) δ 7.54 (s, br, 1H, OH), 7.17 – 7.09 (m, 2H, H6&8), 6.91 (d, J 
= 8.1 Hz, 1H, H9), 6.84 (t, J = 7.5 Hz, 1H, H7), 5.00 (s, 1H, H11), 4.46 (s, 1H, H3), 3.57 (s, 1H, 
H4), 3.40 (d, J = 15.1 Hz, 1H, H4), 2.91 (s, 3H, H14), 1.03 (s, 9H, H13). – rotameric mixture – VT 
@ 50 ⁰C 
13C NMR (125 MHz, Chloroform-d) δ 172.69 (C2), 155.33 (C1&10), 131.71 (C6), 129.12 (C8), 
122.09 (C5), 120.83 (C7), 118.54 (C9), 84.13 (C11), 63.59 (C3), 41.76 (C4), 32.50 (C14), 29.78 (C12), 
26.86 (C13). – rotameric mixture – VT @ 50 ⁰C 
HRMS-ESI (m/z) [M+Na]+ calc. for C16H21ClN2NaO3 347.1132, found 347.1134 








To a solution of 258 (30.0 mg, 0.09 mmol) in dry acetonitrile (0.60 mL) under N2, potassium 
iodide (16.9 mg, 0.10 mmol) and triethylamine (14 μL, 0.10 mmol) were added. The mixture was 
the subjected to the microwave at 150 °C for 5 minutes at very high absorption. The reaction 
mixture was concentrated in vacuo, redissolved in dichloromethane (20 mL) and washed with 
water (10 mL). The aqueous phase was extracted with dichloromethane (3 x 30 mL). The 
combined organics were washed with brine (30 mL), dried over MgSO4, filtered and concentrated 
in vacuo to yield 268 (19.0 mg, 77 %) as a white solid. 
1H NMR (500 MHz, Chloroform-d) δ 7.35 – 7.26 (m, 1H, H8), 7.28 – 7.22 (m, 1H, H6), 7.21 – 
7.14 (m, 2H, H7&9), 5.45 (d, J = 0.8 Hz, 1H, H11), 4.06 (dd, J = 12.0, 2.2 Hz, 1H, H3), 3.29 (dd, J 
= 14.5, 2.2 Hz, 1H, H4), 3.15 – 3.05 (m, 4H, H4&14), 0.97 (s, 9H, H13) 
13C NMR (125 MHz, Chloroform-d) δ 169.76 (C1), 151.30 (C2), 151.05 (C10), 129.51 (C5), 129.05 
(C8), 128.70 (C6), 126.18 (C7), 120.21 (C9), 83.22 (C11), 63.52 (C3), 39.40 (C12), 32.00 (C14), 31.88 
(C4), 26.20 (C13) 
HRMS-ESI (m/z) [M+H]+ calc. for C16H21N2O3 289.1546, found 289.1551 
IR νmax – 2962, 2922, 2852 (C-H), 1699 (C=O) 
















5.4.2 3-Methyl Arogenate 
 
 
(S)-2-((tert-Butoxycarbonyl)amino)-3-(4-hydroxy-3-iodophenyl)propanoic acid (270)134 
To a solution of 3-iodo-L-tyrosine (5.00 g, 16.3 mmol) in dioxane:water (80.0 mL, 1:1) sodium 
hydrogen carbonate (4.10 g, 48.9 mmol) was added portionwise. To this mixture boc anhydride 
(4.30 g, 19.6 mmol) was added and stirred at room temperature overnight. The resulting mixture 
was concentrated in vacuo to approx. 40 mL and the residue was acidified with 2M HCl to pH 2. 
The aqueous was then extracted with ethyl acetate (3 x 50 mL) and the organics was washed with 
brine (30 mL), dried over MgSO4, and concentrated in vacuo to yield 270 (6.63 g, quant.) as a 
white powder. 
1H NMR (400 MHz, Chloroform-d) δ 7.48 (s, 1H, H10), 7.06 (dd, J = 8.3, 2.1 Hz, 1H, H6), 6.91 
(d, J = 8.3 Hz, 1H, H7), 4.95 (d, J = 7.9 Hz, 1H, NH), 4.53 (d, J = 7.3 Hz, 1H, H3), 3.19 – 2.91 
(m, 2H, H4), 1.44 (s, 9H, H12) 





To a solution of 270 (6.30 g, 16.3 mmol) in DMF (65.0 mL), potassium carbonate (5.60 g, 40.8 
mmol), benzyl bromide (4.85 mL, 40.8 mmol), and tetraethylammonium iodide (523 mg, 2.04 
mmol) were added. The reaction mixture was stirred at room temperature overnight. The resultant 
mixture was diluted with ether (150 mL) and washed with water (50 mL). The aqueous phase was 
extracted with ether (3 x 50 mL). The combined organics were washed with 1M HCl (50 mL) and 




column chromatography on silica gel eluting with a gradient of 0-50% ethyl acetate in hexane to 
yield 271 (8.89 g, 92 %) as a white powder.   
1H NMR (500 MHz, Chloroform-d) δ 7.55 (s, 1H, H10), 7.49 (d, J = 7.1 Hz, 2H, H15), 7.42 – 7.29 
(m, 8H, H16,17,20,21&22), 6.93 (d, J = 8.3 Hz, 1H, H6), 6.68 (d, J = 8.3 Hz, 1H, H7), 5.20 – 5.07 (m, 
4H, H13,18), 5.00 (d, J = 8.0 Hz, 1H, NH), 4.57 (m, 1H, , H3), 2.99 (m, 2H, H4), 1.43 (s, 9H, H12) 
13C NMR (125 MHz, Chloroform-d) δ 171.64 (C2), 156.47 (C8), 155.12 (C1), 140.42 (C10), 136.63  
(C14), 135.19 (C19), 130.57 (C6), 130.38 (C5), 128.78 (C16), 128.70 (C20&21), 128.66 (C17), 128.03 
(C22), 127.09  (C15), 112.63 (C7), 86.89 (C9), 80.19 (C11), 71.03 (C18), 67.37 (C13), 54.63 (C3), 
37.06 (C4), 28.46 (C12) 
HRMS-ESI (m/z) [M+Na+] calc. for C28H30INO5Na, 610.1061; found 610.1053 
IR νmax – 3363 (N-H), 2975, 2931 (C–H), 1740, 1711 (C=O) 
Rf - 0.54 in 25% EtOAc in Hexane 





To a solution of 271 (8.70 g, 14.8 mmol) in EtOH (30.0 mL), methylamine (33 % wt. in 
EtOH)(12.9 mL, 104 mmol) was added. The mixture was stirred at room temperature for 2 days. 
The solution was concentrated in vacuo, redissolved in dichloromethane (80 mL) and washed 
with a saturated aqueous solution of NaHCO3 (50 mL). The aqueous phase was extracted with 
dichloromethane (3 x 30 mL). The combined organics were washed with brine (30 mL), dried 
over MgSO4 and concentrated in vacuo to yield 272 (7.75 g, Quant.) as a white powder. 
1H NMR (500 MHz, Chloroform-d) δ 7.63 (d, J = 2.2 Hz, 1H, H10), 7.51 – 7.44 (m, 2H, H15), 
7.39 (t, J = 7.4 Hz, 2H, H16), 7.32 (t, J = 7.4 Hz, 1H, H17), 7.10 (dd, J = 8.4, 2.2 Hz, 1H, H6), 6.77 
(d, J = 8.4 Hz, 1H, H7), 5.78 (s, 1H, NH), 5.12 (s, 2H, H13), 5.07 – 4.96 (m, 1H, NH), 4.21 (m, 
1H, H3), 2.95 (m, 2H, H4), 2.74 (d, J = 4.8 Hz, 3H, H18), 1.41 (s, 9H, H12) 
13C NMR (125 MHz, Chloroform-d) δ 171.63 (C1), 156.38 (C2), 155.50 (C8), 140.29 (C10), 136.57 
(C14), 131.45 (C5), 130.41 (C6), 128.70 (C16), 128.06 (C17), 127.13 (C15), 112.76 (C7), 86.99 (C9), 
71.05 (C13), 56.15 (C3), 37.51 (C4), 28.44 (C12), 26.32 (C18) 




IR νmax – 3325 (NH), 2970, 2921, 2851 (C-H), 1683, 1649 (C=O) 
Rf - 0.51 in 10% MeOH in dichloromethane 
mp 114-116 °C  





To a solution of 272 (7.75 g, 15.2 mmol) in Dry degassed dioxane (100 mL), cesium carbonate 
(24.9 g, 76.4 mmol), SPhos Pd G2 (1.01 g, 1.52 mmol) and Methyl boronic acid (4.60 g, 76.4 
mmol) were added. The mixture was stirred at 90 oC overnight. The solution was diluted with 
dichloromethane (100 mL) and water (100 mL). The aqueous phase was extracted with 
dichloromethane (3 x 50 mL). The combined organic phases dried over MgSO4 and concentrated 
in vacuo. Purification was carried out by column chromatography on silica gel eluting with 0-
100% EtOAc in petroleum ether to yield 275 (4.43 g, 73 %) as a yellow powder. 
1H NMR (500 MHz, Chloroform-d) δ 7.45 – 7.41 (m, 2H, H15), 7.38 (t, J = 7.5 Hz, 2H, H16), 7.35 
– 7.28 (m, 1H, H17), 7.11 (d, J = 8.3 Hz, 0.25H, H6), 6.99 (s, 1H, H10), 6.95 (d, J = 8.3 Hz, 0.75H, 
H6), 6.91 (m, 0.25H, H7), 6.80 (d, J = 8.3 Hz, 0.75H, H7), 5.66 (s, 1H, NH), 5.05 (s, 2H, H13), 4.21 
(m, 1H, H3), 3.03 – 2.97 (m, 1H, H4), 2.91 (m, 1H, H4), 2.72 (d, J = 4.9 Hz, 3H, H18), 2.25 (s, 3H, 
H19), 1.41 (s, 9H, H12) – rotameric mixture 
13C NMR (125 MHz, Chloroform-d) δ 172.02 (C2), 156.01 (C8), 155.54 (C1), 137.51 (C14), 131.79 
(C10), 130.46 (C6), 128.72 (C5), 128.65 (C16), 127.92 (C17), 127.61 (C9), 127.58 (C6), 127.23 (C15), 
115.16 (C7), 111.66 (C7), 80.24 (C11), 70.03 (C13), 56.37 (C3), 38.11 (C4), 28.44 (C12), 26.26 (C18), 
16.49 (C19) – rotameric mixture 
HRMS-ESI (m/z) [M+Na]+ calc. for C23H30N2O4Na, 421.2098; found 421.2101 
IR νmax – 3317 (N-H), 3063, 3032 (Ar-H), 2973, 2929, 2856 (C-H), 1704, 1658 (C=O) 
Rf - 0.65 in dichloromethane 
mp 134-135 °C  







To a solution of 275 (4.30 g, 10.8 mmol) in MeOH (43.0 mL) at 0 oC, acetyl chloride (4.15 mL, 
58.3 mmol) was slowly added. The mixture was warmed to room temperature and stirred 
overnight. The solution was diluted with dichloromethane (200 mL) and washed with saturated 
NaHCO3 (50 mL) and brine (30 mL). The organic phase was dried over MgSO4 and concentrated 
in vacuo. Purification was carried out by column chromatography on silica gel eluting with a 
gradient of 0-10% methanol in dichloromethane to yield 274 (3.11 g, 97%) as a yellow powder.  
1H NMR (500 MHz, Chloroform-d) δ 7.46 – 7.41 (m, 2H, H15), 7.41 – 7.36 (m, 2H, H16), 7.34 – 
7.29 (m, 1H, H17), 7.02 (d, J = 2.2 Hz, 1H, H10), 6.98 (dd, J = 8.2, 2.2 Hz, 1H, H6), 6.82 (d, J = 
8.2 Hz, 1H, H7), 5.06 (s, 2H, H13), 3.57 (dd, J = 9.4, 4.1 Hz, 1H, H3), 3.19 (dd, J = 13.8, 4.1 Hz, 
1H, H3), 2.82 (d, J = 5.0 Hz, 3H, H12), 2.60 (dd, J = 13.8, 9.4 Hz, 1H, H4), 2.27 (s, 3H, H11) 
13C NMR (125 MHz, Chloroform-d) δ 175.01 (C2), 155.97 (C8), 137.56 (C10), 131.79 (C14), 
129.86 (C5), 128.65 (C16), 127.90 (C17), 127.55 (C6), 127.53 (C9), 127.21 (C15), 111.69 (C7), 70.05 
(C13), 56.72 (C3), 40.26 (C4), 25.95 (C12), 16.55 (C11) 
HRMS-ESI (m/z) [M+H]+ calc. for C18H23N2O2, 299.1754; found 299.1747 
IR νmax – 3366, 3299 (N-H), 3064, 3032 (Ar-H), 2921 (C-H), 1654 (C=O) 
Rf - 0.25 in 10% MeOH in dichloromethane 
mp 78-80 °C  





To a solution of 274 (3.00 g, 10.1 mmol) in dichloromethane (10.0 mL), MgSO4 (3.00 g, 100% 




temperature overnight. The solution was filtered and washed with dichloromethane (3 x 30 mL). 
The filtrate was concentrated in vacuo to yield 276 (3.68 g, Quant.) as a white powder. 
1H NMR (400 MHz, Chloroform-d) δ 7.45 – 7.40 (m, 2H, H15), 7.40 – 7.34 (m, 2H, H16), 7.33 – 
7.28 (m, 1H, H17), 6.91 (d, J = 5.0 Hz, 1H, NH), 6.86-6.79 (m, 3H, H1,7&10), 6.75 (d, J = 8.0 Hz, 
1H, H6), 5.05 (s, 2H, H13), 3.63 (dd, J = 10.5, 3.0 Hz, 1H, H3), 3.26 (dd, J = 13.5, 3.0 Hz, 1H, H4), 
2.84 (d, J = 5.0 Hz, 3H, H18), 2.64 (dd, J = 13.5, 10.5 Hz, 1H, H4), 2.23 (s, 3H, H19), 0.89 (s, 9H, 
H12) 
13C NMR (100 MHz, Chloroform-d) δ 174.26 (C1), 173.72 (C2), 155.52 (C8), 137.64 (C14), 132.76 
(C10), 129.73 (C5), 128.60 (C16), 128.23 (C7&1), 127.81 (C17), 127.12 (C15), 126.71 (C9), 111.44 
(C6), 74.67 (C3), 70.00 (C13), 40.23 (C4), 36.38 (C11), 26.79 (C12), 26.01 (C18), 16.49 (C19) 




carbonyl chloride (277) 
To a solution of 276 (3.68 g, 10.1 mmol) in THF (20.0 mL), phosgene (10.8 mL, 15% in toluene, 
15.1 mmol) was added. The mixture was stirred at room temperature for 2 hours. Pyridine (1.63 
mL, 20.1 mmol) was then added and the mixture stirred for a further 2 hours. The solution was 
concentrated in vacuo and redissolved in dichloromethane (50 mL). The organic phase was 
washed with HCl (1M, 3 x 30 mL) and brine (20 mL), then dried over MgSO4 and concentrated 
in vacuo. Purification was carried out by column chromatography on silica gel eluting with a 
gradient of 0-100% EtOAc in hexane to yield 277 (3.46 g, 80 %) as a pale yellow powder. 
1H NMR (400 MHz, Chloroform-d) δ 7.43 (d, J = 7.0 Hz, 2H, H15), 7.41 – 7.35 (m, 2H, H16), 
7.33 – 7.29 (m, 1H, H17), 7.00-6.90 (m, 2H, H6&10), 6.76 (d, J = 8.3 Hz, 1H, H7), 5.04 (s, 2H, H13), 
4.72 (s, 0.54H, H1), 4.60 (s, 0.46H, H1), 4.41 (m, 0.54H, H3), 4.37 (m, 0.46H, H3), 3.78 (m, 0.46H, 
H4), 3.65 (m, 0.54H, H4), 3.27 (m, 0.46H, H4), 3.18 (m, 0.54H, H4), 2.86 (s, 1.62H, H19), 2.75 (s, 
1.38H, H19), 2.23 (s, 3H, H20), 1.00 (s, 4.86H, H12), 0.93 (s, 4.14H, H12) – rotameric mixture 
13C NMR (125 MHz, Chloroform-d) δ 170.05 (C2), 169.64 (C2), 156.24 (C8), 156.02 (C8), 147.42 
(C18), 146.24 (C18), 137.55 (C14), 137.46 (C14), 132.48 (C10), 132.26 (C10), 128.58 (C16&6), 127.85 




63.89 (C3), 62.87 (C3), 41.80 (C11), 41.70 (C11), 35.92 (C4), 32.14 (C19), 32.09 (C4), 26.79 (C12), 
26.54 (C12), 16.34 (C20) – rotameric mixture 
HRMS-ESI (m/z) [M+H]+ calc. for C24H29N2O3Cl, 429.1939; found 429.1924 
IR νmax – 2963, 2931 (C-H), 1739, 1708 (C=O) 
Rf - 0.59 in 50% EtOAc in Hexane 
mp 92-94 °C  





To a solution of 277 (3.35 g, 7.82 mmol) in THF (39.0 mL) under N2, palladium on active carbon 
(10 wt. %) (670 mg, 20 % wt.) was added. The mixture was then stirred at room temperature for 
2 hours under hydrogen atmosphere. The reaction mixture was filtered over a pad of celite and 
concentrated in vacuo to yield 278 (2.61 g, 94 %) as a white powder. 
1H NMR (500 MHz, Chloroform-d) δ 6.93 (s, 1H, H10), 6.87 (d, J = 8.2 Hz, 1H, H6/7), 6.65 (t, J 
= 8.6 Hz, 1H, H6/7), 4.73 (s, 0.55H, H1), 4.62 (s, 0.45H, H1) 4.44 – 4.34 (m, 1H, H3), 3.84 – 3.72 
(m, 0.55H, H4), 3.64 (m, 0.45H, H4) 3.26 (m, 0.45H, H4), 3.15 (m, 0.55H, H4), 2.88 (s, 1.65H, 
H13), 2.77 (s, 1.35H, H13), 2.19 (s, 3H, H15), 1.00 (s, 4.95H, H12), 0.93 (s, 4.05H, H12) – rotameric 
mixture 
13C NMR (126 MHz, Chloroform-d) δ 170.19 (C2), 169.77 (C2), 153.47 (C8), 153.14 (C8), 147.54 
(C14), 146.31 (C14), 132.83 (C10), 132.61 (C10), 128.88 (C6/7), 128.73 (C6/7), 126.16 (C5), 125.77 
(C5), 124.02 (C9), 123.71 (C9), 114.95 (C6/7), 114.82 (C6/7), 83.59 (C1), 82.99 (C1), 63.95 (C3), 
62.95 (C3), 41.83 (C11), 41.71 (C11), 35.87 (C4), 32.19 (C4), 32.04 (C13), 26.80 (C12), 26.55 (C12), 
15.75 (C15) – rotameric mixture 
HRMS-ESI (m/z) [M+H-H2O]+ calc. for C17H23N2O3, 303.1703; found 303.1703 
IR νmax – 3363 (O-H), 2968, 2875 (C-H), 1738, 1691 (C=O) 
Rf - 0.46 in 10% MeOH in Dichloromethane 
mp 134-135 °C  









To a solution of 278 (1.1 g, 3.08 mmol) in MeCN (4.4 mL), triethylamine (0.46 mL, 3.39 mmol) 
was added. The mixture was then heated under microwave irradiation at 150 °C for 10 minutes. 
The reaction mixture was concentrated in vacuo, redissolved in dichloromethane (20 mL) and 
washed with water (20 mL). The aqueous phase was extracted with dichloromethane (3 x 20 mL).  
The organic layer was washed with brine (10 mL), dried over MgSO4 and concentrated in vacuo 
to yield 279 (926 mg, Quant., 1:1) as a white powder.  
1H NMR (400 MHz, Chloroform-d) δ 6.90 (dd, J = 9.8, 3.0 Hz, 0.5H, H6), 6.71 – 6.65 (m, 1H, 
H6&10), 6.52 – 6.44 (m, 1H, H7&10), 6.40 (d, J = 9.8 Hz, 0.5H, H7), 4.85 (t, J = 1.4 Hz, 1H, H1), 
4.45 (m, 1H, H3), 3.04 (d, J = 1.2 Hz, 3H, H15), 2.59 (m, 1H, H4), 2.44 (m, 1H, H4), 1.96 (t, J = 
1.4 Hz, 3H, H13), 1.05 (s, 4.5H, H12), 1.04 (s, 4.5H, H12) - as 1:1 mix of diastereomers 
13C NMR (100 MHz, Chloroform-d) δ 185.60 (C8), 185.50 (C8), 174.87 (C2), 174.72 (C2), 171.70 
(C14), 171.68 (C4), 146.08 (C6/10), 143.37 (C6), 141.70 (C7/10), 139.22 (C9), 138.81 (C6/10), 137.97 
(C9), 132.08 (C7/10), 130.73 (C7), 82.03 (C1), 82.01 (C1), 57.13 (C3), 56.94 (C3), 54.16 (C5), 54.05 
(C5), 38.53 (C11), 37.65 (C4), 37.58 (C4), 31.61 (C15), 31.60 (C15), 25.98 (C12), 25.95 (C12), 16.34 
(C13), 16.31 (C13) 
HRMS-ESI (m/z) [M+Na]+ calc. for C17H22N2O3Na, 325.1523; found 325.1515. 
Rf – 0.28/0.34 in 5% MeOH in dichloromethane.  
The diastereomers could be separated by column chromatography on silica gel eluting with a 









spiro[cyclohexane-1,6'-pyrrolo[1,2-c]imidazole]-2,5-diene-1',5'-dione & diastereomers 
(280) 
To a solution of 279 (0.93 g, 3.08 mmol) in dry methanol (30 mL) under N2, cerium(III) chloride 
heptahydrate (175 mg, 4.62 mmol) was added and the reaction mixture was stirred for 15 minutes 
at room temperature. The reaction mixture was then cooled to -78 °C and sodium borohydride 
(1.72 g, 4.62 mmol) was added. The resultant mixture was left to stir for a further 30 minutes at -
78 °C and then quenched with water (10 mL). The mixture was then diluted with EtOAc (50 mL) 
and washed with water (30 mL). The aqueous phase was extracted with EtOAc (3 x 30 mL). The 
combined organics were washed with brine (30 mL), dried over MgSO4, filtered and concentrated 
in vacuo. Purification was carried out by column chromatography on silica gel eluting with 0-
10% MeOH in dichloromethane to yield 280 (615 mg, 66 %, d.r. = 1.5:1.5:1.2:1) as clear oils.   
280a 
(177 mg, 18%) 
1H NMR (500 MHz, Chloroform-d) δ 6.12 (dd, J = 9.7, 4.2 Hz, 1H, H7), 5.92 (dd, J = 9.7, 1.6 
Hz, 1H, H6), 5.34-5.30 (m, 1H, H10), 4.77 (d, J = 1.1 Hz, 1H, H1), 4.34 (m, 1H, H3), 4.27 (dd, J = 
11.1, 4.2 Hz, 1H, H8), 3.00 (s, 3H, H15), 2.47 (dd, J = 13.2, 7.8 Hz, 1H, H4), 2.13 (dd, J = 13.2, 
8.6 Hz, 1H, H4), 1.97 (d, J = 11.2 Hz, 3H, O-H), 1.93 (d, J = 1.5 Hz, 1H, H13), 1.01 (s, 9H, H12) 
13C NMR (125 MHz, Chloroform-d) δ 178.52 (C2), 172.58 (C14), 139.69 (C9), 130.70 (C7), 128.86 
(C6), 125.25 (C10), 82.05 (C1), 65.29 (C8), 56.92 (C3), 51.71 (C5), 38.98 (C4), 38.50 (C11), 31.49 
(C15), 25.99 (C12), 20.43 (C13) 
IR νmax – 3416 (O-H), 2965 (C-H), 1700 (C=O) 
HRMS-ESI (m/z) [M+Na]+ calc. for C17H24N2O3Na, 327.1679; found 327.1680 
Rf – 0.38 in 10% MeOH in dichloromethane 
mp 173-175 °C  
[α]𝟐𝟔𝑫  = -4 (c = 1 in CHCl3) 
Carbonyl ‘down’ confirmed by NOE (Figure 10) 






(181 mg, 18%) 
1H NMR (500 MHz, Chloroform-d) δ 6.23 (dd, J = 9.7, 4.2 Hz, 1H, H7), 5.66 – 5.57 (m, 2H, 
H6&9), 4.78 (d, J = 1.1 Hz, 1H, H1), 4.36 (m, 1H, H3), 4.27 (dd, J = 11.2, 4.2 Hz, 1H, H8), 3.00 (d, 
J = 0.4 Hz, 3H, H15), 2.46 (dd, J = 13.2, 7.8 Hz, 1H, H4), 2.16 (dd, J = 13.2, 8.6 Hz, 1H, H4), 1.92 
(d, J = 1.2 Hz, 3H, H13), 1.80 (d, J = 11.2 Hz, 1H, OH) 1.03 (s, 9H, H12) 
13C NMR (125 MHz, Chloroform-d) δ 178.66 (C2), 172.59 (C14), 138.65 (C9), 131.71 (C7), 129.86 
(C6), 123.34 (C10), 82.00 (C1), 65.24 (C8), 56.97 (C3), 51.46 (C5), 38.94 (C4), 38.49 (C11), 31.51 
(C15), 26.01 (C12), 20.42 (C13) 
IR νmax – 3416 (O-H), 2966 (C-H), 1698 (C=O) 
HRMS-ESI (m/z) [M+Na]+ calc. for C17H24N2O3Na, 327.1679; found 327.1683 
Rf – 0.35 in 10% MeOH in dichloromethane 
mp 56-58 °C  
[α]𝟐𝟔𝑫  = -8 (c = 1 in CHCl3) 
Carbonyl ‘up’ confirmed by NOE (Figure 10) 
Major isomer assumed as cis  
280c 
(137 mg, 14%) 
1H NMR (500 MHz, Chloroform-d) δ 6.03 (dd, J = 9.8, 3.2 Hz, 1H, H7), 5.88 (dt, J = 9.8, 1.9 Hz, 
1H, H6), 5.34 – 5.29 (m, 1H, H10), 4.79 (d, J = 1.1 Hz, 1H, H1), 4.49 (d, J = 8.5 Hz, 1H, H8), 4.33 
(m, 1H, H3), 2.99 (s, 3H , H15), 2.45 (dd, J = 13.1, 7.5 Hz, 1H, H4), 2.17 (dd, J = 13.1, 9.0 Hz, 1H, 
H4), 1.93 (s, 3H, H13), 1.56 (d, J = 9.1 Hz, 1H, OH), 1.01 (s, 9H, H12) 
13C NMR (125 MHz, Chloroform-d) δ 178.31 (C2), 172.59 (C14), 138.27 (C9), 129.98 (C7), 126.70 
(C6), 123.73 (C10), 81.73 (C1), 65.31 (C8), 56.81 (C3), 51.32 (C5), 38.95 (C4), 38.49 (C11), 31.48 
(C15), 25.96 (C12), 20.15 (C13) 
IR νmax – 3417 (O-H), 2966 (C-H), 1697 (C=O) 
HRMS-ESI (m/z) [M+Na]+ calc. for C17H24N2O3Na, 327.1679; found 327.1690 
Rf – 0.32 in 10% MeOH in dichloromethane 
mp >200 °C decomposition 
[α]𝟐𝟔𝑫  = 20 (c = 1 in CHCl3) 
Carbonyl ‘down’ confirmed by NOE (Figure 10) 








(120 mg, 12%) 
1H NMR (500 MHz, Chloroform-d) δ 6.14 (dd, J = 9.6, 3.3 Hz, 1H, H7), 5.61 – 5.54 (m, 2H, 
H6&10), 4.79 (d, J = 1.2 Hz, 1H, H1), 4.48 (s, br, 1H, H8), 4.35 (m, 1H, H3), 3.00 (s, 3H, H15), 2.45 
(dd, J = 13.0, 7.5 Hz, 1H, H4), 2.16 (dd, J = 13.0, 8.9 Hz, 1H, H4), 1.90 (s, 3H, H13), 1.55 (s, 1H, 
OH), 1.02 (s, 9H, H12) 
13C NMR (125 MHz, Chloroform-d) δ 178.42 (C2), 172.62 (C14), 136.82 (C9), 131.55 (C7), 128.42 
(C6), 121.92 (C10), 81.72 (C1), 65.26 (C8), 57.05 (C3), 51.35 (C5), 39.09 (C4), 38.48 (C11), 31.50 
(C15), 25.99 (C12), 20.17 (C13) 
IR νmax – 3425 (O-H), 2967 (C-H), 1698 (C=O) 
HRMS-ESI (m/z) [M+Na]+ calc. for C17H24N2O3Na, 327.1679; found 327.1676 
Rf – 0.30 in 10% MeOH in dichloromethane 
mp 160-162 °C  
[α]𝟐𝟔𝑫  = -20 (c = 1 in CHCl3) 
Carbonyl ‘up’ confirmed by NOE (Figure 10)  
Minor isomer assumed as trans & confirmed by crystal below  
 
Table 1 Crystal data and structure refinement for 280d.  
Empirical formula  C17H24N2O3  
Formula weight  304.38  
Temperature/K  100(2)  
Crystal system  monoclinic  
Space group  P21  
a/Å  5.7444(2)  
b/Å  12.0901(5)  
c/Å  12.1546(6)  
α/°  90  
β/°  95.471(3)  
γ/°  90  
Volume/Å3  840.30(6)  
Z  2  
ρcalcg/cm3  1.203  
μ/mm-1  0.083  
F(000)  328.0  
Crystal size/mm3  0.32 × 0.24 × 0.2  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.762 to 54.164  











3-Methyl Arogenate (338), Spiroarogenate (339), Imidazolidinone protected arogenate (340) 
and rearomatised side product (341) 
To a solution of 280a (151 mg, 0.50 mmol) in water (2.50 mL), barium hydroxide (255 mg, 1.49 
mmol) and barium carbonate (98.0 mg, 0.50 mmol) were added. The mixture was stirred at 40 °C 
for 16 hours, and then sodium carbonate anhydrous (315 mg, 2.98 mmol) and water (15 mL) were 
added. The resulting barium carbonate salt was filtered through a Whatman 0.45 μm Nylon 
syringe filter. The aqueous phase was lyophilised. The solid was redissolved in water (15 mL), 
filtered through a Millipore Millex-HN 0.45 μm Nylon syringe filter and purified by Hypercarb 
HPLC with a gradient of 0-80% acetonitrile in 10 mM sodium carbonate-bicarbonate buffer (pH 
9.2) to yield: 
338 as the disodium salt (14 % by quantitative NMR using a stock solution of EtOH) as a white 
powder. 
339 as the sodium salt (29 % by quantitative NMR using a stock solution of EtOH) as a white 
powder. 
340 as the disodium salt (14% by quantitative NMR using a stock solution of EtOH) as a white 
powder. 
341 as the sodium salt (4 % by quantitative NMR using a stock solution of EtOH) + 19% 
recovered starting material* as a white powder 
* poor conversion may be due to a larger sample requiring longer reaction times to reach 
completion.  
 
Reflections collected  6822  
Independent reflections  3061 [Rint = 0.0355, Rsigma = 0.0476]  
Data/restraints/parameters  3061/1/205  
Goodness-of-fit on F2  1.021  
Final R indexes [I>=2σ (I)]  R1 = 0.0417, wR2 = 0.0841  
Final R indexes [all data]  R1 = 0.0544, wR2 = 0.0903  





1H NMR (500 MHz, Deuterium Oxide) δ 5.86 – 5.63 (m, 2H, H6&7), 5.46 (s, 0.8H, H10), 5.41 (s, 
0.2H, H10), 4.27 – 4.25 (m, 0.2H, H8), 4.25 – 4.21 (m, 0.8H, H8), 3.55 (m, 0.8H, H3), 2.88 (m, 
0.2H, H3), 1.89 – 1.70 (m, 2H, H4), 1.67 (s, 2.4H, H11), 1,64 (s, 0.6H, H11) – 80:20 mixture of 
sodium:barium salts 
13C NMR (126 MHz, Deuterium Oxide) δ 188.83 (C1), 188.09 (C2), 141.15 (C8), 138.52 (C6/7), 
133.68 (C6/7), 132.91 (C10), 71.43 (C8), 61.21 (C3), 57.54 (C5), 47.79 (C4), 25.85 (C11) 
HRMS-Nanospray (m/z) [M-H]- calc. for C11H14NO5, 240.0872; found 240.0879 
[α]𝟐𝟑𝑫  = -80 (c = 0.1 in H2O) 
CD spectra – Positive Cotton effect below 230 nm 
 
 
1H NMR (500 MHz, Deuterium Oxide) δ 5.98 (dd, J = 9.9, 3.3 Hz, 1H, H7), 5.79 (m, 1H, H6), 
5.48 – 5.41 (m, 1H, H10), 4.34 (d, J = 3.3 Hz, 1H, H8), 4.17 (dd, J = 8.6, 6.5 Hz, 1H , H3), 2.43 
(dd, J = 13.3, 8.6 Hz, 1H, H4), 2.01 (dd, J = 13.3, 6.5 Hz, 1H, H4), 1.82 – 1.69 (m, 3H, H11) 
13C NMR (126 MHz, Deuterium Oxide) δ 188.31 (C1/2), 187.72 (C1/2), 145.06 (C9), 137.33 (C7), 
136.60 (C6), 132.74 (C10) 72.24 (C8), 63.11 (C3), 56.94 (C5), 47.79 (C4), 27.22 (C11) 
HRMS-ESI (m/z) [M+Na+H]+ calc. for C11H13NO4, 246.0737; found 246.0739 
[α]𝟐𝟑𝑫  = 40 (c = 0.1 in H2O) 









5.4.3 Grignard addition derivatives 
General procedure for Grignard addition 
 
To a solution of 222 (1 eq.) in dry THF (0.10 M) under N2 at -78 °C, the relevant Grignard reagent 
(2M in THF, 1.5 eq.) was slowly added and the reaction mixture was stirred for 2 hours at room 
temperature. The reaction mixture was then cooled to 0 °C and quenched slowly with water. The 
mixture was concentrated in vacuo, diluted with water and extracted with ether. Purification was 
carried out by column chromatography on silica gel eluting with 0-100% EtOAc in Hexane to 
yield the corresponding alkylated product.  
(1s,3'S,4R,7a'S)-3'-(tert-Butyl)-4-butyl-4-hydroxy-2'-methyl-2',3',7',7a'-tetrahydro-
1'H,5'H-spiro[cyclohexane-1,6'-pyrrolo[1,2-c]imidazole]-2,5-diene-1',5'-dione (283) 
Only one diastereomer isolated (crude NMR d.r. = >9:1) 
Major isolated diastereomer (441 mg, 75 %) as a pale-yellow oil   
1H NMR (400 MHz, Chloroform-d) δ 6.00 (dd, J = 10.0, 1.5 Hz, 1H, H6), 5.94 – 5.85 (m, 2H, 
H7), 5.62 (dd, J = 10.0, 1.5 Hz, 1H, H6), 4.79 (d, J = 1.1 Hz, 1H, H1), 4.35 (m, 1H, H3), 3.00 (s, 
3H, H12), 2.42 (dd, J = 13.2, 7.7 Hz, 1H, H4), 2.25 – 2.13 (m, 2H, H4 & OH), 1.66 – 1.56 (m, 2H, 
H13), 1.36 – 1.24 (m, 2H, H15), 1.15 – 1.05 (m, 2H, H14), 1.02 (s, 9H, H11), 0.87 (t, J = 7.3 Hz, 3H, 
H16) 
13C NMR (100 MHz, Chloroform-d) δ 178.21 (C2), 172.46 (C9), 135.63 (C6), 134.79 (C7), 128.70 
(C6), 127.33 (C7), 81.90 (C1), 67.69 (C8), 56.99 (C3), 50.86 (C5), 39.93 (C13), 38.97 (C4), 38.52 
(C10), 31.51 (C12), 26.69 (C14), 25.99 (C11), 23.09 (C15), 14.16 (C16) 
HRMS-ESI (m/z) [M+Na+] calc. for C20H30N2O3Na, 369.2149; found 369.2164 
IR νmax – 3416 (O-H), 2957, 2931 (C–H), 1697 (C=O) 
Rf - 0.47 in 10% MeOH in dichloromethane 







Only one diastereomer isolated (crude NMR d.r. = >9:1) 
Major isolated diastereomer (202 mg, 74 %) as a clear oil 
1H NMR (500 MHz, Chloroform-d) δ 7.31 – 7.23 (m, 2H, H17), 7.20 – 7.13 (m, 3H, H16&18), 6.09 
(dd, J = 9.9, 1.9 Hz, 1H, H7), 6.00 (dd, J = 9.8, 1.9 Hz, 1H, H7), 5.94 (dd, J = 9.8, 2.2 Hz, 1H, 
H6), 5.68 (dd, J = 9.9, 2.2 Hz, 1H, H6), 4.80 (s, 1H, H1), 4.38 (m, 1H, H3), 3.01 (s, 3H, H12), 2.54 
– 2.38 (m, 4H, H4,14 & O-H), 2.21 (m, 1H, H4), 1.99 – 1.91 (m, 2H, H13), 1.03 (s, 9H, H11) 
13C NMR (100 MHz, Chloroform-d) δ 178.01 (C2), 172.40 (C9), 141.84 (C15), 135.26 (C7), 134.37 
(C7), 129.35 (C6), 128.53 (C17), 128.40 (C16), 127.92 (C6), 126.02 (C18), 81.97 (C1), 67.46 (C8), 
57.00 (C3), 50.99 (C5), 41.79 (C13), 38.81 (C4), 38.81 (C10), 31.53 (C12), 30.77 (C14), 26.01 (C11) 
HRMS-ESI (m/z) [M+Na+] calc. for C24H30N2O3Na, 417.2149; found 417.2152 
IR νmax – 3405 (O-H), 2964, 2931 (C–H), 1693 (C=O) 
Rf - 0.53 in 10% MeOH in dichloromethane 
[α]𝟐𝟓𝑫  = 16 (c = 1 in CHCl3) 
 
 
n-Butyl Arogenate (343) and Spiroarogenate (342) 
To a solution of 283 (31.3 mg, 0.09 mmol) in water (0.45 mL), barium hydroxide (46.3 mg, 0.27 
mmol) and barium carbonate (17.8 mg, 0.09 mmol) were added. The mixture was stirred at 80 °C 
for 24 hours, and then sodium carbonate anhydrous (57.0 mg, 0.54 mmol) and water (5.00 mL) 
were added. The resulting barium carbonate salt was filtered through a Whatman 0.45 μm Nylon 
syringe filter. The aqueous phase was lyophilised. The solid was redissolved in water (3 mL), 
filtered through a Millipore Millex-HN 0.45 μm Nylon syringe filter and purified by Hypercarb 
HPLC with a gradient of 0-80% acetonitrile in 10 mM sodium carbonate-bicarbonate buffer (pH 
9.2) to yield: 
343 as the disodium salt* (46 % by quantitative NMR using a stock solution of EtOH) as a white 
powder. 





Starting material (4 % by quantitative NMR using a stock solution of EtOH). 
* <4% rearomatisation  
 
 
1H NMR (500 MHz, Deuterium Oxide) δ 5.97 (dd, J = 10.1, 2.3 Hz, 0.3H, H7/9), 5.91 (dd, J = 
10.1, 2.3 Hz, 0.7H, H7/9), 5.82 (dd, J = 10.1, 2.3 Hz, 1H, H7/9), 5.77 – 5.61 (m, 2H, H6&10), 3.64 
(m, 0.7H, H3), 3.02 (m, 0.3H, H3), 2.08 – 1.99 (m, 0.3H, H4), 1.92 – 1.76 (m, 1.7H, H4), 1.50 – 
1.37 (m, 2H, H11), 1.15 (m, 2H, H13), 1.06 (m, 2H, H12), 0.73 (q, J = 7.5 Hz, 3H, H14) – Mixture 
of salts (30:70 sodium:barium) 
13C NMR (126 MHz, Deuterium Oxide) δ 184.02 (C2), 182.55 (C1), 133.23 (C6/10), 132.63 (C6/10), 
131.98 (C7/9), 131.50 (C7/9), 69.80 (C8), 56.38 (C3), 51.68 (C5), 42.53 (C4), 41.61 (C11), 26.95 
(C12), 23.71 (C13), 14.66 (C14)  – Major salt reported 
HRMS-Nanospray (m/z) [M-H]- calc. for C14H20NO5, 282.1341; found 282.1336 
[α]𝟐𝟒𝑫  = 80 (c = 0.1 in H2O) 
CD spectra – Positive Cotton effect below 230 nm 
 
  
1H NMR (500 MHz, Deuterium Oxide) δ 5.78 – 5.70 (m, 3H, H6/7/9/10), 5.67 (dd, J = 10.2, 2.1 Hz, 
1H, H6/7/9/10), 4.13 (dd, J = 8.7, 6.2 Hz, 1H, H3), 2.39 (dd, J = 13.3, 8.7 Hz, 1H, H4), 1.99 (dd, J = 
13.3, 6.2 Hz, 1H, H4), 1.48 – 1.40 (m, 2H, H11), 1.13 (m, 2H, H13), 0.98 – 0.88 (m, 2H, H12), 0.70 
(q, J = 7.4 Hz, 3H, H14) 
13C NMR (126 MHz, Deuterium Oxide) δ 188.47 (C1/2), 188.08 (C1/2), 141.17 (C6/10), 141.09 
(C6/10), 136.91 (C7/9), 136.33 (C7/9), 76.49 (C8), 63.55 (C3), 56.48 (C5), 47.87 (C11), 47.66 (C4), 
34.34 (C12), 30.59 (C12), 21.56 (C13) 
HRMS-Nanospray (m/z) [M-H]- calc. for C14H18NO4, 264.1236; found 264.1227 
[α]𝟐𝟓𝑫  = 80 (c = 0.1 in H2O) 





Phenethyl Arogenate (346), Spiroarogenate (345) and Imidazolidinone protected arogenate 
(349) 
To a solution of 284 (30.3 mg, 0.08 mmol) in water (0.39 mL), barium hydroxide (40.2 mg, 0.23 
mmol) and barium carbonate (15.7 mg, 0.08 mmol) were added. The mixture was stirred at 80 °C 
for 24 hours, and then sodium carbonate anhydrous (49.0 mg, 0.46 mmol) and water (5.00 mL) 
were added. The resulting barium carbonate salt was filtered through a Whatman 0.45 μm Nylon 
syringe filter. The aqueous phase was lyophilised. The solid was redissolved in water (3 mL), 
filtered through a Millipore Millex-HN 0.45 μm Nylon syringe filter and purified by Hypercarb 
HPLC with a gradient of 0-80% acetonitrile in 10 mM sodium carbonate-bicarbonate buffer (pH 
9.2) to yield: 
346 as the disodium salt (59 % by quantitative NMR using a stock solution of EtOH) as a white 
powder. 
345 as the sodium salt (25 % by quantitative NMR using a stock solution of EtOH) as a white 
powder. 
349 as the disodium salt (6 % by quantitative NMR using a stock solution of EtOH). 
 
 
1H NMR (500 MHz, Deuterium Oxide) δ 7.20 – 7.03 (m, 5H, H14,15&16), 6.02 – 5.89 (m, 1H, H7/9), 
5.89 – 5.79 (m, 1H, H7/9), 5.71 (m, 2H, H14), 3.62 (m, 0.8H, H3), 3.01 – 2.97 (m, 0.2H, H3), 2.42 
– 2.27 (m, 2H, H12), 2.00 (m, 0.2H, H4), 1.87 – 1.60 (m, 3.8H, H4&11) 
13C NMR (126 MHz, Deuterium Oxide) δ 183.72 (C2), 182.12 (C1), 143.84 (C13), 133.67 (C7/9), 
131.20 (C7/9), 130.71 (C6/10), 129.83 (C14/15&6/10), 129.62 (C14/15), 127.10 (C16), 69.30 (C8), 56.21 
(C3), 51.49 (C5), 43.73 (C11), 42.33 (C4), 31.22 (C12) 





1H NMR (500 MHz, Deuterium Oxide) δ 7.38 – 7.31 (m, 2H, H15), 7.28 – 7.20 (m, 3H, H14&16), 
5.99 – 5.88 (m, 3H, H9,7&6/10), 5.84 (dd, J = 10.0, 2.3 Hz, 1H, H6/10), 4.27 (dd, J = 8.7, 6.1 Hz, 1H, 
H3), 2.56 (dd, J = 13.4, 8.7 Hz, 1H, H4), 2.51 – 2.39 (m, 2H, H12), 2.16 (dd, J = 13.4, 6.1 Hz, 1H, 
H4), 1.95 – 1.85 (m, 2H, H11) 
13C NMR (126 MHz, Deuterium Oxide) δ 188.06 (C1), 187.79 (C2), 150.38 (C13), 140.47 (C7/9), 
140.40 (C7/9), 137.19 (C6/10), 136.74 (C15), 136.62 (C6/10), 136.57 (C14), 134.12 (C16), 75.99 (C8), 
63.31 (C3), 56.28 (C5), 49.74 (C11), 47.35 (C4), 38.37 (C12) 







To a solution of 222 (300 g, 1.04 mmol) in (10.0 mL) under N2, palladium on active carbon (10 
wt. %) (60.0 mg, 20 % wt.) was added. The mixture was then stirred at room temperature 
overnight under hydrogen atmosphere. The reaction mixture was filtered over a pad of celite and 
concentrated in vacuo to yield 285 (303 mg, Quant.) as a white powder. 
1H NMR (400 MHz, Chloroform-d) δ 4.82 (d, J = 1.1 Hz, 1H, H1), 4.30 (t, J = 8.1 Hz, 1H, H3), 
3.03 (s, 3H, H12), 2.96 – 2.85 (m, 1H, H7/9), 2.61 – 2.48 (m, 2H, H4&7/9), 2.48 – 2.35 (m, 1H, H7/9), 
2.35 – 2.15 (m, 3H, H6/10&7/9), 2.10 – 1.93 (m, 2H, H4&6/10), 1.82 – 1.72 (m, 1H, H6/10), 1.03 (s, 9H, 
H13) 
13C NMR (100 MHz, Chloroform-d) δ 209.60 (C8), 181.50 (C2), 172.69 (C11), 81.49 (C1), 56.68 





HRMS-ESI (m/z) [M+Na+] calc. for C16H24N2O3Na, 315.1679; found 315.1689 
IR νmax – 2962, 2871 (C–H), 1697 (C=O) 
Rf - 0.35 in 100% EtOAc 
mp 177-178 °C  





To a solution of 285 (200 mg, 0.68 mmol) in dry methanol (7 mL) under N2 at 0 °C, sodium 
borohydride (45 mg, 1.20 mmol) was slowly added. The resultant mixture was allowed to warm 
to room temperature and left to stir overnight. The reaction mixture was quenched with water (20 
mL) and the mixture was then concentrated in vacuo. The crude product was then diluted with 
water (50 mL). The aqueous phase was extracted with dichloromethane (3 x 30 mL). The 
combined organic phases were dried over MgSO4, filtered and concentrated in vacuo. Purification 
was carried out by column chromatography on silica gel eluting with 0-80% Acetone in 
dichloromethane to yield 286 (179 mg, 89 %, d.r. = 1.1:1) as white powders.   
286b Minor (cis – desired) 
1H NMR (500 MHz, Chloroform-d) δ 4.77 (d, J = 1.1 Hz, 1H, H1), 4.21 (m, 1H, H3), 3.83 (dh, J 
= 7.1, 3.6 Hz, 1H, H8), 2.96 (s, 3H, H14), 2.40 (m, 1H, H4), 2.11 – 1.95 (m, 3H, H6/10&7/9), 1.87 – 
1.74 (m, 2H, H4&7/9), 1.71 – 1.60 (m, 2H, H7/9), 1.54-1.44 (m, 2H, H6/10 & OH), 1.32 – 1.23 (m, 
1H, H6/10), 1.00 (s, 9H, H13) 
13C NMR (125 MHz, Chloroform-d) δ 182.66 (C2), 173.29 (C11), 81.31 (C1), 67.48 (C8), 56.77 
(C3), 46.18 (C5), 38.39 (C12), 37.59 (C4), 31.45 (C14), 30.40 (C7/9), 30.40 (C7/9), 30.08 (C6/10), 29.32 
(C6/10), 25.97 (C13) 
HRMS-ESI (m/z) [M+Na+] calc. for C16H26N2O3Na, 317.1836; found 317.1842 
IR νmax – 3423 (O-H), 2955, 2929, 2870 (C–H), 1688 (C=O) 
Rf - 0.35 in 10% MeOH in dichloromethane 
mp 173-174 °C  





286a Major (trans) 
1H NMR (500 MHz, Chloroform-d) δ 4.76 (d, J = 1.2 Hz, 1H, H1), 4.21 (m, 1H, H3), 3.67 (ddt, J 
= 14.3, 9.9, 4.1 Hz, H8), 2.96 (s, 3H, H14), 2.59 (m, 1H, H4), 2.06 - 1.92 (m, 2H, H6/10&7/9), 1.91 – 
1.70 (m, 3H, H4,6/10&7/9), 1.70-1.59 (m, 2H, H6/10 & OH), 1.50 – 1.40 (m, 2H, H7/9), 1.33 – 1.19 (m, 
1H, H6/10), 1.00 (s, 9H, H13) 
13C NMR (125 MHz, Chloroform-d) δ 182.97 (C2), 173.21 (C11), 81.59 (C1), 69.39 (C8), 56.85 
(C3), 46.62 (C5), 38.37 (C12), 35.77 (C4), 31.57 (C7/9), 31.45 (C14), 31.36 (C7/9), 31.32 (C6/10), 30.78 
(C6/10), 26.00 (C13) 
HRMS-ESI (m/z) [M+Na+] calc. for C16H26N2O3Na, 317.1836; found 317.1828 
IR νmax – 3405 (O-H), 2951, 2926, 2859 (C–H), 1685 (C=O) 
Rf - 0.32 in 10% MeOH in dichloromethane 
mp 197-198 °C  
[α]𝟐𝟔𝑫  = -4 (c = 1 in CHCl3) 















Table 1 Crystal data and structure refinement for 286a. 
Empirical formula C16H26N2O3 
Formula weight 294.39 
Temperature/K 99.97 
Crystal system monoclinic 












Crystal size/mm3 0.424 × 0.266 × 0.074 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.082 to 55.932 
Index ranges -7 ≤ h ≤ 7, -17 ≤ k ≤ 17, -13 ≤ l ≤ 13 
Reflections collected 18866 
Independent reflections 3773 [Rint = 0.0301, Rsigma = 0.0227] 
Data/restraints/parameters 3773/1/198 
Goodness-of-fit on F2 1.051 
Final R indexes [I>=2σ (I)] R1 = 0.0318, wR2 = 0.0801 
Final R indexes [all data] R1 = 0.0339, wR2 = 0.0812 





(3R,5s,8S)-8-Hydroxy-1-oxo-2-azaspiro[4.5]decane-3-carboxylic acid (350) 
To a solution of 286b (30.0 mg, 0.10 mmol) in water (0.50 mL), sodium hydroxide (12.0 mg, 
0.30 mmol) was added. The mixture was stirred at 90 °C for 16 hours in a sealed tube. The 
resulting mixture was then neutralised (approx. pH = 8) and lyophilised. The mixture was 
redissolved in ethanol and filtered to remove excess salt.  The product was purified by Hypercarb 
HPLC with a gradient of 0-100% acetonitrile in 100 mM ammonium bicarbonate buffer to yield 
350 (19.3 mg, 80%) as a white powder. 
1H NMR (500 MHz, Deuterium Oxide) δ 4.16 (m, 1H, H3), 3.99 (s, 1H, H8), 2.50 (m, 1H, H4), 
2.01 (m, 1H, H4), 1.96 – 1.81 (m, 2H, H6&10), 1.81 – 1.59 (m, 4H, H7&9), 1.43 – 1.24 (m, 2H, 
H6&10) 
13C NMR (125 MHz, Deuterium Oxide) δ 184.73 (C1), 179.73 (C2), 65.56 (C8), 54.62 (C3), 44.32 
(C5), 36.01 (C4), 27.77 (C7/9), 27.71 (C7/9), 27.23 (C6/10), 26.56 (C6/10) 
HRMS-Nanospray (m/z) [M-H]- calc. for C10H14NO4, 212.0923; found 212.0928 
























To a solution of 4-Benzyloxybenzyl alcohol (2.00 g, 9.35 mmol) in dry, degassed DCM (45.0 
mL) under N2 at 0 °C, phosphorus tribromide (0.97 mL, 10.3 mmol) in DCM (45.0 mL) was added 
dropwise. The mixture stirred for 3 hours at 0 °C then warmed to room temperature and stirred 
for a further 2 hours. The reaction mixture was quenched with water (30 mL) and extracted with 
ethyl acetate (3 x 50 mL). The organic layer was washed with brine (30 mL), dried over MgSO4, 
filtered and concentrated in vacuo to yield 306 (2.60 g, Quant.) as a white solid.         
1H NMR (400 MHz, Chloroform-d) δ 7.45 – 7.30 (m, 7H, H3,8,9&10), 6.96 – 6.91 (m, 2H, H4), 5.07 
(s, 2H, H6), 4.50 (s, 2H, H1) 












To a solution of 310 (50.0 mg, 0.18 mmol) and 306 (61.0 mg, 0.22 mmol) in dry, degassed THF 
(1.00 mL) under N2 at -78 °C, KHMDS (1 M, 0.22 mL) was added. The mixture was warmed to 
room temperature and stirred for 2 hours. The reaction mixture was quenched with water (2 mL) 
and extracted with ethyl acetate (3 x 5 mL). The combined organics were washed with brine (5 
mL), dried over MgSO4, filtered and concentrated in vacuo to yield 311 (77.4 mg, 90 %) as a 
clear oil.   
1H NMR (400 MHz, Chloroform-d) δ 7.44 – 7.27 (m, 5H, H11,12&13), 7.10 – 7.01 (m, 2H, H6), 
6.89 – 6.80 (m, 2H, H7), 5.06 – 4.98 (m, 2H, H9), 4.53 (s, 0.52H, H14), 4.47 (s, 0.48H, H14), 3.67 




(s, 1.4H, H1), 1.80 (s, 1.4H, H18), 1.71 (s, 1.6H, H18), 1.01 (s, 4.8H, H16), 0.91 (s, 4.2H, H16) – 
rotameric mixture          
13C NMR (126 MHz, Chloroform-d) δ 171.72 (C2), 171.68 (C2), 158.05 (C8), 157.88 (C8), 148.38 
(C17), 146.82 (C17), 136.95 (C10), 136.87 (C10), 131.15 (C6), 130.94 (C6), 128.57 (C11/12), 128.55 
(C11/12), 127.99 (C13), 127.96 (C13), 127.59 (C11/12), 127.56 (C11/12), 127.45 (C5), 127.22 (C5), 
114.63 (C7), 114.56 (C7), 82.69 (C14), 82.58 (C14), 70.70 (C9), 69.94 (C9), 69.89 (C3), 68.50 (C3), 
42.57 (C4), 40.00 (C15), 39.79 (C4), 39.35 (C15), 31.78 (C1), 31.40 (C1), 27.54 (C16), 26.84 (C16), 
23.41 (C18), 22.44 (C18) – rotameric mixture 




carbonyl chloride (313) 
To a solution of 312 (200 mg, 0.73 mmol) and 306 (244 mg, 0.89 mmol) in dry, degassed THF 
(3.60 mL) under N2 at -78 °C, KHMDS (1 M, 0.89 mL) was added. The mixture was warmed to 
room temperature and stirred for 2 hours. The reaction mixture was quenched with water (5 mL) 
and extracted with ethyl acetate (3 x 10 mL). The combined organics were washed with brine (10 
mL), dried over MgSO4, filtered and concentrated in vacuo to yield 313 (201 mg, 59 %) as a clear 
oil.       
 1H NMR (400 MHz, Chloroform-d) δ 7.48 – 7.27 (m, 5H, H11,12&13), 7.06 (dd, J = 8.6, 6.2 Hz, 
2H, H6), 6.89 – 6.79 (m, 2H, H7), 5.06 – 4.96 (m, 2H, H9), 4.53 (s, 0.65H, H14), 4.27 (s, 0.35H, 
H14), 3.58 (m, 1H, H4), 3.15 (m, 1H, H4), 2.74 (s, 1.95H, H1), 2.64 (s, 1.05H, H1), 2.36 – 2.10 (m, 
2.35H, H18&19), 1.92 (dd, J = 14.6, 5.1 Hz, 0.65H, H18), 1.10 – 0.96 (m, 11.85H, H16&20), 0.93 (s, 
3.15H, H16) – rotameric mixture  
13C NMR (101 MHz, Chloroform-d) δ 171.03 (C2), 158.12 (C8), 157.90 (C8), 149.22 (C17), 147.26 
(C17), 137.05 (C10), 136.96 (C10), 131.47 (C6), 131.34 (C6), 128.65 (C11/12), 128.62 (C11/12), 128.07 
(C13), 128.03 (C13), 127.65 (C11/12), 127.25 (C5), 126.69 (C5), 114.68 (C7), 114.61 (C7), 82.77 
(C14), 73.68 (C3), 71.83 (C3), 69.99 (C9), 69.94 (C9), 46.27 (C18), 46.09 (C18), 42.34 (C4), 39.26 
(C15), 38.90 (C15), 38.17 (C4), 31.61 (C1), 31.30 (C1), 27.84 (C16), 27.38 (C16), 25.18 (C20), 25.06 








carbonyl chloride (315) 
To a solution of 314 (200 mg, 0.65 mmol) and 306 (210 mg, 0.78 mmol) in dry, degassed THF 
(3.20 mL) under N2 at -78 °C, KHMDS (1 M, 0.78 mL) was added. The mixture was warmed to 
room temperature and stirred for 2 hours. The reaction mixture was quenched with water (5 mL) 
and extracted with ethyl acetate (3 x 10 mL). The combined organics were washed with brine (10 
mL), dried over MgSO4, filtered and concentrated in vacuo to yield 315 (323 mg, 81 %) as a clear 
oil.           
1H NMR (500 MHz, Chloroform-d) δ 7.44 – 7.15 (m, 10H, H11/12/13/20/21&22), 7.06 (dd, J = 11.1, 
8.6 Hz, 2H, H6), 6.91 – 6.82 (m, 2H, H7), 5.08 – 4.99 (m, 2H, H9), 4.23 (s, 0.48H, H14), 4.06 (s, 
0.52H, H14), 3.72 (m, 1H, H4/18), 3.58 – 3.39 (m, 2H, H4/18), 3.13 (m, 0.52H, H4/18), 2.98 (m, 0.48H, 
H4/18), 2.62 (s, 1.44H, H1), 2.55 (s, 1.56H, H1), 0.61 (s, 4.32H, H16), 0.35 (s, 4.68H, H16) – 
rotameric mixture       
13C NMR (126 MHz, Chloroform-d) δ 169.87 (C2), 169.72 (C2), 158.14 (C8), 157.96 (C8), 149.34 
(C17), 148.18 (C17), 136.89 (C10), 136.82 (C10), 135.78 (C19), 131.48 (C6), 131.29 (CPhenyl), 131.28 
(CPhenyl), 131.25 (C6), 128.61 (CPhenyl), 128.57 (CPhenyl), 128.55 (CPhenyl), 128.45 (CPhenyl), 128.00 
(C13/22), 127.98 (C13/22), 127.56 (CPhenyl), 127.55 (CPhenyl), 127.45 (C13/22), 127.34 (C13/22), 126.68 
(C5), 126.30 (C5), 114.66 (C7), 114.63 (C7), 82.65 (C14), 82.48 (C14), 75.88 (C3), 74.03 (C3), 69.94 
(C9), 69.88 (C9), 43.07 (C4/18), 41.81 (C4/18), 41.06 (C4/18), 39.86 (C4/18), 38.23 (C15), 38.15 (C15), 
31.21 (C1), 31.18 (C1), 27.22 (C16), 26.35 (C16) – rotameric mixture 











To a solution of 311 (280 mg, 0.60 mmol) in THF (6.00 mL) under N2, palladium on active carbon 
(10 wt. %) (56.0 mg, 20 % wt.) was added. The mixture was then stirred at room temperature for 
4 hours under hydrogen atmosphere. The reaction mixture was filtered over a pad of celite and 
concentrated in vacuo to yield 316 (203 mg, Quant.) as a clear oil. 
1H NMR (500 MHz, Chloroform-d) δ 7.07 – 7.01 (m, 2H, H6), 6.78 – 6.72 (m, 2H, H7), 4.61 (s, 
0.52H, H9), 4.53 (s, 0.48H, H9), 3.70 (d, J = 14.3 Hz, 0.48H, H4), 3.57 (d, J = 14.3 Hz, 0.52H, 
H4), 3.15 – 3.06 (m, 0.52H, H4), 3.02 (d, J = 14.3 Hz, 0.48H, H4), 2.81 (s, 1.56H, H1), 2.75 (s, 
1.44H, H1), 1.83 (s, 1.44H, H12), 1.75 (s, 1.56H, H12), 1.05 (s, 4.68H, H11), 0.94 (s, 4.32H, H11) – 
rotameric mixture 
13C NMR (126 MHz, Chloroform-d) δ 171.83 (C2), 171.80 (C2), 155.10 (C8), 154.84 (C8), 148.45 
(C13), 146.83 (C13), 131.33 (C6), 131.11 (C6), 126.93 (C5), 126.59 (C5), 115.16 (C7), 115.02 (C7), 
82.77 (C9), 82.65 (C9), 70.72 (C3), 68.54 (C3), 42.54 (C4), 39.96 (C4), 39.79 (C4), 39.34 (C4), 31.82 
(C1), 31.44 (C1), 27.54 (C11), 26.84 (C11), 23.40 (C12), 22.43 (C12) – rotameric mixture 




carbonyl chloride (318) 
To a solution of 313 (250 mg, 0.53 mmol) in THF (6.00 mL) under N2, palladium on active carbon 
(10 wt. %) (50.0 mg, 20 % wt.) was added. The mixture was then stirred at room temperature for 
4 hours under hydrogen atmosphere. The reaction mixture was filtered over a pad of celite and 
concentrated in vacuo to yield 318 (203 mg, 95 %) as a clear oil. 
1H NMR (500 MHz, Chloroform-d) δ 7.09 – 7.02 (m, 2H, H6), 6.79 – 6.71 (m, 2H, H7), 4.60 (s, 




H1), 2.37 – 2.30 (m, 0.56H, H12/13), 2.29 – 2.13 (m, 1.69H, H12/13), 1.95 (dd, J = 14.6, 5.1 Hz, 
0.75H, H12), 1.09 – 1.04 (m, 12H, H11&14), 0.96 (s, 3H, H11) – rotameric mixture 
13C NMR (126 MHz, Chloroform-d) δ 171.00 (C2), 155.04 (C8), 154.70 (C8), 149.19 (C15), 147.17 
(C15), 131.58 (C6), 131.45 (C6), 126.96 (C5), 126.40 (C5), 115.09 (C7), 114.97 (C7), 82.76 (C9), 
73.60 (C3), 71.76 (C3), 46.20 (C12), 46.04 (C12), 42.22 (C4), 39.18 (C10), 38.82 (C10), 38.05 (C4), 
31.58 (C1), 31.24 (C1), 27.76 (C11), 27.30 (C11), 25.08 (C14), 24.97 (C14), 24.84 (C14), 24.66 (C14), 
23.75 (C13), 23.56 (C13) – rotameric mixture 




carbonyl chloride (320) 
To a solution of 315 (375 mg, 0.74 mmol) in THF (7.00 mL) under N2, palladium on active carbon 
(10 wt. %) (74.0 mg, 20 % wt.) was added. The mixture was then stirred at room temperature for 
4 hours under hydrogen atmosphere. The reaction mixture was filtered over a pad of celite and 
concentrated in vacuo to yield 320 (308 mg, Quant.) as a white powder. 
1H NMR (500 MHz, Chloroform-d) δ 7.45 – 7.41 (m, 1H, H14), 7.36 (m, 1H, H14), 7.31 – 7.29 
(m, 1H, H15), 7.28 – 7.21 (m, 2H, H15&16), 7.11 – 7.01 (m, 2H, H6), 6.76 (m, 2H, H7), 4.89 (s, 
0.51H, OH), 4.84 (s, 0.49H, OH), 4.32 (s, 0.49H, H9), 4.14 (s, 1H, H9), 3.75 (m, 1H, H4/12), 3.58 
(m, H4/12), 3.55 – 3.44 (m, 1.51H, H4/12), 3.17 (m, H4/12), 3.01 (m, 0.49H, H4/12), 2.71 (s, 1.47H, 
H1), 2.65 (s, 1.53H, H1), 0.66 (s, 4.45H, H11), 0.40 (s, 4.55H, H11) – rotameric mixture 
13C NMR (126 MHz, Chloroform-d) δ 169.93 (C2), 169.78 (C2), 155.09 (C8), 154.85 (C8), 149.37 
(C17), 148.16 (C17), 135.74 (C13), 131.70 (C6), 131.49 (C6), 131.28 (C14), 131.24 (C14), 128.62 
(C15), 128.45 (C15), 127.47 (C16), 127.36 (C16), 115.13 (C7), 115.02 (C7), 82.68 (C9), 82.53 (C9), 
75.82 (C3), 74.00 (C3), 43.03 (C4/12), 41.83 (C4/12), 41.08 (C4/12), 39.79 (C4/12), 38.24 (C10), 38.16 
(C10), 31.25 (C1), 31.21 (C1), 27.22 (C11), 26.34 (C11) – rotameric mixture 








To a solution of 316 (200 mg, 0.60 mmol) in MeCN (3.00 mL), triethylamine (92 μL, 0.66 mmol) 
was added. The mixture was then heated under microwave irradiation at 150 °C for 30 minutes. 
The reaction mixture was concentrated in vacuo, redissolved in dichloromethane (20 mL) and 
washed with water (10 mL). The aqueous phase was extracted with dichloromethane (3 x 10 mL). 
The combined organics were washed with brine (10 mL), dried over MgSO4, filtered and 
concentrated in vacuo to yield 317 (180 mg, Quant.) as a yellow foam. 
1H NMR (500 MHz, Chloroform-d) δ 7.07 (dd, J = 10.0, 3.0 Hz, 1H, H6), 6.64 (dd, J = 10.0, 3.0 
Hz, 1H, H6), 6.45 (dd, J = 10.0, 1.8 Hz, 1H, H7), 6.40 (dd, J = 10.0, 1.8 Hz, 1H, H7), 4.86 (s, 1H, 
H1), 3.02 (s, 3H, H12), 2.71 (d, J = 13.7 Hz, 1H, H4), 2.36 (d, J = 13.7 Hz, 1H, H4), 1.78 (s, 3H, 
H13), 1.08 (s, 9H, H11) 
13C NMR (126 MHz, Chloroform-d) δ 184.66 (C8), 177.32 (C9), 174.12 (C2), 147.22 (C6), 144.73 
(C6), 131.90 (C7), 130.77 (C7), 83.48 (C1), 63.17 (C3), 53.94 (C5), 45.39 (C4), 36.52 (C10), 31.31 
(C12), 27.02 (C11), 26.66 (C13) 
Rf = 0.58 in 5% MeOH in DCM 





To a solution of 318 (192 mg, 0.41 mmol) in MeCN (2.00 mL), triethylamine (63 μL, 0.45 mmol) 
was added. The mixture was then heated under microwave irradiation at 150 °C for 30 minutes. 
The reaction mixture was concentrated in vacuo, redissolved in dichloromethane (20 mL) and 
washed with water (10 mL). The aqueous phase was extracted with dichloromethane (3 x 10 mL). 
The combined organics were washed with brine (10 mL), dried over MgSO4, filtered and 




1H NMR (500 MHz, Chloroform-d) δ 7.05 (dd, J = 10.0, 3.0 Hz, 1H, H6), 6.67 (dd, J = 10.0, 3.0 
Hz, 1H, H6), 6.45 (dd, J = 10.0, 1.8 Hz, 1H, H7), 6.42 (dd, J = 10.0, 1.8 Hz, 1H, H7), 4.84 (s, 1H, 
H1), 3.03 (s, 3H, H12), 2.63 (s, 2H, H4), 2.13 – 2.06 (m, 2H, H13), 1.91 – 1.83 (m, 1H, H14), 1.13 – 
1.09 (m, 12H, H11&15), 1.03 (d, J = 6.3 Hz, 3H, H15) 
13C NMR (126 MHz, Chloroform-d) δ 184.71 (C8), 176.86 (C9), 173.46 (C2), 147.46 (C6), 144.72 
(C6), 131.63 (C7), 130.77 (C7), 83.38 (C1), 65.32 (C3), 54.02 (C5), 48.65 (C13), 41.64 (C4), 36.13 
(C10), 31.15 (C12), 27.26 (C11), 25.15 (C14), 24.48 (C15), 24.26 (C15) 
Rf = 0.73 in 5% MeOH in DCM 





To a solution of 320 (308 mg, 0.74 mmol) in MeCN (4.00 mL), triethylamine (104 μL, 0.81 
mmol) was added. The mixture was then heated under microwave irradiation at 150 °C for 30 
minutes. The reaction mixture was concentrated in vacuo, redissolved in dichloromethane (20 
mL) and washed with water (10 mL). The aqueous phase was extracted with dichloromethane (3 
x 10 mL). The combined organics were washed with brine (10 mL), dried over MgSO4, filtered 
and concentrated in vacuo to yield 321 (275 mg, 98 %) as an orange foam. 
1H NMR (500 MHz, Chloroform-d) δ 7.46 – 7.32 (m, 5H, H15,16&17), 6.49 (dd, J = 10.0, 3.0 Hz, 
1H, H6), 6.28 (dd, J = 10.0, 1.8 Hz, 1H, H7), 5.89 (dd, J = 10.1, 1.8 Hz, 1H, H7), 5.04 (dd, J = 
10.1, 3.0 Hz, 1H, H6), 4.91 (s, 1H, H1), 3.28 (d, J = 14.5 Hz, 1H, H13), 3.19 (d, J = 14.5 Hz, 1H, 
H13), 3.09 (s, 3H, H12), 2.55 (s, 2H, H4), 1.25 (s, 9H, H11) 
13C NMR (126 MHz, Chloroform-d) δ 184.57 (C8), 178.92 (C9), 174.20 (C2), 147.70 (C6), 144.31 
(C6), 134.94 (C14), 131.16 (C15/16), 130.85 (C7), 129.80 (C7), 129.34 (C15/16), 128.29 (C17), 85.24 
(C1), 66.80 (C3), 53.13 (C5), 43.16 (C13), 38.97 (C4), 36.62 (C10), 31.39 (C12), 27.42 (C11) 
Rf = 0.70 in 5% MeOH in DCM 








To a solution of 317 (180 mg, 0.60 mmol) in dry methanol (6.00 mL) under N2, cerium(III) 
chloride heptahydrate (335 mg, 0.90 mmol) was added and stirred for 15 minutes at room 
temperature. The reaction mixture was then cooled to 0 °C and sodium borohydride (45.0 mg, 
1.20 mmol) was added. The resultant mixture was left to stir for a further 30 minutes and then 
quenched with water (5 mL).  The mixture was then diluted with EtOAc (20 mL) and washed 
with water (15 mL). The aqueous phase was extracted with EtOAc (3 x 10 mL) and brine (10 
mL). The combined organics were dried over MgSO4, filtered and concentrated in vacuo. 
Purification was carried out by column chromatography on silica gel eluting with 0-10% MeOH 
in dichloromethane to yield 322 (140 mg, 77 %) as a clear oil.  
1H NMR (400 MHz, Chloroform-d) δ 6.19 (m, 1H, H6), 6.15 – 6.04 (m, 2H, H6&7), 5.59 (m, 1H, 
H7), 4.80 (s, 1H, H1), 4.45 (m, 1H, H8), 2.98 (s, 3H, H12), 2.40 (d, J = 13.6 Hz, 1H, H4), 2.23 (d, 
J = 13.6 Hz, 1H, H4), 2.12 – 2.04 (m, 1H, OH), 1.71 (s, 3H, H13), 1.06 (s, 9H, H11) 
13C NMR (101 MHz, Chloroform-d) δ 181.32 (C2), 174.81 (C9), 131.26 (C6/7), 130.80 (C6/7), 
130.48 (C6/7), 129.51 (C6/7), 83.25 (C1), 62.98 (C3), 61.35 (C8), 50.52 (C5), 47.47 (C4), 36.39 (C10), 
31.15 (C12), 27.01 (C11), 26.93 (C13) 
Rf = 0.55 in 5% MeOH in DCM 





To a solution of 319 (140 mg, 0.40 mmol) in dry methanol (4 mL) under N2, cerium(III) chloride 
heptahydrate (224 mg, 0.60 mmol) was added and stirred for 15 minutes at room temperature. 
The reaction mixture was then cooled to 0 °C and sodium borohydride (31 mg, 0.8 mmol) was 




(10 mL).  The mixture was then diluted with EtOAc (20 mL) and washed with water (15 mL). 
The aqueous phase was extracted with EtOAc (3 x 10 mL) and brine (10 mL). The combined 
organics were dried over MgSO4, filtered and concentrated in vacuo. Purification was carried out 
by column chromatography on silica gel eluting with 0-10% MeOH in dichloromethane to yield 
324 (70.0 mg, 50 %) as a yellow oil.   
1H NMR (500 MHz, Chloroform-d) δ 6.19 (m, 1H, H6), 6.14 (m, 1H, H6), 6.06 – 6.02 (m, 1H, 
H7), 5.61 (m, 1H, H7), 4.76 (s, 1H, H1), 4.45 (m, 1H, H8), 2.97 (s, 3H, H12), 2.51 (d, J = 13.9 Hz, 
1H, H4), 2.30 (d, J = 13.9 Hz, 1H, H4), 2.10 – 2.04 (m, 1H, H14), 2.00 (dd, J = 14.2, 5.6 Hz, 1H, 
H13), 1.80 (dd, J = 14.2, 6.2 Hz, 1H, H13), 1.09 – 1.06 (m, 13H, H11&15), 0.99 (d, J = 6.5 Hz, 3H, 
H15) 
13C NMR (126 MHz, Chloroform-d) δ 180.95 (C2), 174.07 (C9), 131.05 (C6/7), 130.96 (C6/7), 
130.73 (C6/7), 129.56 (C6/7), 83.25 (C1), 65.20 (C3), 61.20 (C8), 50.60 (C5), 48.63 (C13), 43.47 (C4), 
35.95 (C10), 30.92 (C12), 27.19 (C11), 24.86 (C14), 24.34 (C15), 24.25 (C15) 
Rf = 0.53 in 5% MeOH in DCM 





To a solution of 321 (275 mg, 0.73 mmol) in dry methanol (7.00 mL) under N2, cerium(III) 
chloride heptahydrate (406 mg, 1.10 mmol) was added and stirred for 15 minutes at room 
temperature. The reaction mixture was then cooled to 0 °C and sodium borohydride (55 mg, 1.45 
mmol) was added. The resultant mixture was left to stir for a further 30 minutes and then quenched 
with water (10 mL).  The mixture was then diluted with EtOAc (20 mL) and washed with water 
(15 mL). The aqueous phase was extracted with EtOAc (3 x 10 mL) and brine (10 mL). The 
combined organics were dried over MgSO4, filtered and concentrated in vacuo. Purification was 
carried out by column chromatography on silica gel eluting with 0-10% MeOH in 
dichloromethane to yield 326 (205 mg, 74 %) as a pale-yellow oil.   
1H NMR (500 MHz, Chloroform-d) δ 7.41 – 7.30 (m, 5H, H15,16&17), 6.09 (m, 1H, H6), 5.73 (m, 
1H, H7), 5.50 (m, 1H, H7), 4.84 (s, 1H, H1), 4.34 (dd, J = 9.9, 2.3 Hz, 1H, H6), 4.26 (t, J = 4.1 Hz, 
1H, H8), 3.28 – 3.11 (m, 2H, H13), 3.05 (s, 3H, H12), 2.45 (d, J = 14.5 Hz, 1H, H4), 2.28 (d, J = 




13C NMR (126 MHz, Chloroform-d) δ 183.01 (C2), 174.67 (C9), 135.16 (C14), 132.17 (C7), 131.07 
(C15/16), 130.68 (C6), 129.74 (C7), 129.15 (C6), 128.86 (C15/16), 127.76 (C17), 84.96 (C1), 66.60 
(C3), 60.74 (C8), 50.19 (C5), 43.38 (C13), 41.17 (C4), 36.44 (C10), 31.19 (C12), 27.33 (C11) 
Rf = 0.65 in 5% MeOH in DCM 
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